

AACR American Association
for Cancer Research®

**ANNUAL
MEETING
2025 CHICAGO**

APRIL 25–30, 2025

AACR.ORG/AACR2025 | #AACR25



PROGRAM GUIDE

TABLE OF CONTENTS

1	Supporters	60	AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
7	Friday, April 25	60	Award Lecture AACR Award for Outstanding Achievement in Chemistry in Cancer Research
11	Saturday, April 26	61	Award Lecture AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research
21	Plenary Session	61	Award Lecture AACR-St. Baldrick's Foundation Award for Outstanding Achievement in Pediatric Cancer Research
22	Sunday, April 27	62	Award Lecture AACR Award for Outstanding Achievement in Basic Cancer Research
22	Opening Ceremony	62	Award Lecture AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research
22	Plenary Session	64	Tuesday, April 29
23	Award Lecture Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research	64	Plenary Session
28	Clinical Trials Plenary Session	64	Poster Session
28	Poster Session	70	Clinical Trials Plenary Session
30	Award Lecture AACR Award for Lifetime Achievement in Cancer Research	70	AACR Gertrude B. Elion Cancer Research Award Lecture
37	Award Lecture AACR James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research	74	Poster Session
37	Clinical Trials Plenary Session	82	Award Lecture AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention
38	Award Lecture AACR-Irving Weinstein Foundation Distinguished Lectureship	82	AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology
38	Award Lecture AACR-Princess Takamatsu Memorial Lectureship	83	Award Lecture AACR Award for Outstanding Achievement in Blood Cancer Research
38	Award Lecture AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research	83	Award Lecture AACR-Women in Cancer Research Charlotte Friend Lectureship
38	Presidential Address	86	Wednesday, April 30
40	AACR Annual Reception	86	Plenary Session
41	Monday, April 28	86	Poster Session
41	Poster Session	90	Plenary Session
47	Clinical Trials Plenary Session		
51	Poster Session		
60	Award Lecture AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship		

CURE, PROGRESS, PROMISE

Cure Level

AstraZeneca

GSK

Victoria's Secret Global Fund for Women's Cancers
in Partnership with Pelotonia and AACR

Progress Level

AbbVie Inc.

Daiichi Sankyo, Inc.

Gilead and Kite Oncology

Lilly

Revolution Medicines

Promise Level

Amgen, Inc.

American Brain Tumor Association

American Cancer Society

Bayer

Boehringer Ingelheim

Breast Cancer Research Foundation

Cancer Research Institute

Canadian Institutes of Health Research

Chris "CJ" Johnson Foundation

Debbie's Dream Foundation

Exact Sciences

Exelixis, Inc.

Fondazione Pezcoller

Genmab

Incyte Corporation

Ipsen Biopharmaceuticals, Inc.

Irving Weinstein Foundation

Johnson & Johnson Innovative Medicine

Joey's Wings

Judy Nicholson Kidney Cancer Foundation

Kidney Cancer Action Network

Kidney Cancer Association

Ludwig Institute for Cancer Research

Merck & Co., Inc.

Northwestern University Lurie Cancer Center

Novartis

Pacific Biosciences

Pfizer, Inc.

Prostate Cancer Foundation

Rare Cancer Research Foundation

Regeneron

Sanofi

Sidney Kimmel Cancer Center at Jefferson

Silken Twine Charity

St. Baldrick's Foundation

The Mark Foundation

TOUCH, The Black Breast Cancer Alliance

University of Chicago Cancer Center

University of Illinois Cancer Center

UT Southwestern Medical Center

THE SCIENTIFIC PROGRAM

Major Symposia

Dharma Master Jiantai Symposium in Targeted Therapy

Advances in Organ Site Research Session

Dharma Master Jiantai Session on Advances in Lung Cancer

Advances in Early Detection Research Sessions

Dharma Master Jiantai Session on Advances in Biomarkers

The Margaret Foti Foundation

AACR AWARDS AND LECTURESHIPS

AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention

American Cancer Society

AACR Award for Outstanding Achievement in Blood Cancer Research

AbbVie, Inc., through an independent educational grant

AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology

Cancer Research Institute

AACR Gertrude B. Elion Cancer Research Award

GSK

AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research

Lilly

AACR-Irving Weinstein Foundation Distinguished Lectureship

Irving Weinstein Foundation

AACR-St. Baldrick's Foundation Award for Outstanding Achievement in Pediatric Cancer Research

St. Baldrick's Foundation

AACR Team Science Award

Lilly

Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research

Fondazione Pezcoller

AACR Outstanding Investigator Award for Breast Cancer Research

Breast Cancer Research Foundation

AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship

Gilead and Kite Oncology

AACR-Women in Cancer Research Charlotte Friend Lectureship

Gilead and Kite Oncology

AACR-Distinguished Lectureship In Breast Cancer Research

Aflac

AACR-Princess Takamatsu Memorial Lectureship

Princess Takamatsu Cancer Research Fund

AACR-Wuan Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research

Wuan Ki Hong Endowment Fund

AACR CONSTITUENCY GROUPS

Minorities in Cancer Research

Boehringer Ingelheim

Women in Cancer Research

AstraZeneca

Boehringer Ingelheim

Novartis

2025 AACR RUNNERS FOR RESEARCH 5K RUN/WALK

Presenting Sponsor

AstraZeneca

Pioneer Sponsor

Revolution Medicines

Premier Sponsor

UT Southwestern Medical Center

Innovator Sponsor

Lilly

Sidney Kimmel Cancer Center at Jefferson

Enthusiast Sponsor

Pacific Biosciences

AACR TRAVEL GRANTS AND SCHOLAR AWARDS

AACR Minority Scholar in Cancer Research Awards

Exact Sciences
NCI
Merck & Co., Inc.

AACR Undergraduate Scholar Awards

Members of the AACR Science Education Committee
• Kathleen W. Scotto, PhD
• John E. Leonard, MS, PhD

AACR-Women in Cancer Research Scholar Awards

Victoria's Secret Global Fund for Women's Cancers
in Partnership with Pelotonia and AACR
Novartis

AACR Global Scholar-in-Training Awards

Victoria's Secret Global Fund for Women's Cancers
in Partnership with Pelotonia and AACR

AACR Scholar-in-Training Awards

AbbVie, Inc., through an independent educational grant
Ajit Singh
Alfred & Cathy Fraser
American Association for Cancer Research
American Brain Tumor Association
Barbara Campell Creighton Scholarship
Breast Cancer Research Foundation
Canadian Institutes of Health Research
Carol Henry
Chris "CJ" Johnson Foundation
Chromophobe and Oncocytic Tumor Alliance
Debbie's Dream Foundation
Doreen J. Putrah Cancer Research Foundation
Exact Sciences
Family of Dan Y. Zhang
Glenn Sykes
International Kidney Cancer Coalition
James V. Buzzitta, MD Family Fund
Joey's Wings
The John Kincade Scholarship Fund

Judy Nicholson Kidney Cancer Foundation
The Estate of June L. Biedler
KidneyCAN
Kidney Cancer Association
Ludwig Institute for Cancer Research
The Margaret Foti Foundation
Nancy Staisey
Pezcoller Foundation
Prostate Cancer Foundation
Rare Cancer Research Foundation
Sanofi
Silken Twine Charity
Stan Divorski and Nancy Staisey
Steve and Nancy Reyda
TOUCH, The Black Breast Cancer Alliance
Triple Negative Breast Cancer Foundation

AACR SCIENTIFIC WORKING GROUPS

AACR Hematologic Malignancies Working Group

Gilead and Kite Oncology

AACR ANNUAL MEETING 2025 SUPPORTERS

AACR Advocacy Partners' Pavilion

AbbVie, Inc.
Bayer
Pfizer, Inc.
Revolution Medicines

AACR Patient Advocacy Roundtable Discussions

AbbVie, Inc.
Pfizer, Inc.

AACR Patient Advocates in Cancer Research Awards

AbbVie, Inc.

AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research Reception

Lilly

Mobile Charging Stations

Daiichi Sankyo, Inc.

Hotel Key Cards

AstraZeneca

Online Registration

Regeneron

Patient Advocacy Poster Session

Bayer

Pfizer, Inc.

Seating

Daiichi Sankyo, Inc.

Revolution Medicines

Poster Sessions

Daiichi Sankyo, Inc.

Revolution Medicines

Fellows of the AACR Academy Induction Ceremony and Celebration Dinner

AbbVie, Inc.

AACR Presidential Event Support

AbbVie, Inc.

AACR Member Appreciation

AbbVie, Inc.

AACR Annual Cancer and Biomedical Research Career Fair

AstraZeneca

Professional Education Grants

AbbVie, Inc., through an independent educational grant

Amgen

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

Incyte Corporation

Ipsen Biopharmaceuticals, Inc.

Lilly

Scientist↔Survivor Program®

AbbVie, Inc.

Canadian Institutes of Health Research (CIHR)

Daiichi Sankyo, Inc.

Exelixis, Inc.

Genmab

Gilead and Kite Oncology

GSK

Johnson & Johnson Innovative Medicine

Lilly

Merck & Co., Inc.

Novartis

Powell-Drescher Ovarian Cancer Research Foundation

RESEARCH GRANTS AND FELLOWSHIPS

ALK Positive, Inc.

AbbVie, Inc., through an independent educational grant

AstraZeneca

Bayer

Bosarge Family Foundation

Breast Cancer Research Foundation

Bristol Myers Squibb

Cancer Research UK

Conquer Cancer, the ASCO Foundation

Debbie's Dream Foundation

EMD Serono

Exelixis, Inc.

Fanconi Cancer Foundation

Friends of the AACR Foundation, Party with a Purpose

Genentech, A Member of the Roche Group

GSK

Incyte Corporation

The John and Elizabeth Leonard Family Foundation

Johnson & Johnson Innovative Medicine

KidneyCAN

Lobular Breast Cancer Alliance

Lustgarten Foundation

The Mark Foundation for Cancer Research

Merck & Co., Inc.
 MPM BioImpact
 Novocure
 Ocular Melanoma Foundation
 Pediatric Brain Tumor Foundation
 Pfizer, Inc.
 QuadW
 The Sontag Foundation
 St. Baldrick's Foundation
 StacheStrong
 Swim Across America
 Takeda Pharmaceuticals
 Triple Negative Breast Cancer Foundation
 Victoria's Secret Global Fund for Women's Cancers
 in Partnership with Pelotonia and AACR

SPECIAL CONFERENCE SUPPORTERS FOR 2024

AbbVie, Inc.
 AstraZeneca
 Bristol Myers Squibb
 City of Hope
 Genentech, A Member of the Roche Group
 Gilead and Kite Oncology
 GSK
 Incyte Corporation
 Ipsen Biopharmaceuticals, Inc.
 Leerink Partners
 Let's Win Pancreatic Cancer
 Lilly
 Lustgarten Foundation
 Merck & Co., Inc.
 Novartis
 Pfizer, Inc.
 Royalty Pharma

SUSTAINING MEMBERS

Leadership Sustaining Members

Amgen, Inc.
 AstraZeneca
 Bayer
 Boehringer Ingelheim Pharmaceuticals, Inc.
 Bristol Myers Squibb
 Genentech, A Member of the Roche Group
 Gilead and Kite Oncology
 Lilly
 Merck & Co., Inc.
 Pfizer, Inc.

Strategic Sustaining Members

AbbVie, Inc.
 Eisai
 Incyte Corporation
 Novartis

Major Sustaining Members

BeOne Medicines
 Daiichi Sankyo, Inc.
 Exact Sciences
 Exelixis, Inc.
 Fondazione Pezcoller
 Genmab
 Johnson & Johnson Innovative Medicine
 Novocure
 Regeneron
 Sanofi
 Takeda Pharmaceuticals

Associate Sustaining Members

Byondis
 Charles River Laboratories
 GRAIL
 QIAGEN Sciences, Inc.
 Servier
 Verastem Oncology
 Zai Lab

PROFESSIONAL DEVELOPMENT SESSION**1:00 p.m.–4:00 p.m.**

Hall C - McCormick Place North (Level 1)

Grant Writing Workshop:**Tips for Success from Experienced Scientists****NOT ELIGIBLE FOR CME CREDIT****Cochairs:** Mariana C. Stern, Los Angeles, CA; Filippo Pederzoli, New York, NY**1:00 p.m. Welcome from AACR Science and Education and Career Advancement Committee Chair.** Brian M. Rivers, Atlanta, GA**Opening Remarks.** Mariana C. Stern, Los Angeles, CA**Foundation and other funding opportunities.**

Judy N. Quong, Philadelphia, PA

Title to be announced. Douglas R. Hurst, Atlanta, GA

Additional speakers to be announced

**EDUCATIONAL SESSIONS****3:00 p.m.–4:30 p.m.**

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)

Advances in Gene and Cellular Therapy**Chair:** Nina Bhardwaj, New York, NY**3:00 p.m. Chair Introduction.** Nina Bhardwaj, New York, NY**3:01 p.m. Countering tumor microenvironment forces to enhance adoptive T cell therapy for solid tumor.** Daniel J. Powell, Philadelphia, PA**3:30 p.m. Physical and biological approaches for gene and T cell delivery against solid tumors.** Shulin Li, Houston, TX**4:00 p.m. Tuning CARs to navigate the barriers in solid tumors.** Prasad S. Adusumilli, New York, NY

Room S102 - McCormick Place South (Level 1)

Escape versus Elimination: Understanding the Interplay between Cancer and the Adaptive Immune System**Chair:** Herbert Levine, Boston, MA**3:00 p.m. Chair Introduction.** Herbert Levine, Boston, MA**3:01 p.m. Quantifying immune and cancer co-evolution.** Nicholas McGranahan, London, United Kingdom**3:31 p.m. Stochastic modeling of the tumor-adaptive immune interaction.** Jason T. George, Houston, TX**4:00 p.m. Immune evasion via tumor adaptation.** Herbert Levine, Boston, MA

Room S404 - McCormick Place South (Level 4)

The Interplay Between Nuclear Topology, Gene Regulation, and Cancer**Chair:** Jane Skok, New York, NY**3:00 p.m. Chair Introduction.** Jane Skok, New York, NY**3:30 p.m. Dysregulation of nuclear topology in cancer: Clinical implications and emerging mechanisms.** Aaron Viny, New York, NY**3:01 p.m. Factors that determine chromatin organization in different cell states.** Jane Skok, New York, NY**4:00 p.m. How a 3D transcription factor and chromatin network in stem cells can poise genes for developmental progression.** Bradley Cairns, Salt Lake City, UT

Room S103 - McCormick Place South (Level 1)

Lineage Plasticity and Resistance to Cancer Therapy

Chair: Cory Abate-Shen, New York, NY

3:00 p.m. Chair Introduction. Cory Abate-Shen, New York, NY

3:01 p.m. The basics for understanding lineage plasticity in cancer: Insights from studying in bladder cancer. Cory Abate-Shen, New York, NY

3:31 p.m. Epithelial-mesenchymal plasticity in pancreatic tumor progression and resistance to immunotherapy. Ben Z. Stanger, Philadelphia, PA

4:01 p.m. Deciphering lineage plasticity in prostate cancer: Insights and therapeutic implication. Amina Zoubeydi, Vancouver, BC, Canada

Room S105 - McCormick Place South (Level 1)

Multimodal Spatiotemporal Mapping of Cell States, Organization, and Interactions

Chair: Itay Tirosh, Rehovot, Israel

3:00 p.m. Chair Introduction. Itay Tirosh, Rehovot, Israel

3:01 p.m. Uncovering the spatial organization of cell states in glioma and in head and neck cancer. Itay Tirosh, Rehovot, Israel

3:30 p.m. High-resolution and noninvasive profiling of the tumor microenvironment with spatial ecotypes. Aaron M. Newman, San Mateo, CA

4:00 p.m. Inferring reproducible tumor microenvironment ecosystems from scRNA-seq atlases. Kieran Campbell, Toronto, ON, Canada

Room S106 - McCormick Place South (Level 1)

The Science and Art of Community Outreach and Engagement: Building Sustainable Healthy Communities

Chair: Sakinah C. Suttiratana, New Haven, CT

3:00 p.m. Chair Introduction. Sakinah C. Suttiratana, New Haven, CT

3:01 p.m. Exploring a partner engagement portfolio for sustained learning and community health benefits. Sakinah C. Suttiratana, New Haven, CT

4:00 p.m. Community-engaged dissemination and implementation science for cancer prevention and control. Chelsey R. Schlechter, Salt Lake City, UT

3:30 p.m. The science and art of community engagement for translating research into cancer-related policy and implementation. Kimlin Tam Ashing, Duarte, CA



METHODS WORKSHOP

3:00 p.m.–4:30 p.m.

Room S401 - McCormick Place South (Level 4)

Statistical and Design Considerations for Dose Optimization

Chair: Ying Yuan, Houston, TX

3:00 p.m. Introduction. Ying Yuan, Houston, TX

3:01 p.m. Dose optimization design and strategy for oncology drug development. Yong Zang, Indianapolis, IN

3:31 p.m. Using backfill for flexible and efficient dose optimization. Ying Yuan, Houston, TX

4:00 p.m. Dose finding for drug combinations and the use of intra-patient dose escalation strategies. Ying Lu, Stanford, CA



EDUCATIONAL SESSIONS

4:45 p.m.–6:15 p.m.

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)

Accelerating Cancer Research with AI and Data Science: Multi-scale Multi-Modal Integration for Deeper Insights

Chair: David W. Craig, Duarte, CA

- 4:45 p.m. Chair Introduction.** David W. Craig, Duarte, CA
- 4:46 p.m. Resolving spatial subclonal genomic heterogeneity using the integration of multi-omic genomic approaches in solid tumors.** David W. Craig, Duarte, CA
- 5:15 p.m. Genomic constraints and local adaptation in the cancer niche: AI-powered insights from single cells and spatially profiled tissues.** Maria Secrier, London, United Kingdom
- 5:45 p.m. Integrating molecular profiles and MRI phenotypes to map the heterogeneity of the GBM microenvironment.** Leland Hu, Phoenix, AZ

Room S404 - McCormick Place South (Level 4)

Advancing the Translational Potential of Comparative Oncology

Chair: Heather Lynn Gardner, North Grafton, MA

- 4:45 p.m. Chair Introduction.** Heather Lynn Gardner, North Grafton, MA
- 4:46 p.m. Immunological responses to Listeria-based immunotherapy correlate with outcome in dogs with osteosarcoma.** Nicola J. Mason, Philadelphia, PA
- 5:16 p.m. Clinical validation of intratumoral cytokines through inclusion of cancer-bearing pet dogs.** Timothy M. Fan, Urbana, IL
- 5:46 p.m. Leveraging longitudinal multi-omics to develop prognostic biomarker approaches in canine osteosarcoma.** Heather Lynn Gardner, Boston, MA

Room S103 - McCormick Place South (Level 1)

DNA Damage Response (DDR) Inhibitors Revisited: Paths to the Clinic

Chair: Thanos D. Halazonetis, Geneva, Switzerland

- 4:45 p.m. Chair Introduction.** Thanos D. Halazonetis, Geneva, Switzerland
- 4:46 p.m. Strategies to mitigate the toxicity of DDR inhibitors.** Thanos D. Halazonetis, Geneva, Switzerland
- 5:15 p.m. Enhancing lutetium-177 radionuclide therapy with DDR inhibitors.** Julie Nonnekens, Rotterdam, Netherlands
- 5:45 p.m. Rational DDRi combinations with immunotherapy and ADCs.** Panagiotis A. Konstantinopoulos, Boston, MA

Room S106 - McCormick Place South (Level 1)

Drug Repurposing in Oncology: Opportunities and Challenges

Chair: Naoko Takebe, Oklahoma City, OK

- 4:45 p.m. Chair Introduction.** Naoko Takebe, Oklahoma City, OK
- 5:15 p.m. Repurposing drugs to overcome PARP inhibitor resistance.** Alan D. D'Andrea, Boston, MA
- 4:46 p.m. Acetalax (Oxyphenisatin acetate) for triple-negative breast cancer: A drug repurposing opportunity.** Naoko Takebe, Oklahoma City, OK
- 5:45 p.m. Application of artificial intelligence for drug repositioning in cancer.** Robert Wieder, Newark, NJ
- 5:55 p.m. Application of artificial intelligence for drug repositioning in cancer.** Nabil Adam, Newark, NJ

Room S401 - McCormick Place South (Level 4)

How to Measure Cancer Evolution

Chair: Ewa Szczurek, Neuherberg, Germany

- 4:45 p.m. Chair Introduction.** Ewa Szczurek, Neuherberg, Germany
- 4:46 p.m. Measuring selection in tumors and normal tissues.** Núria López-Bigas, Barcelona, Spain
- 5:15 p.m. Quantifying mutation and selection in cancer evolution by site, by stage, and by somatic genetic context.** Jeffrey Townsend, New Haven, CT
- 5:45 p.m. Modeling cancer evolution from single cell DNA data.** Ewa Szczurek, Neuherberg, Germany

Room S105 - McCormick Place South (Level 1)

The Microbiota and Cancer Prevention, Diagnosis, and Treatment

Chair: Laurence Zitvogel, Villejuif, France

- 4:45 p.m. Chair Introduction.** Laurence Zitvogel, Villejuif, France
- 4:46 p.m. Tumor-infiltrating microbes and their impact on the tumor microenvironment.** Christopher D. Johnston, Houston, TX
- 5:15 p.m. Optimizing microbiome modulation to enhance cancer immunotherapy efficacy.** Bertrand Routy, Montreal, QC, Canada
- 5:45 p.m. Gut dysbiosis: a risk factor for cancer patients.** Laurence Zitvogel, Villejuif, France

Room S102 - McCormick Place South (Level 1)

Reprogramming Tumor Immunity: From Suppression to Therapeutic Activation

Chair: Polly Leilei Chen, Neuherberg, Germany

- 4:45 p.m. Chair Introduction.** Polly Leilei Chen, Neuherberg, Germany
- 4:46 p.m. Immuno-genomic cancer evolution drives immune landscapes in the tumor microenvironment.** Hiroyoshi Nishikawa, Tokyo, Japan
- 5:11 p.m. Stress-induced reprogramming of tumor immunity: Shaping therapeutic responses.** Michael B. Yaffe, Cambridge, MA
- 5:36 p.m. RNA-mediated immunosuppression in cancer: Intrinsic mechanisms and tumor microenvironmental crosstalk.** Polly Leilei Chen, Cambridge, MA

PROFESSIONAL DEVELOPMENT SESSION

5:00 p.m.–6:30 p.m.

Hall C - McCormick Place North (Level 1)

How to Design a Successful Career Path: From Doctoral to the First Five Years of a Cancer Research Career

NOT ELIGIBLE FOR CME CREDIT

Cochairs: Kathleen W. Scotto, New Brunswick, NJ; John M. Carethers, La Jolla, CA; Sara Pedron-Haba, Urbana, IL; Valerie Odero-Marrah, Baltimore, MD; Wayne R. Lawrence, Bethesda, MD



EDUCATIONAL SESSIONS

8:00 a.m.–9:30 a.m.

Room S101 - McCormick Place South (Level 1)

Academic Entrepreneurship: Getting Your Discovery to Patients, Part 1 — Liftoff

NOT ELIGIBLE FOR CME CREDIT

Chair: Michael A. Caligiuri, Duarte, CA

Introduction. Michael A. Caligiuri, Duarte, CA

Panelists: Tom Cirrito, Walnut, CA; Levi A. Garraway, San Francisco, CA; Ferran Prat, Boston, MA

Room S103 - McCormick Place South (Level 1)

Cancer Metastasis: Non-Genetic Drivers

Chair: Don X. Nguyen, New Haven, CT

8:00 a.m. Chair Introduction. Don X. Nguyen, New Haven, CT

8:01 a.m. Epigenetic regulation of tumor cell clustering during metastasis. Don X. Nguyen, New Haven, CT

8:30 a.m. Vascular control of tumor progression and metastasis. Hellmut G. Augustin, Heidelberg, Germany

9:00 a.m. Unraveling STING's context-dependent functions in cancer with systems biology. Ashley M. Laughney, New York, NY

Room S404 - McCormick Place South (Level 4)

CAR-T Cells in Hematological Malignancies: Innovations and Pitfalls

Chair: Marco Ruella, Philadelphia, PA

8:00 a.m. Chair Introduction. Marco Ruella, Philadelphia, PA

8:01 a.m. Harnessing T-Cell immunotherapy for blood cancers: Lessons from viral-specific T-Cells. Catherine Bollard, Washington, DC

8:30 a.m. Advancing CAR T cells for pediatric blood cancers: Challenges and innovative strategies. Stephen Gottschalk, Memphis, TN

9:00 a.m. Engineering the next generation of CAR T-cells: Overcoming resistance and enhancing efficacy. Marco Ruella, Philadelphia, PA

Room S406 (Vista Ballroom) - McCormick Place South (Level 4)

Chemistry to the Clinic Part 1 of 3: Expanding the Therapeutic Window of Antibody Drug Conjugates in Cancer

Chair: Greg Thurber, Ann Arbor, MI

8:00 a.m. Chair Introduction. Greg Thurber, Ann Arbor, MI

8:01 a.m. P5-labeling for generating highly efficacious antibody-conjugates for cancer therapy. Christian Hackenberger, Berlin, Germany

8:30 a.m. Harnessing glycoengineering to empower the development of antibody-drug conjugates. Jamie B. Spangler, Baltimore, MD

9:00 a.m. Design of novel antibody drug conjugates and ADC combinations to maximize the therapeutic window. Greg Thurber, Ann Arbor, MI

Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)

Early Detection of Primary Cancer and Minimal Residual Disease by Liquid Biopsies

Chair: Klaus Pantel, Hamburg, Germany

8:00 a.m. Chair Introduction. Klaus Pantel, Hamburg, Germany

8:01 a.m. Liquid biopsy to understand the biology of the metastatic cascade. Catherine Alix-Panabières, Clapiers, France

8:31 a.m. Early detection of cancer: The NCI perspective. Sudhir Srivastava, Rockville, MD

9:01 a.m. European consortia on early detection of cancer and minimal residual disease. Klaus Pantel, Hamburg, Germany

Room S402 - McCormick Place South (Level 4)

The Ecology of Cancer**Chair:** Carlo C. Maley, Tempe, AZ

- 8:00 a.m. Chair Introduction.** Carlo C. Maley, Tempe, AZ
- 8:01 a.m. Key principles of ecology for cancer biologists and physicians.** Joel Brown, Tampa, FL
- 8:30 a.m. Moving beyond “seed and soil”: Using cancer ecology to understand lethal metastasis.** Sarah R. Amend, Baltimore, MD
- 9:00 a.m. Applying landscape ecology statistics to analyze the tumor microenvironment.** Carlo C. Maley, Tempe, AZ

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)

The Evolution of Cancer Hallmarks: Insights and Moving Forward**Chair:** Manel Esteller, Badalona, Barcelona, Catalonia, Spain

- 8:00 a.m. Chair Introduction.** Manel Esteller, Badalona, Barcelona, Catalonia, Spain
- 8:01 a.m. Epigenetic hallmarks of cancer.** Manel Esteller, Badalona, Barcelona, Catalonia, Spain
- 8:30 a.m. Circadian clock disruption: A hallmark of cancer.** Chi Van Dang, New York, NY
- 9:00 a.m. Hallmarks of precancer.** Ken S. Lau, Nashville, TN

Room S105 - McCormick Place South (Level 1)

Innovative Approaches in TME Biology: From Profiling to Function**Chair:** Alexander Swarbrick, Darlinghurst, Australia

- 8:00 a.m. Chair Introduction.** Alexander Swarbrick, Darlinghurst, Australia
- 8:01 a.m. Mapping the metastatic microenvironment.** Ilaria Malanchi, London, United Kingdom
- 8:30 a.m. Decoding the premalignant breast cancer microenvironment.** Nicholas E. Navin, Houston, TX
- 9:00 a.m. Integrating multi-omic profiling with small molecule screens to discover mediators of stromal plasticity.** Alexander Swarbrick, Darlinghurst, Australia

Room S401 - McCormick Place South (Level 4)

Mechanisms Driving Sex Differences in Non-Reproductive Cancers**Chair:** Amy Moran, Portland, OR

- 8:00 a.m. Chair Introduction.** Amy Moran, Portland, OR
- 8:01 a.m. Sex differences in glioblastoma gene regulation.** Joshua B. Rubin, St Louis, MO
- 8:30 a.m. Genetic determinants of cancer sex bias.** Srinivas Raghavan Viswanathan, Boston, MA
- 9:00 a.m. Sex hormones as mediators of cancer immunity.** Amy Moran, Portland, OR

Room S403 - McCormick Place South (Level 4)

Social Determinants of Health and Cancer Outcomes: From the Sidewalk to the Bench and Back Again**Chair:** Chanita Hughes Halbert, Los Angeles, CA

- 8:00 a.m. Chair Introduction.** Chanita Hughes Halbert, Los Angeles, CA
- 8:01 a.m. Social drivers of cancer health disparities: Measurement issues and intervention opportunities.** Chanita Hughes Halbert, Los Angeles, CA
- 8:30 a.m. The impact of both social and biological drivers in men with prostate cancer.** Clayton C. Yates, Baltimore, MD
- 9:00 a.m. Chronic social stressors and breast cancer biology: Laboratory insights.** Suzanne D. Conzen, Dallas, TX



METHODS WORKSHOP
8:00 a.m.–9:30 a.m.

Room S405 - McCormick Place South (Level 4)

Can Anti-Cancer Drugs be Administered in Shorter Courses or at Lower Doses to Improve Access to Effective Treatment: What Evidence Do We Need to Change Practice?**Chair:** Ian F. Tannock, Toronto, ON, Canada

- 8:00 a.m. Introduction.** Ian F. Tannock, Toronto, ON, Canada

8:01 a.m. Immune checkpoint inhibitors: Are they interchangeable and how low can you go? Daniel Goldstein, Tel Aviv, Israel

8:31 a.m. Access to effective anti-cancer drugs in low- and middle-income countries: Current situation and strategies to improve access. Amol Patel, Lucknow, India

Room S102 - McCormick Place South (Level 1)
Integrating Computational Pathology, AI, and Spatial Multi-Omics in 2D and 3D

Chair: Linghua Wang, Houston, TX

8:00 a.m. Introduction. Linghua Wang, Houston, TX

8:01 a.m. AI-driven smart spatial omics. Mingyao Li, Houston, TX

8:31 a.m. Precision mapping of tumor ecosystems via computational pathology and spatial multi-omics. Linghua Wang, Houston, TX

9:00 a.m. AI-driven 3D spatial mapping of the tumor immune microenvironment for precision oncology. Tae Hyun Hwang, Nashville, TN

Room S106 - McCormick Place South (Level 1)
Utilizing AACR Project GENIE Real-world Clinico-genomic Data

Chair: Shawn M. Sweeney, Philadelphia, PA

8:00 a.m. Chair Introduction. Shawn M. Sweeney, Philadelphia, PA

8:05 a.m. Exploring the mutational signature landscape of over 200,000 cases from AACR GENIE. Vasileios Stathias, Miami, FL

8:30 a.m. Generating the BPC GENIE BRCA 1.0-public analytic dataset: A guide to data preparation and analysis. Walid Khaled Chatila, New York, NY

8:55 a.m. Using GENIE BPC datasets to train ML/AI models for automated patient data extraction at scale. Justin Jee, New York, NY

PROFESSIONAL DEVELOPMENT SESSION
8:30 a.m.-4:00 p.m.

Hall C - McCormick Place North (Level 1)
20th Annual Undergraduate Student Caucus and Poster Competition

NOT ELIGIBLE FOR CME CREDIT

Chair: Brian M. Rivers, Atlanta, GA

AACR CANCER AND BIOMEDICAL RESEARCH CAREER FAIR
9:00 a.m.-3:00 p.m.

NOT ELIGIBLE FOR CME

Room E354 B (Lakeside Ballroom) - McCormick Lakeside Center (Level 3)



EDUCATIONAL SESSIONS
10:00 a.m.-11:30 a.m.

Room S101 - McCormick Place South (Level 1)
Academic Entrepreneurship: Getting Your Discovery to Patients, Part 2 — Preparing for a Perfect Landing

NOT ELIGIBLE FOR CME CREDIT

Chair: William N. Hait, New Brunswick, NJ

Introduction. William N. Hait, New Brunswick, NJ

Panelists: Omer Butt, Candelaria Arenas, PR; Jeffrey A. Engelman, Watertown, MA; Melissa McCracken, Boston, MA; Rami Rahal, Boston, MA; Jose Mejia Oneto, San Francisco, CA

Room S403 - McCormick Place South (Level 4)

Cancer Predisposition in Childhood Cancer: Implications for Prevention, Surveillance, Interception, and Survivorship Care

Chair: David Malkin, Toronto, ON, Canada

10:00 a.m. Chair Introduction. David Malkin, Toronto, ON, Canada

10:01 a.m. Childhood cancer predisposition syndromes: Genetic testing and interpreting results in different settings. Sharon E. Plon, Houston, TX

10:26 a.m. The impact of multi-modal early detection approaches on survival in cancer predisposition. David Malkin, Toronto, ON, Canada

10:51 a.m. Cancer interception: Present and future. Steven M. Lipkin, New York, NY

Room S102 - McCormick Place South (Level 1)

Finding an Old Needle in a Haystack: Targeting Aging Pathways for Cancer Therapy

Chair: Darren J. Baker, Rochester, MN

10:00 a.m. Chair Introduction. Darren Baker, Rochester, MN

10:01 a.m. Somatic evolution in the normal lung - how aging and smoking alter tissue adaptive landscapes. James V. DeGregori, Aurora, CO

10:30 a.m. A complex TiME - how the tumor microenvironment governs tumor progression. Ashani T. Weeraratna, Baltimore, MD

11:00 a.m. Targeting senescent stromal cells to impact tumorigenesis. Darren Baker, Rochester, MN

Room S105 - McCormick Place South (Level 1)

Genome Stability in Tumor Suppression: Beyond DNA Replication and Repair

Chair: Ashok R. Venkitaraman, Singapore, Singapore

10:00 a.m. Chair Introduction. Ashok R. Venkitaraman, Singapore, Singapore

10:01 a.m. Tissue microenvironment, mechanical stress, and chromosome integrity in tumor suppression. Marco Foiani, Milan, Italy

10:31 a.m. Triggers for cancer genome evolution. Ashok R. Venkitaraman, Singapore, Singapore

11:01 a.m. Special powers of genomically unstable head and neck cancer cells. Agata Smogorzewska, New York, NY

Room S401 - McCormick Place South (Level 4)

Lymph Node Biology: The Tumor Immune Microenvironment and Metastasis

Chair: Timothy P. Padera, Boston, MA

10:00 a.m. Chair Introduction. Timothy P. Padera, Boston, MA

10:01 a.m. Tumor lymphangiogenesis shapes the tumor immune microenvironment. Melody A. Swartz, Chicago, IL

10:30 a.m. Lymph node metastasis and the evolution of T cell responses. Nathan E. Reticker-Flynn, Stanford, CA

11:00 a.m. Lymphatic system regulation of anti-cancer immunity. Timothy P. Padera, Boston, MA

Room S402 - McCormick Place South (Level 4)

Natural Killer Cells: Advances in Basic Biology and Clinical Applications

Chair: Michael A. Caligiuri, Duarte, CA

10:00 a.m. Chair Introduction. Michael A. Caligiuri, Duarte, CA

10:01 a.m. Innate immune lymphocytes, including NK cells. Michael A. Caligiuri, Duarte, CA

10:30 a.m. NK cells: From bench to bedside. Jianhua Yu, Irvine, CA

11:00 a.m. iPSC-derived NK cells and TriKE engagers. Jeffrey S. Miller, Minneapolis, MN

Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)

Next Generation Antibody Drug Conjugates

NOT ELIGIBLE FOR CME CREDIT

Chair: E.G. Elisabeth de Vries, Groningen, Netherlands

10:00 a.m. Chair Introduction. E.G. Elisabeth de Vries, Groningen, Netherlands

10:01 a.m. Insights into ADC properties and design: Lessons from clinical development. Raffaele Colombo, Vancouver, BC, Canada

10:26 a.m. Molecular imaging insights into antibody drug conjugates. E.G. Elisabeth de Vries, Groningen, Netherlands

10:51 a.m. ADCs in the clinic: Gaps, controversies, and hopes for the future. Joshua Z. Drago, New York, NY

11:16 a.m. Panel Discussion

Room S404 - McCormick Place South (Level 4)

Predictive Biomarkers of Response to (Neo)Adjuvant Treatment in Breast Cancer: What's New? Dedicated to the Memory of V. Craig Jordan

Chair: Christos Sotiriou, Brussels, Belgium

10:00 a.m. Chair Introduction. Christos Sotiriou, Brussels, Belgium

10:01 a.m. Novel HER2 classification and a summary of predictors to anti-HER2 therapies. Christos Sotiriou, Brussels, Belgium

10:26 a.m. Molecular and cellular biomarkers of response to chemo/immunotherapy in early-stage TNBC. Giampaolo Bianchini, Milan, Italy

10:51 a.m. Novel clinical trial designs for biomarker discovery/validation: How to move forward? Theodoros Foukakis, Stockholm, Sweden

Room S106 - McCormick Place South (Level 1)

Transposable Elements in Cancer: Contributions to Tumor Biology and Novel Therapeutic Targets

Chair: Katherine B. Chiappinelli, Washington, DC

10:00 a.m. Chair Introduction. Katherine B. Chiappinelli, Washington, DC

10:01 a.m. Transposable elements and the cancer epigenome. Ting Wang, Saint Louis, MO

10:21 a.m. The viral mimicry response to transposable elements in cancer. Katherine B. Chiappinelli, Washington, DC

11:00 a.m. Title to be announced. Benjamin Dylan Greenbaum, New York, NY

Room S406 (Vista Ballroom) - McCormick Place South (Level 4)

Tumor Immunology and Immunotherapy for Nonimmunologists: New-Generation Technologies for Immune-profiling and Spatial Imaging

Chair: Catherine J. Wu, Boston, MA

10:00 a.m. Chair Introduction. Catherine J. Wu, Boston, MA

10:01 a.m. Genomic and immunoproteomic approaches for cancer antigen discovery. Catherine J. Wu, Boston, MA

10:30 a.m. Grand serology. Sacha Gnjatich, New York, NY

11:00 a.m. Do we really need everything everywhere at once? Strategic priorities in spatial-omics. Sizun Jiang, Boston, MA

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)

Tumor Metabolism and the Tumor Microenvironment

Chair: Alexander Muir, Chicago, IL

10:00 a.m. Chair Introduction. Alexander Muir, Chicago, IL

10:01 a.m. What is there to eat around here? How metabolic constraints in the tumor microenvironment impact cancer biology. Alexander Muir, Chicago, IL

10:30 a.m. Metabolic stress as a driver of stromal plasticity: Adaptation, survival, and CAF subtype conversion. Cosimo Commisso, La Jolla, CA

11:00 a.m. The metabolic cross-talk between cancer cells and CD8+ T cells in the tumor microenvironment. Ilaria Elia, Leuven, Belgium



METHODS WORKSHOP

10:00 a.m.–11:30 a.m.

Room S103 - McCormick Place South (Level 1)

Biostatistics Workshop: The Fundamentals of Design, Objectives, and Endpoints for a Precise, Rigorous, and Successful Early-Phase Clinical Trial

Chair: Wendy B. London, Boston, MA

10:00 a.m. Introduction. Wendy B. London, Boston, MA

10:05 a.m. Working with a biostatistician to define objectives and endpoints for your clinical trial: Precision of language matters. Wendy B. London, Boston, MA

10:25 a.m. Evaluating design options for your phase 1 trial: Rule-based designs versus Bayesian adaptive designs. Nolan A. Wages, Richmond, VA

10:45 a.m. Design considerations for phase 2 clinical trials. Shing M. Lee, New York, NY

PROFESSIONAL DEVELOPMENT SESSION

12:00 p.m.–4:00 p.m.

Room S504 - McCormick Place South (Level 5)

WICR Workshop: Women and Power: Building Personal Resilience and Responding Dynamically to Stressors Over Your Career Lifetime

NOT ELIGIBLE FOR CME CREDIT

Chair: Shiva Malek, Cambridge, MA



EDUCATIONAL SESSIONS

12:30 p.m.–2:00 p.m.

Room S101 - McCormick Place South (Level 1)

“FLASH”ing Tumors with Radiation: From Preclinical Models to Patient Trials in Less than a Decade

Chair: Constantinos Koumenis, Philadelphia, PA

12:30 p.m. Chair Introduction. Constantinos Koumenis, Philadelphia, PA

12:31 p.m. Preclinical proton and carbon therapy FLASH RT studies. Constantinos Koumenis, Philadelphia, PA

1:00 p.m. Preclinical electron FLASH studies. Erinn Rankin, Stanford, CA

1:30 p.m. Ongoing and planned clinical trials. Anthony Mascia, Cincinnati, OH

Room S106 - McCormick Place South (Level 1)

Regulatory Science and Policy Session Bridging the Gap: Ensuring a Broad Representation of Patients in Cancer Clinical Trials

NOT ELIGIBLE FOR CME CREDIT

Moderator: Camille A. Campbell, Birmingham, AL

Speakers: Phyllis Jehne Pettit Nassi, Salt Lake City, UT; Dario R. Roque, Durham, NC

Panelists: Poorna Kushalnagar, Washington, DC; Bianca N. Islam, Cleveland, OH

Room S103 - McCormick Place South (Level 1)

Cancer Vaccines 101

Chair: Mads Hald Andersen, Herlev, Denmark

12:30 p.m. Chair Introduction. Mads Hald Andersen, Herlev, Denmark

12:31 p.m. RNA-based cancer vaccines. Smita K. Nair, Durham, NC

1:00 p.m. Dendritic cell vaccines. Kristen Radford, South Brisbane, Australia

1:30 p.m. Immune modulatory vaccines. Mads Hald Andersen, Herlev, Denmark

Room S406 (Vista Ballroom) - McCormick Place South (Level 4)

Chemistry to the Clinic Part 2 of 3: MYC—The Last Frontier in Undruggable Targets

Chair: Laura Soucek, Barcelona, Spain

12:30 p.m. Chair Introduction. Laura Soucek, Barcelona, Spain

12:31 p.m. Towards therapeutic strategies to directly target cMyc. Jody M. Mason, Bath, United Kingdom

1:00 p.m. Emerging synthetic strategies to target MYC in cancer. Raymond E. Moellering, Chicago, IL

1:30 p.m. MYC in cancer: From undruggable target to clinical trials. Laura Soucek, Barcelona, Spain

Room S402 - McCormick Place South (Level 4)

Cyclins that Don't Cycle: Understanding and Targeting Transcriptional CDKs in Cancer

Chair: Bruce E. Clurman, Seattle, WA

12:30 p.m. Chair Introduction: Targeting the cell cycle in 2025. Bruce E. Clurman, Seattle, WA

12:37 p.m. CDK regulation of the RNAPII transcription cycle: Molecular mechanisms and therapeutic opportunities. Robert P. Fisher, New York, NY

1:04 p.m. Therapeutic targeting of transcriptional CDKs across low molecular weight modalities. Eric S. Fischer, Boston, MA

1:32 p.m. Targeting lineage plasticity with transcriptional CDK inhibitors. Sita Kugel, Seattle, WA

Room S404 - McCormick Place South (Level 4)

Environmental Exposures for Cancer Population Sciences Research

Chair: Trang VoPham, Seattle, WA

12:30 p.m. Chair Introduction. Trang VoPham, Seattle, WA

12:31 p.m. Environmental determinants of cancer for exposome research. Trang VoPham, Seattle, WA

12:56 p.m. Linking the environment to cancer using causal inference tools. Hari Iyer, New Brunswick, NJ

1:21 p.m. Air pollution: An unseen risk factor for cancer? Jaime E. Hart, Boston, MA

Room S403 - McCormick Place South (Level 4)

Extrachromosomal DNA (ecDNA) in Cancer

Chair: Roel Verhaak, New Haven, CT

12:30 p.m. Chair Introduction. Roel Verhaak, New Haven, CT

12:31 p.m. Extrachromosomal DNA amplifications drive disease progression in cancer. Roel Verhaak, New Haven, CT

1:00 p.m. Extrachromosomal DNA, epigenetic stochasticity and tumor evolution. Chia-Lin Wei, Seattle, WA

1:30 p.m. Title to be announced. Andrea Ventura, New York, NY

Room S105 - McCormick Place South (Level 1)

Molecular Imaging for Drug Development and as a Biomarker for Treatment Decisions

Chair: David Mankoff, Philadelphia, PA

12:30 p.m. Chair Introduction. David A. Mankoff, Philadelphia, PA

12:31 p.m. Molecular imaging to guide drug development and precision oncology: Overview and framework. David A. Mankoff, Philadelphia, PA

1:00 p.m. Novel PET and optical markers for developing cell therapy and other "living" treatments. Mark Sellmyer, Philadelphia, PA

1:30 p.m. Molecular imaging to Direct cancer treatment in the clinic: Breast cancer example. Farrokh Dehdashti, St. Louis, MO

Room S102 - McCormick Place South (Level 1)

Myeloid Cell Biology in the Tumor Microenvironment and Reprogramming Myeloid Cells to Enhance Anti-tumor Immune Responses

Chair: Jelani C. Zarif, Baltimore, MD

12:30 p.m. Chair Introduction. Jelani C. Zarif, Baltimore, MD

12:31 p.m. Glutamine antagonist prodrug JHU083 reprograms immune-suppressive tumor-associated macrophages (TAMs) to drive tumor immunity in urologic cancers. Jelani C. Zarif, Baltimore, MD

1:00 p.m. **Unraveling the complexities of tumor associated macrophages for anti-cancer therapy.** Jennifer L. Guerriero, Boston, MA

1:30 p.m. **Strategies to block T cell exclusion in tumors by reprogramming macrophages.** Judith A. Varner, La Jolla, CA

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)

T-Cell Engagers: Engineering, Translation, and Comparison with CAR-T Cell Therapy

Chair: Yvonne Y. Chen, Los Angeles, CA

12:30 p.m. **Chair Introduction.** Yvonne Y. Chen, Los Angeles, CA

12:31 p.m. **Protein engineering considerations for bispecific T-cell engagers.** Yvonne Y. Chen, Los Angeles, CA

12:54 p.m. **Overcoming antigen escape, T cell exhaustion, and on-target toxicity with T cell engagers.** James M. Olson, Seattle, WA

1:17 p.m. **CARs versus T cell engagers: Which will prevail in the solid tumor microenvironment?** Brad Nelson, Victoria, BC, Canada

Room S401 - McCormick Place South (Level 4)

Tumor Cell Dormancy

Chair: Clare M. Isacke, London, United Kingdom

12:30 p.m. **Chair Introduction.** Clare M. Isacke, London, United Kingdom

12:31 p.m. **Breast cancer dormancy: Regulation by the metastatic microenvironment.** Clare M. Isacke, London, United Kingdom

1:00 p.m. **Melanoma dormancy: Strategies to prevent metastatic outgrowth.** Maria Soledad Sosa, New York, NY

1:30 p.m. **Early onset colorectal cancer initiation: The role of E. coli in age-dependent cell cycle entry.** Karuna Ganesh, New York, NY



METHODS WORKSHOPS

12:30 p.m.–2:00 p.m.

Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)

Application of AI and Natural Language Processing to Advance Cancer Research and Treatment

Chair: Eliezer M. Van Allen, Boston, MA

12:30 p.m. **Introduction.** Eliezer M. Van Allen, Boston, MA

12:31 p.m. **Modeling emergent cell behaviors in the TME with virtual cells.** Elana Fertig, Baltimore, MD

1:00 p.m. **Utilization of language models for medical information retrieval.** Travis Zack, San Francisco, CA

1:30 p.m. **Precision cancer medicine in the era of machine learning and clinical multi-omics.** Eliezer M. Van Allen, Boston, MA

Room S405 - McCormick Place South (Level 4)

Statistics Made Simple, Engaging, and Practical: A Primer for Non-Statisticians

Chair: J. Jack Lee, Houston, TX

12:30 p.m. **Chair Introduction.** J. Jack Lee, Houston, TX

12:31 p.m. **Enhancing quantitative reasoning through statistical thinking and exploratory data analysis.** J. Jack Lee, Houston, TX

1:00 p.m. **Boosting the quality and impact of preclinical studies through the power of statistics.** Mi-Ok Kim, San Francisco, CA

1:30 p.m. **Statistical support of clinical and translational studies: Ensuring rigor and reproducibility.** Roger J. Lewis, Los Angeles, CA

Room S104 - McCormick Place South (Level 1)

Using Master Protocols to Evaluate New Therapies for Rare Diseases

Chair: Mary W. Redman, Seattle, WA

12:30 p.m. **Introduction.** Mary W. Redman, Seattle, WA

- 12:35 p.m.** **Basket trials in rare cancers: Future designs informed from past experience.** Megan Othus, Seattle, WA
- 1:05 p.m.** **Lessons learned from a decade of Lung-MAP: A master protocol to evaluate biomarker-driven and immunotherapies in previously treated non-small cell lung cancer.** Mary W. Redman, Seattle, WA
- 1:35 p.m.** **Panel Discussion**



EDUCATIONAL SESSIONS

2:30 p.m.–4:00 p.m.

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1) **Artificial Intelligence in Cancer Immunology**

Chair: Franziska Michor, Boston, MA

- 2:30 p.m.** **Chair Introduction.** Franziska Michor, Boston, MA
- 2:31 p.m.** **Data science, machine learning, and artificial intelligence in cancer immunology.** Franziska Michor, Boston, MA
- 3:00 p.m.** **Personalizing CAR-T cell therapy through AI and multimodal data fusion.** Roni Shouval, New York, NY
- 3:30 p.m.** **Modeling microbiome initiated immune responses in cancer using protein language model.** Noam Auslander, Philadelphia, PA

Room S406 (Vista Ballroom) - McCormick Place South (Level 4) **Chemistry to the Clinic Part 3 of 3: Advances in Ligand Discovery to Enable Previously Intractable Targets**

Chair: Michael A. Erb, La Jolla, CA

- 2:30 p.m.** **Chair Introduction.** Michael A. Erb, La Jolla, CA
- 2:31 p.m.** **Targeting transcription with molecular glues.** Michael A. Erb, La Jolla, CA
- 3:00 p.m.** **Discovery of small molecule-mediated protein degradation pathways.** Xiaoyu Zhang, Evanston, IL
- 3:30 p.m.** **Reimagining druggability using chemoproteomic platforms.** Daniel K. Nomura, Berkeley, CA

Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1) **Ex Vivo Models of the TME**

Chair: Calvin J. Kuo, Stanford, CA

- 2:30 p.m.** **Chair Introduction.** Calvin J. Kuo, Stanford, CA
- 2:31 p.m.** **In vitro models of the tumor microenvironment.** Calvin J. Kuo, Stanford, CA
- 3:00 p.m.** **High resolution dynamic ex vivo profiling of the immune TME.** David A. Barbie, Andover, MA
- 3:30 p.m.** **Fibroblast activation pathways in pancreatic cancer-CAF co-cultures.** David A. Tuveson, Cold Spring Harbor, NY

Room S405 - McCormick Place South (Level 4) **Extracellular Vesicles and Exosomes: Basic and Applied Biology Informing Translational Opportunities**

Chair: Raghu Kalluri, Houston, TX

- 2:30 p.m.** **Chair Introduction.** Raghu Kalluri, Houston, TX
- 2:31 p.m.** **New mouse models to study the basic and applied biology of extracellular vesicles and exosomes in cancer.** Raghu Kalluri, Houston, TX
- 3:00 p.m.** **Successful phase I clinical translation of engineered exosomes targeting KrasG12D offers new insights into immunotherapy combinations for pancreatic cancer.** Valerie S. LeBleu, Chicago, IL
- 3:30 p.m.** **Contribution of EVs in influencing cell-state heterogeneity in glioblastoma.** Mario L. Suva, Newton, MA

Room S402 - McCormick Place South (Level 4) **GLP-1: From Diabetes to Weight Loss to Cancer**

Chair: Rong Xu, Cleveland, OH

- 2:30 p.m.** **Chair Introduction.** Rong Xu, Cleveland, OH
- 2:31 p.m.** **Breaking the obesity-cancer link: Preclinical evidence for the anticancer effects of GLP-1RAs.** Stephen D. Hursting, Chapel Hill, NC
- 3:01 p.m.** **Integrating GLP1-RAs into clinical cancer care.** Sherry Shen, New York, NY

3:31 p.m. **GLP-1RAs and cancer prevention: Target trial emulation using real-world data.** Rong Xu, Cleveland, OH

Room S404 - McCormick Place South (Level 4)

Lessons Learned Between Solid Tumors and Hematologic Malignancies

Chair: Kenneth C. Anderson, Wellesley, MA

2:30 p.m. **Chair Introduction.** Kenneth C. Anderson, Wellesley, MA

3:00 p.m. **Studying therapeutic resistance to elucidate secondary vulnerabilities in melanoma.** Keith Thomas Flaherty, Cambridge, MA

3:30 p.m. **Getting ex-vivo gene therapies to market, keeping them safe.** Stephan A. Grupp, Philadelphia, PA

2:31 p.m. **Targeting myeloma in the bone marrow microenvironment.** Kenneth C. Anderson, Wellesley, MA

Room S105 - McCormick Place South (Level 1)

Prediction and Design of Biomolecules Using Machine Learning Models

Chair: Possu Huang, Stanford, CA

2:30 p.m. **Chair Introduction.** Possu Huang, Stanford, CA

2:31 p.m. **Machine learning for biomolecular structure prediction.** Frank Dimaio, Seattle, WA

3:15 p.m. **SHAPES of protein generative models.** Possu Huang, Stanford, CA

Room S106 - McCormick Place South (Level 1)

Regulatory Science and Policy Session

Rising Early-Onset Cancers: Understanding the Shift and Exploring Policy Solutions

NOT ELIGIBLE FOR CME CREDIT

Moderator: Elizabeth M. Jaffee, Baltimore, MD

Speakers: John Wong, Omaha, NE; Zsafia K. Stadler, New York, NY

Panelists: Manju George, Omaha, NE; Andrea Cercek, New York, NY; Ulrike Peters, Seattle, WA

Room S403 - McCormick Place South (Level 4)

Side Effects of Cancer Immunotherapy

Chair: Robert Zeiser, Freiburg im Breisgau, Germany

2:30 p.m. **Chair Introduction.** Robert Zeiser, Freiburg im Breisgau, Germany

2:31 p.m. **Novel strategies for the treatment of ICI colitis and ICANS.** Robert Zeiser, Freiburg im Breisgau, Germany

3:00 p.m. **Learning from our mistakes.** Elad Sharon, Boston, MA

3:30 p.m. **Checkpoint inhibitor pneumonitis: Mechanisms of injury.** Karthik Suresh, Baltimore, MD

Room S101 - McCormick Place South (Level 1)

Somatic Mosaicism as a Driver of Cancer and Inflammatory Diseases

Chair: Lucy A. Godley, Chicago, IL

2:30 p.m. **Chair Introduction.** Lucy A. Godley, Chicago, IL

2:31 p.m. **Somatic mosaicism as a driver of hematopoietic malignancies and inflammatory diseases.** Lucy A. Godley, Chicago, IL

3:00 p.m. **Clonal hematopoiesis: From pre-malignant blood cancer lesion to mediator of inflammatory diseases.** Alexander Bick, Nashville, TN

3:30 p.m. **Impact of somatic epigenetic regulator gene mutations in VEXAS syndrome.** Terra L. Lasho, Rochester, MN

Room S401 - McCormick Place South (Level 4)

Theranostics: The Nuts and Bolts

Chair: Kayvan R. Keshari, New York, NY

2:30 p.m. **Chair Introduction: Overview of state of radiotheranostics.** Kayvan R. Keshari, New York, NY

2:35 p.m. **Design, development and translation of radiotheranostics.** Julie L. Sutcliffe, Windsor, CA

3:05 p.m. **Evolving role of translational and clinical theranostics.** Robert Flavell, San Francisco, CA



METHODS WORKSHOPS

2:30 p.m.–4:00 p.m.

Room S102 - McCormick Place South (Level 1)

Clinical Trial Design Workshop: Complexities of Current Phase I Clinical Trials

Chair: David S. Hong, Houston, TX

- 2:30 p.m.** **Introduction.** David S. Hong, Houston, TX
- 2:31 p.m.** **The challenges now and ahead in phase 1.** David S. Hong, Houston, TX
- 2:51 p.m.** **Trial design and dose optimization: Defining the right dose.** Shivaani Kummar, Portland, OR
- 3:11 p.m.** **Biomarkers and endpoints in phase 1 clinical trials: Have they delivered?** Michael Cecchini, New Haven, CT
- 3:11 p.m.** **Panel discussion**

Room S103 - McCormick Place South (Level 1)

Reading the Tumor Tea Leaves: Integrating Novel Tumor Biomarkers in Epidemiological Research

Chair: Paul A. Scheet, Houston, TX

- 2:30 p.m.** **Chair Introduction.** Paul A. Scheet, Houston, TX
- 2:31 p.m.** **Phenotyping the genotype: The genetics and risk of acquired chromosomal alterations.** Paul A. Scheet, Houston, TX
- 3:00 p.m.** **Harnessing genetic and immune interplay to intercept and treat malignancy.** Christina Curtis, Stanford, CA
- 3:30 p.m.** **Integration of breast tissue biomarkers in epidemiologic research: Opportunities to understand etiologic pathways.** Rulla M. Tamimi, New York, NY



PLENARY SESSION

4:15 p.m.–6:15 p.m.

Hall B1 - McCormick Place North (Level 3)

Discovery Science Plenary: Novel Mechanisms Influencing Cancer Evolution

Chair: Ashok R. Venkitaraman, Singapore, Singapore

- 4:15 p.m.** **Introduction.** Ashok R. Venkitaraman, Singapore, Singapore
- 4:20 p.m.** **Somatic mutation and selection in normal tissues at epidemiological scale.** Inigo Martincorena, Cambridge, United Kingdom
- 4:47 p.m.** **Can metabolism be targeted to cure liver (and other!) cancers?** M. Celeste Simon, Philadelphia, PA
- 5:14 p.m.** **Simultaneous perturbation of epigenetic and signaling pathways rewires transcription and synergistically induce AML differentiation.** Yang Shi, Oxford, United Kingdom
- 5:41 p.m.** **The human microbiome as a diagnostic and treatment-supporting target in oncology.** Nicola Segata, Trento, Italy
- 6:08 p.m.** **Wrap-up and opportunities for the future.** Ashok R. Venkitaraman, Singapore, Singapore

PROFESSIONAL DEVELOPMENT SESSION

5:00 p.m.–7:00 p.m.

Great Lakes AB - Marriott Marquis Chicago

Personalized Career Conversations

NOT ELIGIBLE FOR CME CREDIT

Cochairs: Christopher G. Sistrunk, Duarte, CA; Jose G. Trevino, Richmond, VA; Arti P. Varanasi, Baltimore, MD; Heather K. Beasley, Mount Juliet, TN

CAREER DEVELOPMENT FORUM**7:00 a.m.–8:30 a.m.**

Grant Park - Hyatt Regency McCormick Place

WICR Career Development Forum: Lifelong Career Development—Strategies for Success**NOT ELIGIBLE FOR CME CREDIT****Cochairs:** Mariana C. Stern, Los Angeles, CA; Dineo Khabele, St. Louis, MO**Panelists:** Susan M. Galbraith, Gaithersburg, MD; Lisa M. Newman, New York, NY**OPENING CEREMONY****7:45 a.m.–9:30 a.m.**

Hall B1 - McCormick Place North (Level 3)

NOT ELIGIBLE FOR CME CREDIT

Join us on Sunday for the Annual Meeting Opening Ceremony, a yearly tradition marking the start of four days filled with outstanding and innovative science.

Highlights of this year's Opening Ceremony include:

- Remarks from AACR CEO Margaret Foti and AACR President Patricia M. LoRusso
- AACR Award for Lifetime Achievement in Cancer Research
- AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research
- AACR Team Science Award
- AACR June L. Biedler Prizes for Cancer Journalism
- AACR Distinguished Public Service Awards
- 2025 Class of Fellows of the AACR Academy

Don't miss this exciting event!

**PLENARY SESSION****9:30 a.m.–11:30 a.m.**

Hall B1 - McCormick Place North (Level 3)

Opening Plenary: Unifying Cancer Science and Medicine—A Continuum of Innovation for Impact**Cochairs:** Lillian L. Siu, Toronto, ON, Canada; Matthew G. Vander Heiden, Cambridge, MA**9:30 a.m. Introduction.** Matthew G. Vander Heiden, Cambridge, MA**9:35 a.m. Introduction.** Lillian L. Siu, Toronto, ON, Canada**9:40 a.m. PL02-01 Overcoming the undruggable nature of the most common human oncogene, K-Ras.** Kevan M. Shokat, San Francisco, CA**10:07 a.m. The influence of extrachromosomal DNA (ecDNA) in cancer.** Paul S. Mischel, Stanford, CA**10:34 a.m. Unraveling the complexity of cancer ecosystems.** Johanna A. Joyce, Lausanne, Switzerland**11:01 a.m. Addressing tumor heterogeneity: Personalized cancer vaccines.** Catherine J. Wu, Boston, MA**NCI-NIH-SPONSORED SESSIONS****On-Demand****(Available at 11:30 a.m. on Sunday, April 27)****NOT ELIGIBLE FOR CME CREDIT**

These sessions will be available for registrants to view on the AACR Annual Meeting 2025 virtual meeting platform. There will be no live presentations.

Enhancing FAIR Sharing and Reuse of Cancer Research Data**Presenters:** Ying Huang, Rockville, MD; Mousumi Ghosh, Bethesda, MD; Ina Felau, Bethesda, MD

NCI Drug Development Resources and Grant Writing Strategies for New and Early-Stage Investigators

Moderator: Christophe Marchand, Bethesda, MD

Presenters: Christophe Marchand, Bethesda, MD; Sundar Venkatachalam, Bethesda, MD; William Greenberg, Rockville, MD

NCI Funding Opportunities to Support Early Career Cancer Researchers

Moderator: Nastaran Zahir, Bethesda, MD

Presenters: Mark Damico, Bethesda, MD; Michael K. Schmidt, Bethesda, MD

NCI Resources for Cancer Prevention and Interception Agent Discovery and Development

Moderator: Robert H. Shoemaker, Bethesda, MD

Presenters: Altaf Mohammed, Rockville, MD; Lillian Kuo, Rockville, MD; Vignesh Gunasekharan, Rockville, MD; Brian Cholewa, Bethesda, MD

Resources from the NCI-Sponsored Human Tumor Atlas Network

Presenters: Sharmistha Ghosh-Janjigian, Rockville, MD; Indu Kohaar, Uniformed Services University, Bethesda, MD; Adam Taylor, Seattle, WA; Erin Beck, Bethesda, MD

AWARD LECTURE

12:00 p.m.–12:45 p.m.

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)
Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research

NOT ELIGIBLE FOR CME CREDIT

Chair: Giulio F. Draetta, Houston, TX

Funder Remarks. Enzo Galligioni, Trento, Italy

Illuminating and reprogramming the immuno-evasive tumor microenvironment to enable immunotherapy. Douglas Hanahan, Lausanne, Switzerland



ADVANCES IN HEMATOLOGIC MALIGNANCIES

1:00 p.m.–2:30 p.m.

Room E351 - McCormick Lakeside Center (Level 3)

Novel Approaches to Tracking Clonal Selection, Transformation, and Clinical Application of MRD: Lessons from Acute Myeloid Leukemia (AML) and Applications to Other Cancers

Chair: Paresh Vyas, Oxford, United Kingdom

1:00 p.m. Chair Introduction. Paresh Vyas, Oxford, United Kingdom

1:05 p.m. Identifying and quantitating somatic clonal selection and its transformation to AML. Paresh Vyas, Oxford, United Kingdom

1:30 p.m. Diagnosis and monitoring technologies in AML. Michael Heuser, Halle, Germany

1:55 p.m. Clinical application of MRD in AML. Roland B. Walter, Seattle, WA



ADVANCES IN ORGAN SITE RESEARCH

1:00 p.m.–2:30 p.m.

Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)

Dharma Master Jiantai Advances in Lung Cancer Research Session: Aging and Environmental Cues Drive Lung Cancer Development and Spread

Chair: Thomas U. Marron, New York, NY

1:00 p.m. Chair Introduction. Thomas U. Marron, New York, NY

- 1:02 p.m.** **The seed AND the soil: How cancer-induced and aging-related immune dysregulation collide to promote lung cancer.** Thomas U. Marron, New York, NY
- 1:24 p.m.** **The role of metabolites in aging, immunity, and cancer.** Marcia Haigis, Boston, MA
- 1:46 p.m.** **Intersection of tumorigenesis and aging-associated decline in lung regenerative potential.** Tuomas Tammela, New York, NY
- 2:08 p.m.** **Understanding the promotion of lung adenocarcinoma by air pollutants.** William Hill, London, United Kingdom

Room S401 - McCormick Place South (Level 4)

DNA Damage and Inflammation in the Development and Progression of Brain Cancer

Chair: Peter B. Dirks, Toronto, ON, Canada

- 1:00 p.m.** **Chair Introduction.** Peter B. Dirks, Toronto, ON, Canada
- 1:05 p.m.** **Axonal injury drives glioma initiation and progression.** Simona Parrinello, London, United Kingdom
- 1:30 p.m.** **Beyond the neuron: Role for Astrocytes and injury responses in glioblastoma.** Hyun-Kyoung Lee, Houston, TX
- 1:55 p.m.** **Injury-reprogramming at the root of gliomagenesis.** Peter B. Dirks, Toronto, ON, Canada

Room S403 - McCormick Place South (Level 4)

Immunotherapy and Precision Medicine in Hepatobiliary Cancer

Cochairs: Mark Yarchoan, Baltimore, MD; Sita Kugel, Seattle, WA

- 1:00 p.m.** **Introduction.** Sita Kugel, Seattle, WA; Mark Yarchoan, Baltimore, MD
- 1:05 p.m.** **Immunosurveillance regulates the landscape of somatic mosaicism and premalignancy in the liver.** Hao Zhu, Dallas, TX

- 1:30 p.m.** **Tertiary lymphoid structures and HCC: A window into neoadjuvant response.** Mark Yarchoan, Baltimore, MD
- 1:55 p.m.** **Subtype-specific vulnerabilities in cholangiocarcinoma.** Sita Kugel, Seattle, WA



ADVANCES IN POPULATION SCIENCES **1:00 p.m.–2:30 p.m.**

Room S105 - McCormick Place South (Level 1)

Emerging Environmental and Dietary Risk Factors for Cancer: Ultra-Processed Foods, Microplastics, and Per- and Polyfluoroalkyl Substances

Chair: Mingyang Song, Brookline, MA

- 1:00 p.m.** **Chair Introduction.** Mingyang Song, Brookline, MA
- 1:05 p.m.** **PFAS and cancer risks: Epidemiologic evidence to date and key knowledge gaps.** Mark P. Purdue, Bethesda, MD
- 1:30 p.m.** **Plastics in our lives, plastics in our bodies: what we know & what's next.** Roel Vermeulen, Utrecht, Netherlands
- 1:55 p.m.** **Ultra-processed foods and cancer risk: Epidemiologic insights.** Mingyang Song, Boston, MA



ADVANCES IN PREVENTION RESEARCH **1:00 p.m.–2:30 p.m.**

Room S405 - McCormick Place South (Level 4)

Subsequent Neoplasms in Survivors of Childhood Cancer: New Molecular Insights, Prediction and Intervention

Chair: Gregory T. Armstrong, Memphis, TN

- 1:00 p.m.** **Chair Introduction.** Gregory T. Armstrong, Memphis, TN

1:05 p.m. **New insights into underlying molecular mechanisms driving treatment-associated SMNs in survivors of childhood cancer.** Gregory T. Armstrong, Memphis, TN

1:30 p.m. **Not created equal: Developing individualized risk estimates and tailored follow-up of childhood cancer survivors.** David Hodgson, Toronto, ON, Canada

1:55 p.m. **Early surveillance and prevention of SMN: Identifying who, when and how.** Tara O. Henderson, Chicago, IL

1:05 p.m. **Harnessing the neoadjuvant window: Immunotherapy in breast cancer.** Elizabeth A. Mittendorf, Boston, MA

1:30 p.m. **Novel local treatment approaches to overcome the pancreatic cancer microenvironment.** Rebekah R. White, La Jolla, CA

1:55 p.m. **Stress and immunogenic cell injury, not immunogenic cell death, enhances the anti-tumor response to immune checkpoint blockade.** Michael B. Yaffe, Cambridge, MA



MAJOR SYMPOSIA

1:00 p.m.–2:30 p.m.

Room E451 - McCormick Lakeside Center (Level 4)

AACR-Bayard D. Clarkson Symposium: Cellular Plasticity and Heterogeneity in Cancer Progression and Resistance

Chair: Arjun Raj, Philadelphia, PA

1:00 p.m. **Introduction.** Arjun Raj, Philadelphia, PA

1:05 p.m. **Intra- and inter-tumoral heterogeneity in small-cell lung cancer progression and metastasis.** Julien Sage, Stanford, CA

1:30 p.m. **Epigenetic regulation of lineage plasticity in castration-resistant prostate cancer.** Michael M. Shen, New York, NY

1:55 p.m. **SY41-01 Do individual cancer cells learn to become therapy resistant?** Arjun Raj, Philadelphia, PA

Room S402 - McCormick Place South (Level 4)

Anti-Cancer Treatments at the Interface of Surgical and Medical Oncology

Chair: Michael B. Yaffe, Cambridge, MA

1:00 p.m. **Introduction: Novel cures at the crossroads of combined surgical and medical oncology.** Michael B. Yaffe, Cambridge, MA

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)

Science Policy Session

Cancer Research at a Crossroads: Sustaining Progress Against Cancer for the Benefit of Patients

NOT ELIGIBLE FOR CME CREDIT

Moderator: Clifton Leaf, New York, NY

Panelists: Monica M. Bertagnolli, Bethesda, MD; W. Kimryn Rathmell, Nashville, TN; Larry Saltzman, Sacramento, CA; Cody L. Wolf, Charlottesville, VA; E. John Wherry, Philadelphia, PA; Kristen Dahlgren, Cornwall, VT

Room S102 - McCormick Place South (Level 1)

ecDNA Amplifications and Genomic Rearrangements: Drivers, Pathology and Therapeutic Opportunities

Chair: Johnathan R. Whetstine, Philadelphia, PA

1:00 p.m. **Introduction.** Johnathan R. Whetstine, Philadelphia, PA

1:05 p.m. **Epigenetic mechanisms: A gateway to generating extrachromosomal DNA amplifications and rearrangements.** Johnathan R. Whetstine, Philadelphia, PA

1:30 p.m. **Cancer genes beyond chromosomes.** Howard Y. Chang, Stanford, CA

1:55 p.m. **The genomic and spatial mobility of extrachromosomal DNA (ecDNA) and its implications for cancer therapy.** Anton Georg Henssen, Berlin, Germany

Room E352 - McCormick Lakeside Center (Level 3)

Frontiers in Radiation-Based Multimodal Therapies: Mechanisms and Opportunities to Reshape Therapeutic Efficacy

Chair: Timothy A. Chan, Cleveland, OH

1:00 p.m. Invited Speaker. Timothy A. Chan, Cleveland, OH

1:05 p.m. SY37-01 Augmenting the therapeutic ratio by combining radiation therapy with inhibitors of the DNA damage response. Anthony Chalmers, Glasgow, United Kingdom

1:30 p.m. Genetic mechanisms shaping radiation and immunotherapy combinations. Timothy A. Chan, Cleveland, OH

1:55 p.m. SY37-02 Adapting radiotherapy to cancer immunotherapy. Silvia C. Formenti, New York, NY

Room E350 - McCormick Lakeside Center (Level 3)

Mechanisms Underlying Geographical and Temporal Differences in Cancer Incidence

Chair: Paul J. Brennan, Lyon, France

1:00 p.m. Introduction. Paul J. Brennan, Lyon, France

1:05 p.m. Causes of the wide global disparities of esophageal squamous cell cancer. Paul J. Brennan, Lyon, France

1:30 p.m. Mutational signature analysis provides clues to the exposures underlying recent increases in incidence of early onset colorectal cancer. Michael R. Stratton, Cambridge

1:55 p.m. Mechanisms underlying cancer susceptibility in gastrointestinal cancers in Asia: The role of dietary shifts and microbiome. Jun Yu, Hong Kong, China

Room E353 C - McCormick Lakeside Center (Level 3)

Mitochondrial Biology in Cancer

Chair: Navdeep S. Chandel, Chicago, IL

1:00 p.m. Introduction. Navdeep S. Chandel, Chicago, IL

1:05 p.m. SY27-01 Mitochondria function in normal and cancer cells. Navdeep S. Chandel, Chicago, IL

1:30 p.m. SY27-02 Exploring the significance of somatic mtDNA mutations in the context of acute leukemia. Mondira Kundu, Memphis, TN

1:55 p.m. Investigating consequences of pathogenic mtDNA mutations in human melanoma. Prashant Mishra, Dallas, TX

Room S404 - McCormick Place South (Level 4)

The Neuroscience of Cancer

Chair: Michelle Monje, Stanford, CA

1:00 p.m. Introduction. Michelle Monje, Stanford, CA

1:05 p.m. SY06-01 Neuronal regulation of brain cancers. Michelle Monje, Stanford, CA

1:30 p.m. Nociceptive neurons promote gastric tumor progression. Timothy C. Wang, New York, NY

1:55 p.m. Neuronal regulation of tumor immunity. Sébastien Talbot, Solna, Sweden

Room S103 - McCormick Place South (Level 1)

The Path to Cancer: The Interplay between Immunology and Somatic Evolution

Chair: Nicholas McGranahan, London, United Kingdom

1:00 p.m. Introduction. Nicholas McGranahan, London, United Kingdom

1:05 p.m. Pre-cancer atlas on fallopian tube precursors to ovarian high-grade serous carcinoma. Ronny I. Drapkin, Philadelphia, PA

1:30 p.m. Unlocking immunity: The role of neutrophils in BRCA-driven cancer initiation. Arianna Calcinotto, Bellinzona, Switzerland

1:55 p.m. Somatic evolution and immune evasion: From normal to cancer. Nicholas McGranahan, London, United Kingdom

Room E450 A - McCormick Lakeside Center (Level 4)

Tissue Mechanics and Physical Forces in Cancer

Chair: Melody A. Swartz, Chicago, IL

- 1:00 p.m.** **Introduction.** Melody A. Swartz, Chicago, IL
- 1:05 p.m.** **Title to be announced.** Melody A. Swartz, Chicago, IL
- 1:30 p.m.** **Forcing cancer initiation and progression through myeloid lipid peroxidation-mediated DNA damage.** Valerie M. Weaver, San Francisco, CA
- 1:55 p.m.** **SY42-01 Targeting fluidic force sensing mechanism to treat brain tumor metastasis.** Xi Huang, Toronto, ON, Canada

Room S106 - McCormick Place South (Level 1)

Regulatory Science and Policy Session

What Defines the Gold Standard for Validating Blood-based Cancer Tests?

NOT ELIGIBLE FOR CME CREDIT

Moderators: Christina A. Clarke Dur, Menlo Park, CA; Bree L. Mitchell, San Carlos, CA

Speakers and Panelists: Elliot Fishman, San Carlos, CA; Earl Hubbell, San Carlos, CA; Sana Raoof, New York, NY

SPECIAL SESSION

1:00 p.m.–2:30 p.m.

Room S406 (Vista Ballroom) - McCormick Place South (Level 4)

New Drugs on the Horizon: Part 1

NOT ELIGIBLE FOR CME CREDIT

Cochairs: Lori S. Friedman, South San Francisco, CA; Daniel K. Nomura, Berkeley, CA

- 1:00 p.m.** **Chair Introduction.** Lori S. Friedman, South San Francisco, CA
- 1:05 p.m.** **ND01 AMG 410: An H/NRAS-sparing pan-KRAS inhibitor with dual GTP(on)/GDP(off)-state activity for the treatment of diverse KRAS-mutant tumors.** Brian A. Lanman, Thousand Oaks, CA

- 1:25 p.m.** **ND02 GDC-2992: A heterobifunctional Androgen Receptor (AR) antagonist and degrader for the treatment of AR wild-type and mutant prostate cancer.** Ciara Metcalfe, South San Francisco, CA

- 1:45 p.m.** **ND03 ABBV-969: A first-in-class dual-targeting PSMA-STEAP1 drug conjugate for the treatment of metastatic castrate-resistant prostate cancer.** Regina M. Reilly, North Chicago, IL

- 2:05 p.m.** **ND04 ABP-102/CT-P72: a novel HER2 x CD3 T cell engager with selective activity for HER2-overexpressing tumors and reduced activity on cells with normal HER2 expression levels.** Adam Pelzek, Woburn, MA

- 2:25 p.m.** **Closing Remarks.** Daniel K. Nomura, Berkeley, CA



MAJOR SYMPOSIUM

1:00 p.m.–2:45 p.m.

Room E450 B - McCormick Lakeside Center (Level 4)

Fusion Oncoprotein-driven Malignancies: From Mechanisms to Therapies

Chair: Kimberly Stegmaier, Boston, MA

- 1:00 p.m.** **Introduction.** Kimberly Stegmaier, Boston, MA
- 1:05 p.m.** **Exploiting fusion oncoproteins toward novel therapies.** Kimberly Stegmaier, Boston, MA
- 1:25 p.m.** **The biology and therapeutic vulnerability of the ZFTA-RELA fusion.** Richard J. Gilbertson, Cambridge, United Kingdom
- 1:45 p.m.** **SY34-01 Developmental dependency and metabolic vulnerabilities in NUP98-rearranged pediatric leukemia.** Elvin Wagenblast, New York, NY
- 2:05 p.m.** **SY34-02 Developing therapeutics for cancers driven by fusion proteins: Lessons from fibrolamellar carcinoma.** Sanford M. Simon, New York, NY
- 2:25 p.m.** **Targeting the NUP98 fusion oncoprotein interactome.** Charles G. Mullighan, Memphis, TN



CLINICAL TRIALS PLENARY SESSION

1:00 p.m.–3:00 p.m.

Arie Crown Theater - McCormick Lakeside Center (Level 2)

Advances in Immunotherapy

Cochairs: Jayesh Desai, Melbourne, Australia; Antoni Ribas, Los Angeles, CA

- 1:00 p.m.** **CT001 Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Phase 3 KEYNOTE-689 study.** Ravindra Uppaluri, Boston, MA
- 1:15 p.m.** **Discussant.** Robert L. Ferris, Pittsburgh, PA
- 1:30 p.m.** **CT002 Circulating tumor DNA status to direct adjuvant immunotherapy for mismatch repair deficient tumors.** Yelena Yuriy Janjigian, New York, NY
- 1:45 p.m.** **Discussant.** Maximilian Diehn, Stanford, CA
- 2:00 p.m.** **CT003 Non operative management of mismatch repair deficient tumors.** Andrea Cercek, New York, NY
- 2:15 p.m.** **Discussant.** Michael J. Overman, Houston, TX
- 2:30 p.m.** **CT004 KEYLYNK-007: Tumor agnostic trial of olaparib plus pembrolizumab in homologous recombination repair mutation- and homologous recombination deficiency- positive advanced cancers.** Timothy A. Yap, Houston, TX
- 2:45 p.m.** **Discussant.** Pamela N. Munster, San Francisco, CA

MEET AND GREET SESSION

1:15 p.m.–2:45 p.m.

NOT ELIGIBLE FOR CME CREDIT

Hall A - McCormick Place South (Level 3)

MICR Meet and Greet

Chair: Melissa B. Davis, Atlanta, GA

MEET AND GREET SESSION

1:30 p.m.–3:00 p.m.

NOT ELIGIBLE FOR CME

Hall A - McCormick Place South (Level 3)

WICR Meet and Greet

Chair: Shiva Malek, Cambridge, MA

MEET AND GREET SESSION

2:00 p.m.–3:00 p.m.

NOT ELIGIBLE FOR CME

AACR Publications Booth 2615 - South Halls A1-2

Meet the Editors-in-Chief of *Cancer Discovery*:
Lewis C. Cantley and Luis A. Diaz, Jr.

POSTER SESSION

2:00 p.m.–5:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Hall A1-2, McCormick Place South

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

Tumor Biology

- Section 1 Cancer Stem Cells
- Section 2 Human and PDX Models 1
- Section 3 Imaging in Animal Models
- Section 4 Molecular Regulation of Metastasis
- Section 5 Stem Cells, Development, and Cancer
- Section 6 The Structural Tumor Microenvironment and Integrin Interactions in Cancer
- Section 7 Where's Waldo: Spatial Complexity of the Tumor Microenvironment 1
- Section 53 Late-Breaking Research: Tumor Biology 1

Molecular/Cellular Biology and Genetics

- Section 8 Cell Signaling and Tumor-Stroma Cell Interactions
- Section 9 Comprehensive Multiomic Profiling of Chromatin Dynamics, DNA Methylation, and Tumor Microenvironments
- Section 10 Growth Factors, Receptors, and GTPase Signaling
- Section 11 Mechanisms of Oncogenesis and Tumor Suppression
- Section 12 Metabolomics
- Section 13 Senescence
- Section 52 Late-Breaking Research: Molecular/Cellular Biology and Genetics 1

Experimental and Molecular Therapeutics

- Section 15 Antireceptors and Other Biological Therapeutic Agents
- Section 16 Biochemical Modulators of Cancer / Differentiation Therapeutic Strategies
- Section 17 Cell Cycle Effects of Anticancer Drugs
- Section 18 Degradors and Glues 1
- Section 19 Drug Resistance in Molecular Targeted Therapies 1
- Section 20 Epigenetic Targets
- Section 21 Gene and Vector-Based Therapy
- Section 22 Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes
- Section 23 Repurposing New and Existing Drugs for Cancer Treatment
- Section 24 Reversal of Drug Resistance 1
- Section 25 Theranostics and Radiotheranostics
- Section 50 Late-Breaking Research: Experimental and Molecular Therapeutics 1

Chemistry

- Section 26 Natural Products

Clinical Research

- Section 27 Cancer Care for All: Innovations in Geriatric Oncology and Broadening Research Representation
- Section 28 Combination Immunotherapies
- Section 29 Diagnostic Biomarkers 2

- Section 30 Precision Medicine in Pediatric Cancer
- Section 31 Predictive Biomarkers 2
- Section 32 Spatial Proteomics and Transcriptomics 1
- Section 33 Survivorship Research and Supportive Care
- Section 34 Targeted Therapies and Combinations 1
- Section 35 Vaccines and Cell Therapies

Immunology

- Section 37 NK Cells and Innate Immunity
- Section 38 Tumor-induced Immune Suppression: Intrinsic and Extrinsic Factors
- Section 39 Virology and Cancer
- Section 40 Viruses and Bacteria in Cancer Therapy
- Section 51 Late-Breaking Research: Immunology 1

Population Sciences

- Section 41 Bridging Gaps in Cancer Care: Disparities, Social Determinants, Innovations, and Strategies
- Section 42 Genomic Diversity and Disparities in Cancer: Global Insights into Epidemiology, Risk, Outcomes, and Precision Medicine

Prevention, Early Detection, and Interception

- Section 43 Behavioral Sciences and Prevention, Screening, and Early Detection

Bioinformatics, Computational Biology, Systems Biology, and Convergent Science

- Section 45 Bioinformatics, Computational Biology, and Systems Biology for Healthcare Equity
- Section 46 Database Resources
- Section 47 Tumor Subtypes and Biomarker Discovery

Multidisciplinary: AACR Project GENIE

- Section 48 AACR Project GENIE Use Cases

**AWARD LECTURE****3:00 p.m.–3:45 p.m.**

Room S102 - McCormick Place South (Level 1)

AACR Award for Lifetime Achievement in Cancer Research**Chair:** Kornelia Polyak, Brookline, MA**Normalizing the tumor microenvironment to improve cancer treatment: Bench to bedside and back.** Rakesh K. Jain, Boston, MA**MEET AND GREET SESSION****3:00 p.m.–4:00 p.m.****NOT ELIGIBLE FOR CME CREDIT**

AACR Publications Booth 2615 - South Halls A1-2

Meet the Editors-in-Chief of *Cancer Research Communications*:

Elaine R. Mardis and Lillian L. Siu

SPECIAL SESSION**3:00 p.m.–4:30 p.m.****NOT ELIGIBLE FOR CME CREDIT**

Room S406 (Vista Ballroom) - McCormick Place South (Level 4)

New Drugs on the Horizon: Part 2**Cochairs:** Danette L. Daniels, Cambridge, MA; Jennifer C. Petter, Waltham, MA**3:00 p.m. Chair Introduction.** Danette L. Daniels, Cambridge, MA**3:05 p.m. ND05** The discovery of BMS-986449, a highly potent and selective degrader of the transcription factors Helios (IKZF2) and Eos (IKZF4) for the treatment of solid tumors. Aaron Balog, Princeton, NJ**3:25 p.m. ND06** Discovery of RMC-5127, an oral, RAS (ON) G12V-selective, noncovalent, tri-complex inhibitor. Anne Edwards, Redwood City, CA**3:45 p.m. ND07** FXX489, a FAP targeting ligand with best-in-class potential for radioligand therapy. Alexei Karpov, Basel, Switzerland**4:00 p.m. ND07** FXX489, a FAP targeting ligand with best-in-class potential for radioligand therapy. Markus Reschke, Basel, Switzerland**4:05 p.m. ND08** FAP-LTBR (RO7567132): A first-in-class bi-specific stromal immunomodulatory agonist designed to enable and enhance efficacy of cancer immunotherapies. Meher Majety, Basel, Switzerland**4:25 p.m. Closing Remarks.** Jennifer C. Petter, Waltham, MA**MINISYMPOSIUM****3:00 p.m.–4:45 p.m.**

Room E450 A - McCormick Lakeside Center (Level 4)

Clinical Research**Real-World Evidence: Clinico-genomics, Clinical Informatics, and Data Science****Cochairs:** Joseph Christopher Murray, Baltimore, MD; Janice M. Mehnert, New York, NY**3:00 p.m. Introduction.** Joseph Christopher Murray, Baltimore, MD**3:05 p.m. 1151** NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in PDAC. Alison M. Schram, New York, NY**3:20 p.m. 1152** The landscape of copy number variations following WGD in 5,980 colorectal cancers. Jierui Xu, New York, NY**3:35 p.m. 1153** Large-scale genomic profiling of colorectal cancer. Axel Grothey, Germantown, TN**3:50 p.m. 1154** SCRUM-Japan MONSTAR-SCREEN-3: A large-scale multi-institutional prospective study platform integrating spatial transcriptomics and multi-omics analysis for comprehensive understanding of tumor microenvironment dynamics. Mitsuho Imai, Kashiwanoha, Japan

- 4:05 p.m.** **1155** Highly CNS-penetrant tyrosine kinase inhibitors improve leptomeningeal overall survival in NSCLC patients with leptomeningeal disease. Xiuning Le, Houston, TX
- 4:20 p.m.** **1157** Investigating the clinical landscape and biological impact of SF3B1 hotspot mutations in breast cancer. Riley Bergman, Nashville, TN
- 4:35 p.m.** **Closing Remarks.** Janice M. Mehnert, New York, NY



CLINICAL TRIALS MINISYMPOSIUM 3:00 p.m.–5:00 p.m.

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)

ADCs and Immunooncology-focused Biological Approaches

Cochairs: Jia Liu, Sydney, Australia; Michael Cecchini, New Haven, CT

- 3:00 p.m.** **Chair Introduction.** Jia (Jenny) Liu, Sydney, Australia
- 3:05 p.m.** **CT008** First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors. Shun Lu, Shanghai, China
- 3:20 p.m.** **CT009** SHR-A1811, a HER2-directed antibody-drug conjugate (ADC), in advanced HER2-mutant non-small cell lung cancer (NSCLC): Updated phase 2 results from HORIZON-Lung. Shun Lu, Shanghai, China
- 3:35 p.m.** **CT010** Phase I dose-escalation and expansion study of JS107, a claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC), as monotherapy or in combination for patients (pts) with advanced solid tumors. Dan-Yun Ruan, Guangzhou, China
- 3:50 p.m.** **CT011** Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304). Aditya Shreenivas, Los Angeles, CA

- 4:05 p.m.** **CT012** Personalized neoantigen vaccine with or without pembrolizumab in patients with microsatellite-stable metastatic colorectal cancer. Saurav Daniel Haldar, Houston, TX
- 4:20 p.m.** **CT013** Phase I trial evaluating BNT116, a TAA-encoding mRNA vaccine, in combination with cemiplimab in frail patients with advanced non-small cell lung cancer (NSCLC). Rafal Dziadziuszko, Gdansk, Poland
- 4:35 p.m.** **CT014** First-in-human, multicenter study of SENTI-202, a CD33/FLT3 selective off-the-shelf logic gated CAR NK cell therapy in hematologic malignancies including AML: Clinical data. Stephen A. Strickland, Nashville, TN
- 4:50 p.m.** **Closing Remarks.** Michael Cecchini, New Haven, CT



LATE-BREAKING MINISYMPOSIUM 3:00 p.m.–4:45 p.m.

Room S403 - McCormick Place South (Level 4)

Minisymposium: Late-Breaking Research

Chair: W. Kimryn Rathmell, Nashville, TN

- 3:00 p.m.** **Introduction.** W. Kimryn Rathmell, Nashville, TN
- 3:05 p.m.** **LB087** Inferring single-cell spatial gene expression with tissue morphology via explainable deep learning. Sheng Li, Los Angeles, CA
- 3:20 p.m.** **LB088** MS-CETSA deep functional proteomics uncovers a new induced DNA-repair programs leading to resistance to DNA-damaging drugs. Pär Nordlund, Stockholm, Sweden
- 3:35 p.m.** **LB089** Exploring androgen receptor alterations (ARa) and their potential association with efficacy of first-line (1L) talazoparib (TALA) + enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): A post hoc analysis of TALAPRO-2. Glenn Liu, Madison, WI

- 3:50 p.m.** **LB091** T cell targeted lentiviral gene delivery using the PACK-IT Platform generates CAR-T cells with superior potency compared to conventional lentivirus and enables in vivo generation of CD19-CAR T cells capable of controlling leukemia in preclinical models. Kylie A. Burdsall, Stanford, CA
- 4:05 p.m.** **LB092** Decoding tumor cell dynamics driven by mutant TP53 gain-of-function activity in squamous cell carcinoma metastasis. Gizem Efe, New York, NY
- 4:20 p.m.** **LB093** Circadian misalignment between cancer cells and immune cells drives immune escape. Chuqian Liang, Boston, MA
- 4:35 p.m.** **Closing Remarks.** W. Kimryn Rathmell, Nashville, TN

MAJOR SYMPOSIUM

3:00 p.m.–5:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Room S402 - McCormick Place South (Level 4)

Science Policy Session

**Patient Advocate Poster Symposium:
Community Outreach and Engagement**

Chair: Patricia Spears, Raleigh, NC

- 3:05 p.m.** **Patient and Community Engagement Programs at NCI-Designated Cancer Centers: Improving patient care.** Electra D. Paskett, Columbus, OH
- 3:20 p.m.** **Cancer research advocates: Satisfaction, frustration, and opportunities.** Bob Riter, Ithaca, NY
- 3:45 p.m.** **ACCESS: Advancing childhood cancer experience, science and survivorship in Canada.** Christine J. Williams, Toronto, ON, Canada
- 4:10 p.m.** **SCHEQ Lung Cancer Health Equity Summit Learnings: Building a community to address disparities.** Rochelle Prosser, Miami, FL
- 4:35 p.m.** **The Bench with Bedside Initiative™: An unconventional collaborative approach between scientists and research participants.** Bodour Salhia, Los Angeles, CA

- 4:50 p.m.** **The Bench with Bedside Initiative™: An unconventional collaborative approach between scientists and research participants.** Audrey Saghian, Los Angeles, CA



MINISYMPOSIA

3:00 p.m.–5:00 p.m.

Room S103 - McCormick Place South (Level 1)

**Bioinformatics, Computational Biology, Systems Biology, and Convergent Science
Artificial Intelligence and Machine Learning for Basic and Translational Research**

Cochairs: Samantha J. Riesenfeld, Chicago, IL; Paul T. Spellman, Los Angeles, CA

- 3:00 p.m.** **Introduction.** Samantha J. Riesenfeld, Chicago, IL
- 3:05 p.m.** **1138 Decoding tumor microenvironment with deep learning: merging spatial transcriptomics and histopathology.** Jiarong Song, Duarte, CA
- 3:20 p.m.** **1139 Massive scale phenotypic screening using generative chemogenomics repurposes safe drugs and discovers new drugs for intercepting early-stage lung adenocarcinoma progression.** Abhilasha Sinha, New York, NY
- 3:35 p.m.** **1140 Digital twins for in vivo metabolic flux estimations in brain cancer patients.** Baharan Meghdadi, Ann Arbor, MI
- 3:50 p.m.** **1141 Improved diagnosis of non-melanoma skin cancer in resource-limited settings.** Steven Song, Chicago, IL
- 4:05 p.m.** **1143 Reliable skeletal muscle area quantification and clinical data integration for predicting cancer cachexia.** Sabeen Ahmed, Tampa, FL
- 4:20 p.m.** **1142 Non-invasive cell free DNA (cfDNA) methylation profiling for accurate proportional quantification of lung cancer subtypes.** William Greenleaf, Stanford, CA
- 4:35 p.m.** **6365 A novel methylation-based classifier to identify cancer signal of origin using blood based testing.** William Greenleaf, Stanford, CA
- 4:50 p.m.** **Closing Remarks.** Paul T. Spellman, Los Angeles, CA

Room E451 - McCormick Lakeside Center (Level 4)

Clinical Research

Liquid Biopsy: Circulating Tumor Cells

Cochairs: Klaus Pantel, Hamburg, Germany; Catherine Alix-Panabières, Clapiers, France

- 3:00 p.m.** **Introduction.** Klaus Pantel, Hamburg, Germany
- 3:05 p.m.** **1144 Development of imaging mass cytometry (IMC) as a tool to characterize circulating tumor cells (CTCs) in pre-clinical mouse models.** Milind Pore, Frederick, MD
- 3:20 p.m.** **1145 Morphological evaluation of chromosomal instability in circulating tumor cells and prediction of taxane resistance in metastatic prostate cancer: a prespecified sub-analysis of the CARD trial.** Ossian Longoria, London, United Kingdom
- 3:35 p.m.** **1146 Identification of genetic mutations using circulating tumor cells, circulating tumor DNA, and exosomes in patients with colorectal cancer.** Koki Hayashi, Tokyo, Japan
- 3:50 p.m.** **1147 Development of a novel assay to detect circulating tumor cells in the cerebrospinal fluid of patients with leptomeningeal disease.** Laura A. Huppert, San Francisco, CA
- 4:05 p.m.** **1148 Longitudinal monitoring of circulating tumor cell burden and single-cell RNA profiling in ALK-positive NSCLC patients.** Yuru Chen, Ann Arbor, MI
- 4:20 p.m.** **1149 Circulating tumor cells bind to leukocytes to promote metastasis formation in breast cancer.** David Scholten, Chicago, IL
- 4:35 p.m.** **1150 Fluorescent dCFPyL (GUL-Cy5) for detecting circulating tumor and immune cells containing cancer extracellular vesicles in early metastatic prostate cancer prognostication.** Omar Alawamry, Toronto, ON, Canada
- 4:50 p.m.** **Closing Remarks.** Catherine Alix-Panabières, Clapiers, France

Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)

Experimental Therapeutics

Antibody-Based Cancer Therapeutic Agents

NOT ELIGIBLE FOR CME CREDIT

Cochairs: Mythili Shastri, Nashville, TN; Giuseppe Curigliano, Milan, Italy

- 3:00 p.m.** **Introduction.** Mythili Shastri, Nashville, TN
- 3:05 p.m.** **1158 Preclinical characterization of AZD0516, a novel STEAP2 antibody-drug conjugate (ADC) for the treatment of prostate cancer.** Darlene Monlish, Gaithersburg, MD
- 3:20 p.m.** **1159 Preclinical characterization of a novel STEAP1 antibody-drug conjugate ADRX-0405 for the treatment of mCRPC.** Sabine Rottmann, San Diego, CA
- 3:35 p.m.** **1160 Debio 1562M, a 2nd generation ADC targeting CD37, shows high potency against AML and MDS and safe toxicological profile for future clinical development.** Lisa Ivanschitz, Lausanne, Switzerland
- 3:50 p.m.** **1161 A systematic evaluation of off-target binding in antibody-based biologics during clinical and preclinical development.** Alexander Hobby, Philadelphia, PA
- 4:05 p.m.** **1162 In silico optimized Na.m.PT inhibitor for targeted delivery by antibody drug conjugates as novel therapeutic modality for treatment of liquid and solid malignancies.** Pablo Ruedas Batuecas, Ladenburg, Germany
- 4:20 p.m.** **1163 Preclinical investigation of ADCT-242, a novel exatecan-based antibody drug conjugate targeting Claudin-6, as single agent or in combination in ovarian and non-small lung cancer models.** Chris Pickford, London, United Kingdom
- 4:35 p.m.** **1164 SOT106, a novel best-in-class antibody-drug conjugate targeting LRRC15, to treat sarcomas and other advanced solid cancers.** Michaela Fojtu, Prague, Czech Republic
- 4:50 p.m.** **Closing Remarks.** Giuseppe Curigliano, Milan, Italy

Room S401 - McCormick Place South (Level 4)

Experimental Therapeutics

Molecular Targets for Overcoming Resistance

Cochairs: Kenneth P. Nephew, Bloomington, IN; Melissa L. Fishel, Indianapolis, IN

- 3:00 p.m.** **Introduction.** Kenneth P. Nephew, Bloomington, IN
- 3:05 p.m.** **1165 The landscape of molecular targets across 665 next-generation cancer models in the human cancer models initiative identifies opportunities for improved therapy and overcoming resistance.** Dina ElHarouni, Boston, MA
- 3:20 p.m.** **1166 Lurbinectedin synergizes with selinexor by inhibiting DNA damage repair and enhancing immune cell infiltration in neuroendocrine lung and prostate tumors.** Esther Redin, New York, NY
- 3:35 p.m.** **1167 Targeting DNA repair pathways in PDAC: APE1 BER and its therapeutic role in PDAC homeostasis.** Eyram K. Kpenu, Indianapolis, IN
- 3:50 p.m.** **1168 ADAR1 synthetic lethality in BRCA1/2-mutant tumors defines autocrine interferon poisoning as a targetable vulnerability of cancer cells.** Roman M. Chabanon, Villejuif, France
- 4:05 p.m.** **1169 FAT1 alterations contribute to chromosomal instability in cancer cells.** Wei-ting Lu, London, United Kingdom
- 4:20 p.m.** **1170 Decitabine (DAC) induces a DNA damage response (DDR) and synergizes with replication checkpoint inhibitors in acute myeloid leukemia (AML).** Clifford M. Csizmar, Rochester, MN
- 4:35 p.m.** **495 Impact of lineage plasticity on regulating target expression for antibody-drug conjugate therapy in urothelial bladder cancer.** Jiaqian Luo, New York, NY
- 4:50 p.m.** **Closing Remarks.** Melissa L. Fishel, Indianapolis, IN

Room S404 - McCormick Place South (Level 4)

Immunology

Overcoming Tumor Immune Suppression

Cochairs: Yuxuan Phoenix Miao, Chicago, IL; Benjamin D. Greenbaum, New York, NY

- 3:00 p.m.** **Introduction.** Yuxuan Phoenix Miao, Chicago, IL
- 3:05 p.m.** **1172 An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancer.** Kenichi Shimada, Boston, MA
- 3:20 p.m.** **1173 Desaminotyrosine contributes to the anticancer effect of fecal microbial transplantation during immune checkpoint blockade in mice and patients.** Simon Thomas, Villejuif, France
- 3:35 p.m.** **1174 Examining antitumorigenic effects of Ruminococcus gnavus.** Yue Zhang, Pittsburgh, PA
- 3:50 p.m.** **1175 Exercise-induced microbial vitamin B9 metabolite drives CD8 T cell antitumor immunity and promotes ICI efficacy in preclinical melanoma.** Catherine M. Phelps, Pittsburgh, PA
- 4:05 p.m.** **1176 Myeloid-specific disruption of $\alpha 2,6$ -linked sialic acid enhances their regulatory and tumorigenic functions by unmasking Gal-1 specific ligands.** Joaquin P. Merlo, Buenos Aires, Argentina
- 4:20 p.m.** **1177 Tumor-associated macrophages and clinical outcomes to immunotherapy.** Marie Morfouace, Villejuif, France
- 4:35 p.m.** **1178 In vivo, visualization of immune cell dynamics upon the arrival of liver metastatic cells reveals the initiation of initial intravascular immune responses against pioneering tumor cells.** Alvaro Teixeira, Pamplona, Spain
- 4:50 p.m.** **Closing Remarks.** Benjamin D. Greenbaum, New York, NY

Room E352 - McCormick Lakeside Center (Level 3)

Molecular/Cellular Biology and Genetics

Gene Regulation and Transcription Factors

Cochairs: Ming Chen, Durham, NC; Alejandro Sweet-Cordero, San Francisco, CA

- 3:00 p.m. Introduction.** Ming Chen, Durham, NC
- 3:05 p.m. 1179 Epigenetic subtypes and cellular plasticity are driven by an interplay between RUNX2 and FOSL1 in osteosarcoma.** Eunice Lopez Fuentes, San Francisco, CA
- 3:20 p.m. 1180 Epigenetic dysregulation of IGF1 and PPARG2 in dedifferentiated liposarcoma.** Erica Maria Pimenta, Boston, MA
- 3:35 p.m. 1181 Combined inhibition of KAT6 and menin reverses estrogen receptor-driven gene expression programs in breast cancer.** Sarah Naomi Olsen, Boston, MA
- 3:50 p.m. 1182 Modulating splicing of NELFE as a therapeutic strategy for hepatocellular carcinoma.** Laura M. Reynolds, Philadelphia, PA
- 4:05 p.m. 1183 Non-canonical RNA binding of the MYBL2 transcription factor promotes melanoma.** Kaizhen Wang, Tampa, FL
- 4:20 p.m. 1184 Studying circadian disruption in pancreatic ductal adenocarcinoma.** Ksenija Korac, Madison, WI
- 4:35 p.m. 1185 Phosphorylation of the MYC oncoprotein disrupts the direct interaction of MYC with the ASF1A histone chaperone.** Linda Z. Penn, Toronto, ON, Canada
- 4:50 p.m. Closing Remarks.** Alejandro Sweet-Cordero, San Francisco, CA

Room E351 - McCormick Lakeside Center (Level 3)

Molecular/Cellular Biology and Genetics

microRNAs and Other Noncoding RNAs

Cochairs: Yaguang Xi, Athens, GA; Aurora Esquela Kerscher, Norfolk, VA

- 3:00 p.m. Introduction.** Yaguang Xi, Athens, GA
- 3:05 p.m. 1186 microRNA-targeted small molecule inhibitors in metastatic cancers.** Maria-Ancuta Jurj, Houston, TX
- 3:20 p.m. 1187 An integrated DNA interactome and transcriptome profiling reveals a PU.1/enhancer RNA-mediated feedforward regulatory loop regulating myeloid cell function and leukemia relapse.** Asm Waliullah, Charlottesville, VA
- 3:35 p.m. 1188 Understanding the malignant properties of early-stage lung adenocarcinoma through oncofetal IGF2BP3-mediated miRNA structural diversity.** Naoto Tsuchiya, Tokyo, Japan
- 3:50 p.m. 1189 MYB-driven extracellular vesicle-associated microRNAs in pancreatic cancer: potential significance in pathobiology and biomarker development.** Shashi Anand, Jackson, MS
- 4:05 p.m. 1190 Discovery of novel compounds selectively targeting LIN28 to modulate let-7 expression and exhibit anticancer activity in LIN28 positive tumors.** Myongjae Lee, Seoul, Republic of Korea
- 4:20 p.m. 1191 Epstein-Barr virus IncBARTs interact with BRD4 and CTCF complex to regulate EBV latent replication and promote EBV-associated oncogenesis.** Jiayan Liu, Hong Kong, China
- 4:35 p.m. 1192 Selective sorting of tumor suppressive and oncogenic miRNAs into extracellular vesicles: Implications for cancer progression.** Samira Piltan, West Lafayette, IN
- 4:50 p.m. Closing Remarks.** Aurora Esquela Kerscher, Norfolk, VA

Room E353 C - McCormick Lakeside Center (Level 3)

Tumor Biology

Advancing the Science of Childhood Cancers: From Bench to Bedside

Cochairs: Sharon Castellino, Atlanta, GA; Pratiti Bandopadhyay, Boston, MA

- 3:00 p.m.** **Introduction.** Sharon Castellino, Atlanta, GA
- 3:05 p.m.** **1200 FET fusion oncoproteins disrupt physiologic DNA repair and create a targetable opportunity for ATR inhibitor therapies.** Asmin Tulpule, New York, NY
- 3:20 p.m.** **1201 The PLK4 inhibitor RP-1664 drives centriole modulation and single agent tumor regressions in preclinical neuroblastoma models.** John M. Maris, Philadelphia, PA
- 3:35 p.m.** **1202 Molecular profiles and drug response of ITCC-P4 patient-derived xenograft pediatric cancer models for target identification and prediction of targeted therapies.** Dennis Grger, Berlin, Germany
- 3:50 p.m.** **1203 The structural variation landscape of pediatric cancer.** Robert Greenhalgh, Memphis, TN
- 4:05 p.m.** **1204 Very high throughput genome sequencing for pediatric cancers in France.** Birgit Geoerger, Villejuif, France
- 4:20 p.m.** **1205 Diverse mechanisms of therapy resistance in relapsed childhood B-cell acute lymphoblastic leukemia (B-ALL): a report from the Children's Oncology Group.** Xiaotu Ma, Memphis, TN
- 4:35 p.m.** **1206 The molecular characterization initiative: Nationwide comprehensive clinical profiling of pediatric solid tissue malignancies at scale.** Elaine R. Mardis, Columbus, OH
- 4:50 p.m.** **Closing Remarks.** Pratiti Bandopadhyay, Boston, MA

Room S106 - McCormick Place South (Level 1)

Tumor Biology

The Stromal-Immune Interplay in Cancer Progression

Cochairs: Yash Chhabra, Philadelphia, PA; Xue-Yan He, St. Louis, MO

- 3:00 p.m.** **Introduction.** Yash Chhabra, Philadelphia, PA
- 3:05 p.m.** **1207 The evolution of immunity and immune evasion from early- to end-stage lung cancer.** Sonya Hessey, London, United Kingdom
- 3:20 p.m.** **1208 The neuroimmune impact of chronic stress on triple-negative breast cancer.** Runhua Liu, Birmingham, AL
- 3:35 p.m.** **1209 A novel vascularized tumor-on-a-chip model for tracking melanoma-dendritic cell interactions following combined romidepsin and type I IFN therapy.** Lucia Gabriele, Rome, Italy
- 3:50 p.m.** **1210 Modeling clonal hematopoiesis of indeterminate potential (CHIP) in solid tumors: genotype-specific effects on tumor growth and immune microenvironment.** Sarah C. Reed, Nashville, TN
- 4:05 p.m.** **1211 Sexual dimorphism in macrophage phagocytosis limits immune checkpoint inhibitor efficacy in pancreatic ductal adenocarcinoma.** Zihan Chen, Atlanta, GA
- 4:20 p.m.** **1212 Disruption of G α s/cAMP-mediated acid sensing by breast tumor cells blunts tumor-induced immune suppression and decreases bone metastases by enhancing cytotoxic T cell function.** Kaylee M. O'Donnell, St. Louis, MO
- 4:35 p.m.** **1213 Immune aging impedes intratumoral T-cell activity to reduce response to therapy in triple negative breast cancer.** Milos Spasic, Boston, MA
- 4:50 p.m.** **Closing Remarks.** Xue-Yan He, St. Louis, MO

**MINISYMPOSIUM****3:00 p.m.–5:15 p.m.**

Room S405 - McCormick Place South (Level 4)

Population Sciences**The Impact of Disparities and Lifestyle Choices on Cancer Risks and Outcomes****Cochairs:** Mingyang Song, Brookline, MA; Alison M. Mondul, Ann Arbor, MI

- 3:00 p.m.** **Introduction.** Mingyang Song, Brookline, MA
- 3:05 p.m.** **1193 Allostatic load and risk of colorectal cancer in a multi-ethnic Asian cohort.** Adeline Seow, Singapore, Singapore
- 3:20 p.m.** **1194 Oral contraceptive use and risk of liver cancer: A prospective analysis in over 1.5 million women and systematic review and meta-analysis of observational studies.** Cody Z. Watling, Rockville, MD
- 3:35 p.m.** **1195 Measuring the biological effects of structural racism on aging and cancer outcomes in the U.S.** Brittany D. Jenkins, Baltimore, MD
- 3:50 p.m.** **1196 Race-specific genetic and immunologic insights into colorectal cancer among Hawaiians.** Yuanyuan Fu, Honolulu, HI
- 4:05 p.m.** **1197 Association of increasing alcohol intake over the lifetime with colorectal adenoma and colorectal cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.** Kathryn Hughes Barry, Baltimore, MD
- 4:20 p.m.** **1198 Global analysis of incidence and mortality trends in early-onset and later-onset cancers.** Miyu Terashima, Okayama, Japan
- 4:35 p.m.** **1199 Global cancers attributable to modifiable risk factors: Current and former smoking prevalence.** Veer Shah, New York, NY
- 4:50 p.m.** **1214 Higher risk of adverse pregnancy outcomes among racial and ethnic minority women with cancer in the United States.** Duke Appiah, Lubbock, TX
- 5:05 p.m.** **Closing Remarks.** Alison M. Mondul, Ann Arbor, MI

**AWARD LECTURE****3:15 p.m.–4:00 p.m.**

Room E450 B - McCormick Lakeside Center (Level 4)

AACR James S. Ewing-Thelma B. Dunn Award for Outstanding Achievement in Pathology in Cancer Research**Chair:** Kurt A. Schalper, New Haven, CT**Cancer genomics: Diagnostics and targeted therapy.** Matthew L. Meyerson, Boston, MA**CLINICAL TRIALS PLENARY SESSION****3:30 p.m.–5:30 p.m.**

Arie Crown Theater - McCormick Lakeside Center (Level 2)

New Frontiers in Precision Oncology**Cochairs:** Ryan B. Corcoran, Boston, MA; Elena Elimova, Toronto, ON, Canada

- 3:30 p.m.** **CT016 First-in-human (FIH) phase 1 trial of the oral first-in-class covalent Werner helicase (WRN) inhibitor RO7589831 in patients with microsatellite instable (MSI) and/or mismatch repair deficient (dMMR) advanced solid tumors.** Timothy A. Yap, Houston, TX
- 3:45 p.m.** **Discussant.** Mathew Garnett, Cambridge, MA
- 4:00 p.m.** **CT017 A phase I study evaluating safety, pharmacokinetics, and clinical activity of the novel, paradox breaker BRAF inhibitor RG6344 in patients with BRAF V600-mutant solid tumors.** Maria Vieito, Barcelona, Spain
- 4:15 p.m.** **Discussant.** Rona Yaeger, New York, NY
- 4:30 p.m.** **CT018 A double-blind placebo-controlled randomized phase 2 clinical trial to assess the efficacy of a topical BRAF inhibitor for acneiform rash toxicities from anti-EGFR therapies.** Anisha B. Patel, Houston, TX
- 4:45 p.m.** **Discussant.** Miguel Villalona Calero, Orange, CA

5:00 p.m. CT019 Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors. Kathryn C. Arbour, New York, NY

5:15 p.m. **Discussant.** Trever G. Bivona, San Francisco, CA

 **AWARD LECTURE**
4:00 p.m.–4:45 p.m.

Room S105 - McCormick Place South (Level 1)
AACR-Irving Weinstein Foundation Distinguished Lectureship

Chair: Patricia M. LoRusso, New Haven, CT

Introduction. Patricia M. LoRusso, New Haven, CT

Changing health outcomes with GLP-1 medicines. Daniel J. Drucker, Toronto, ON, Canada

MEET AND GREET SESSION
4:00 p.m.–5:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

AACR Publications Booth 2615 - South Halls A1-2
Meet the Editor-in-Chief of *Cancer Research*:
Christine Iacobuzio-Donahue

 **AWARD LECTURES**
4:30 p.m.–5:15 p.m.

Room S102 - McCormick Place South (Level 1)

AACR-Princess Takamatsu Memorial Lectureship

Chair: Tyler Jacks, Cambridge, MA

Funder Remarks. Yoshinori Murakami, Tokyo, Japan

The age of cancer: Insights and interception. Ronald A. DePinho, Houston, TX

Room E350 - McCormick Lakeside Center (Level 3)

AACR-Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research

Chair: Raymond N. DuBois, Charleston, SC

Towards a precision medicine approach in renal cell carcinoma. Toni K. Choueiri, Boston, MA

 **PRESIDENTIAL ADDRESS**
5:30 p.m.–6:15 p.m.

Room S406 (Vista Ballroom) - McCormick Place South (Level 4)

From 'Omics to Oncology Drugs: Transforming Cancer Care Across the Globe

Chair: William N. Hait, New Brunswick, NJ

5:30 p.m. **Introduction.** William N. Hait, New Brunswick, NJ

5:35 p.m. **From 'omics to oncology drugs: Transforming cancer care across the globe.** Patricia M. LoRusso, New Haven, CT

SPECIAL SESSION**6:30 p.m.–8:30 p.m.****NOT ELIGIBLE FOR CME CREDIT**

Room E354 B (Lakeside Ballroom) - McCormick Lakeside Center
(Level 3)

Networking Hubs**CancerCareers.org: Scientific Careers' Resource Center****Cancer Interception and Early Detection****Data Science and AI/Machine Learning in Cancer Research
and Medicine****Entrepreneurship and Innovation****Novel Generation Clinical Trial Designs, Biomarkers, and Endpoints****TOWN HALL MEETINGS****6:30 p.m.–8:30 p.m.****NOT ELIGIBLE FOR CME CREDIT**

Room S105 - McCormick Place South (Level 1)

**Acquired Resistance to Immunotherapies:
A Cancer Immunology Working Group
Town Hall Meeting**

Cochairs: Catherine J. Wu, Boston, MA; Kunle Odunsi, Chicago, IL

Panelists: Judith Agudo, Boston, MA; Pavan Bachireddy, Houston, TX; David Alexander Braun, New Haven, CT

Room S101 - McCormick Place South (Level 1)

**Bugs and Rads: Tumor Microbiome and Radiation
Response/Toxicity—A Radiation Science and
Medicine Working Group Town Hall Meeting**

Cochairs: Fei-Fei Liu, Toronto, ON, Canada; Quynh-Thu Le, Stanford, CA

Panelists: Lauren E. Colbert, Houston, TX; Nicholas C. Denko, Columbus, OH; Stephen L. Shiao, Los Angeles, CA

Room S103 - McCormick Place South (Level 1)

**Charting the Trajectory for Advancements in
Pediatric Cancer Research: A Pediatric Cancer
Working Group Town Hall Meeting**

Chair: Alejandro Sweet-Cordero, San Francisco, CA

Panelists: Samuel C. Blackman, Seattle, WA; Ian Foulkes, London, United Kingdom; Nancy F. Goodman, Washington, DC; Charles W.M. Roberts, Memphis, TN; Gavin B. Lindberg, Germantown, MD

Room S104 - McCormick Place South (Level 1)

**How AI Will Impact the Future of Pathology:
Now, Soon, and in the Future—A Pathology in
Cancer Research Working Group Town Hall Meeting**

Chair: Massimo Loda, New York, NY

7:05 p.m. Title to be announced. Faisal Mahmood, Boston, MA

7:15 p.m. Conquering overtreatment of ductal carcinoma in situ with PRECISION through integrative team science. Jelle Wesseling, Amsterdam, Netherlands

7:25 p.m. AI-based biomarkers in cancer. Jakob Nikolas Kather, Dresden, Germany

7:35 p.m. The AI-augmented pathologist: Tools for today and tomorrow. Kenneth J. Bloom, Chicago, IL

7:45 p.m. Title to be announced. Jorge S. Reis-Filho, Gaithersburg, MD

Room S102 - McCormick Place South (Level 1)

The Weight of the Matter: Obesity Drugs, Cancer, and Population Health—A Population Sciences Working Group Town Hall Meeting

Cochairs: Paul A. Scheet, Houston, TX; Lorelei A. Mucci, Boston, MA

Panelists: Neil Mukund Iyengar, New York, NY; Jasmine Singh Sukumar, Houston, TX; Edward L. Giovannucci, Boston, MA

AACR ANNUAL RECEPTION

8:30 p.m.–11:30 p.m.

NOT ELIGIBLE FOR CME CREDIT

Room W375 ABC (Skyline Ballroom) - McCormick Place West (Level 3)

AACR Annual Reception, Featuring The Checkpoints

**PLENARY SESSION****8:00 a.m.–10:00 a.m.**

Hall B1 - McCormick Place North (Level 3)

Innovative Technologies Driving Advances in Cancer Research**Chair:** Alberto Bardelli, Turin, Italy

- 8:00 a.m. Introduction.** Alberto Bardelli, Turin, Italy
- 8:05 a.m. Next-generation patient-derived organoid models for solid tumors.** Matthias P. Lütolf, Basel, Switzerland
- 8:32 a.m. Driving new CAR T cells.** Marcela V. Maus, Boston, MA
- 8:59 a.m. Illuminating the cancer journey with cell-free whole genome sequencing.** Trevor J. Pugh, Toronto, ON, Canada
- 9:26 a.m. Utilization of novel methods and clinical trial designs for broader clinical trial access.** Muhammad Shaalan Beg, Dallas, TX
- 9:53 a.m. Wrap-up and opportunities for the future.** Alberto Bardelli, Turin, Italy

POSTER SESSION**9:00 a.m.–12:00 p.m.****NOT ELIGIBLE FOR CME CREDIT**

Halls A1-2, McCormick Place South

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

Tumor Biology

- Section 1 3D Models and Bioprinting
- Section 2 Cancer Evolution In Response to Therapy
- Section 3 Human and PDX Models 2
- Section 4 Model Systems for Metastasis

- Section 5 Novel Therapeutic Targets for Metastasis
- Section 6 Radiation Sciences 1
- Section 7 Uncovering How Secreted Factors Sculpt the Tumor Microenvironment
- Section 54 Late-Breaking Research: Tumor Biology 2

Science Education

- Section 8 2025 AACR Margaret Foti Undergraduate Prizes in Cancer Research

Molecular/Cellular Biology and Genetics

- Section 9 Apoptosis and BCL2 Family
- Section 10 Gene Regulation and Transcription Factors 2
- Section 11 Gene Regulation and Transcription Factors 3
- Section 12 Genome Maintenance: Mechanisms and Novel Therapeutics
- Section 13 Hypoxia and Oxidative Stress
- Section 14 Metabolic Dependencies

Experimental and Molecular Therapeutics

- Section 15 Antibody-Based Cancer Therapeutics 1
- Section 16 Apoptosis: Therapeutic Manipulation / Role of Microenvironment in Therapeutic Response
- Section 17 Cell Death Pathways and Treatment
- Section 18 Degradation and Glues 2
- Section 19 Drug Combination Strategies for Cancer Treatment
- Section 20 Drug Resistance in Molecular Targeted Therapies 2
- Section 21 Kinase and Phosphatase Inhibitors 1
- Section 22 Novel Antitumor Agents 1
- Section 23 Novel Drug Delivery Technologies
- Section 24 Radiation Treatment Combinations for Tumors, Normal Tissue

Chemistry

- Section 25 Drug Delivery
- Section 26 Proteomic Signatures in Cancer

Clinical Research

- Section 27 Diagnostic Biomarkers 3: Early Detection Biomarkers
- Section 28 Liquid Biopsy: Circulating Nucleic Acids 5 / Circulating Tumor Cells 2
- Section 29 Liquid Biopsy: Circulating Tumor Cells 1
- Section 30 Metastasis Biomarkers / Prognostic Biomarkers 1
- Section 31 Predictive Biomarkers 3
- Section 32 Spatial Proteomics and Transcriptomics 2
- Section 33 Spatial Proteomics and Transcriptomics 3: Other Topics/Biomarkers
- Section 34 Therapeutic Antibodies, Including Engineered Antibodies 1

Clinical Trials

- Section 49 Phase 0 and Phase I Clinical Trials

Immunology

- Section 35 Interplay between Immune System and Radio-, Chemo- and Targeted Therapies 1
- Section 36 Local and Systemic Immunity against Cancer: New Analytic and Prognostic Tools
- Section 37 Microbiome, Inflammation, and Cancer
- Section 38 Modulation of Tumor Microenvironment: Enhancing Immunogenicity and Counteracting Suppression
- Section 52 Late-Breaking Research: Immunology 2

Population Sciences

- Section 39 Advancing Genomic and Epigenetic Insights in Cancer Across Diverse Populations: Genetics, Genomics, and Epigenetics
- Section 40 Cancer Disparities in Behavioral, Psychological, Psychosocial, and Molecular Factors

Prevention, Early Detection, and Interception

- Section 42 Biology of Precancers, Development of Early Detection Methods and Biomarkers, and Cancer Interception
- Section 43 Biomarkers and Molecular Targets for Prevention
- Section 53 Late-Breaking Research: Prevention, Early Detection, and Interception

Bioinformatics, Computational Biology, Systems Biology, and Convergent Science

- Section 44 Application of Bioinformatics to Cancer Biology
- Section 45 Artificial Intelligence for Digital Pathology and Spatial Molecular Technologies
- Section 46 Digital Pathology
- Section 47 Quantitative Methods and Pipelines
- Section 51 Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 1

Regulatory Science and Policy

- Section 48 Regulatory Science and Policy

MEET AND GREET
9:15 a.m.-10:15 a.m.

NOT ELIGIBLE FOR CME CREDIT

AACR Publications Booth 2615 - South Halls A1-2
Meet the Editors-in-Chief of *Blood Cancer Discovery*:
Riccardo Dalla-Favera and Kenneth C. Anderson



ADVANCES IN ORGAN SITE RESEARCH

10:15 a.m.–11:45 a.m.

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)

Advances in KRAS Biology Are Providing New Therapeutic Opportunities For Pancreatic Cancer

Chair: Elizabeth M. Jaffee, Baltimore, MD

- 10:15 a.m.** **Chair Introduction.** Elizabeth M. Jaffee, Baltimore, MD
- 10:20 a.m.** **Effects of RAS inhibition on PDAC angiogenesis: Implications for combination therapy.** Kenneth P. Olive, New York, NY
- 10:45 a.m.** **Targeting Resistance to RAS inhibition in pancreatic cancer.** Andrew J. Aguirre, Boston, MA
- 11:10 a.m.** **New developments in KRAS-targeted vaccine-based immunotherapies.** Elizabeth M. Jaffee, Baltimore, MD

Room E353 C - McCormick Lakeside Center (Level 3)

Early-onset Colorectal Cancer: From Clinical Evidence to Biological Insights

Cochairs: Ulrike Peters, Seattle, WA; Alberto Bardelli, Turin, Italy

- 10:15 a.m.** **Chair Introduction.** Ulrike Peters, Seattle, WA
- 10:20 a.m.** **The rising tide of early-onset colorectal cancer: Synthesizing genetic, environmental, and molecular evidence.** Ulrike Peters, Seattle, WA
- 10:45 a.m.** **From the exposome to molecular profiling of early onset colorectal cancers.** Alberto Bardelli, Turin, Italy
- 11:10 a.m.** **Early detection and prevention of early-onset colorectal cancer: Clinical challenges and the paths forward.** Cassandra Fritz, St. Louis, MO



ADVANCES IN PREVENTION RESEARCH

10:15 a.m.–11:45 a.m.

Room E350 - McCormick Lakeside Center (Level 3)

Comparative Oncology: Nature's Solutions to Cancer Prevention

Chair: Amy M. Boddy, Santa Barbara, CA

- 10:15 a.m.** **Chair Introduction.** Amy M. Boddy, Santa Barbara, CA
- 10:20 a.m.** **A life history approach to understanding cancer across vertebrates.** Amy M. Boddy, Santa Barbara, CA
- 10:45 a.m.** **Unveiling drivers of cancer through comparative genomics in primates.** Arcadi Navarro, Barcelona, Spain
- 11:10 a.m.** **Mechanisms of longevity and cancer resistance.** Vera Gorbunova, Rochester, NY



ADVANCES IN TECHNOLOGIES

10:15 a.m.–11:45 a.m.

Room E451 - McCormick Lakeside Center (Level 4)

Digital Twins in Cancer: New Era of Personalized Medicine

Chair: Caroline Chung, Houston, TX

- 10:15 a.m.** **Chair Introduction.** Caroline Chung, Houston, TX
- 10:17 a.m.** **Enabling digital twins in oncology: What will it take?** Caroline Chung, Houston, TX
- 10:38 a.m.** **Designing digital twins for patients who are not average.** Thomas E. Yankeelev, Austin, TX
- 10:59 a.m.** **Dynamic digital twins for personalized early diagnostics and therapeutics.** Mikael Benson, Stockholm, Sweden



ADVANCES IN THE SCIENCE OF CANCER DISPARITIES

10:15 a.m.–11:45 a.m.

Room E352 - McCormick Lakeside Center (Level 3)

Optimizing Outcomes in AYA Cancer Patients

Chair: Melissa M. Hudson, Memphis, TN

- 10:15 a.m. Chair Introduction.** Melissa M. Hudson, Memphis, TN
- 10:20 a.m. Recognizing the unique needs of AYA cancer patients.** Melissa M. Hudson, Memphis, TN
- 10:45 a.m. Collaborating to increase clinical trial participation in AYA cancer patients.** Michael Roth, Memphis, TN
- 11:10 a.m. Health care delivery challenges and opportunities in AYA oncology.** Julie Wolfson, Birmingham, AL



MAJOR SYMPOSIA

10:15 a.m.–11:45 a.m.

Room S404 - McCormick Place South (Level 4)

Clonal Hematopoiesis and Beyond: The Aging Immune System in Cancer

Chair: James V. DeGregori, Aurora, CO

- 10:15 a.m. Introduction.** James V. DeGregori, Aurora, CO
- 10:20 a.m. Microenvironment remodeling as a consequence of clonal hematopoiesis.** Jennifer Trowbridge, Bar Harbor, ME
- 10:40 a.m. SY02-01 Inflammatory memory and selective advantage in human clonal hematopoiesis.** Stephanie Xie, Toronto, ON, Canada
- 11:00 a.m. Selective pressure to preserve proteostasis in aging stem cells promotes the emergence of clonal hematopoiesis.** Robert AJ Signer, La Jolla, CA
- 11:20 a.m. Aging-dependent selection for CHIP mutations through cell-intrinsic and cell-extrinsic mechanisms.** James V. DeGregori, Aurora, CO

Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)

Epigenetic Control of Immune Evasion in Solid Tumors

Chair: Qin Yan, New Haven, CT

- 10:15 a.m. Introduction.** Qin Yan, New Haven, CT
- 10:20 a.m. Epigenetic control of immune evasion in solid tumors.** Qin Yan, New Haven, CT
- 10:45 a.m. SY23-01 Diffuse midline gliomas: From cell cycle to therapeutic opportunities.** Capucine Van Rechem, Stanford, CA
- 11:10 a.m. Chemical biology tools to probe the cancer epigenome.** Cheryl H. Arrowsmith, Toronto, ON, Canada

Room E450 B - McCormick Lakeside Center (Level 4)

Harnessing the Microbiota to Transform Cancer Immunotherapy

Chair: Ravid Straussman, Mazkeret Batia, Israel

- 10:15 a.m. Introduction.** Ravid Straussman, Mazkeret Batia, Israel
- 10:20 a.m. The gut microbiome as predictor and target for cancer immunotherapy response.** Giorgio Trinchieri, Bethesda, MD
- 10:45 a.m. Bacterial-derived small molecules in the treatment of cancer.** Christian Jobin, Gainesville, FL
- 11:10 a.m. SY45-01 Characterizing the effects of the tumor microbiome on the response to immunotherapy.** Ravid Straussman, Rehovot, Israel

Room E351 - McCormick Lakeside Center (Level 3)

Mechanisms and Targeting of Neuroendocrine Dysregulation and Inflammation in Cancer Cachexia

Chair: Teresa A. Zimmers, Portland, OR

- 10:15 a.m. Introduction.** Teresa A. Zimmers, Portland, OR
- 10:20 a.m. Inflammatory Mechanisms and Manifestations in the Macroenvironment of Cancer Cachexia.** Teresa A. Zimmers, Portland, OR
- 10:45 a.m. Neuroendocrine regulation of nutrient intake and processing in cancer cachexia.** Tobias Janowitz, Cold Spring Harbor, NY
- 11:10 a.m. SY09-01 Targeting the vagal gut-brain axis: A new approach to combat cachexia.** Xiling Shen, Houston, TX

Room S103 - McCormick Place South (Level 1)

Mechanisms Driving Tumor Heterogeneity and Therapeutic Responses

Chair: Mariella G. Filbin, Boston, MA

- 10:15 a.m. Chair Introduction.** Mariella G. Filbin, Boston, MA
- 10:20 a.m. Form follows function: Developmental heterogeneity in pediatric brain tumors.** Mariella G. Filbin, Boston, MA
- 10:40 a.m. Epigenetic subclone phylogeny inferred from spatially mapped intratumoral heterogeneity.** Peter W. Laird, Grand Rapids, MI
- 11:00 a.m. SY47-01 Single-cell mapping of tumor ecosystem reveals chemotherapy-induced myeloid-driven spatial exhaustion via NECTIN2-TIGIT ligand-receptor interaction which can be targeted to unleash anti-tumor immunity in ovarian cancer.** Anniina Farkkila, Helsinki, Finland
- 11:20 a.m. SY47-02 Metabolic interactions driving metastasis growth.** Sarah-Maria Fendt, Leuven, Belgium

Room S102 - McCormick Place South (Level 1)

Metabolism and Organelle Biology in Cancer

Chair: Rushika M. Perera, San Francisco, CA

- 10:15 a.m. Introduction.** Rushika M. Perera, San Francisco, CA
- 10:20 a.m. Understanding the role of mitochondrial glutathione in tumor progression.** Kivanc Birsoy, New York, NY
- 10:40 a.m. SY26-01 Cancer-resistant tissues: Powerful approach for novel tumor suppressor identification and therapeutic reactivation.** Zuzana Keckesova, Prague, Czech Republic
- 11:00 a.m. SY26-02 Keeping Mitochondria Happy: How peroxisomes regulate mitochondria oxidative stress.** Peter Kijun Kim, Toronto, ON, Canada
- 11:20 a.m. Decoding novel lysosome functions in pancreatic cancer.** Rushika M. Perera, San Francisco, CA

Room S106 - McCormick Place South (Level 1)

Regulatory Science and Policy Session Regulatory Trends Shaping the Future of Cancer Drug Development

NOT ELIGIBLE FOR CME CREDIT

Moderator: Bea Lavery, San Francisco, CA

Speakers and Panelists: Amy Mckee, Silver Spring, MD; See Phan, Forest City, CA; Ian F. Tannock, Toronto, ON, Canada; Manju George, Omaha, NE; Heinz Josef Lenz, Toronto, ON, Canada

Room E450 A - McCormick Lakeside Center (Level 4)

Targeting Innate Immune Cell Subsets: Dedicated to the Memory of Eva Klein

Chair: Mikala Egeblad, Baltimore, MD

- 10:15 a.m. Introduction.** Mikala Egeblad, Baltimore, MD
- 10:20 a.m. Tumor-promoting neutrophils: Mechanisms and targeting opportunities.** Mikala Egeblad, Baltimore, MD
- 10:45 a.m. Inflammation and cancer: From basic mechanisms to therapeutic targets.** Lisa M. Coussens, Portland, OR
- 11:10 a.m. Engineering NK cells for cancer treatment: From bench to bedside.** Katayoun Rezvani, Houston, TX

Room S401 - McCormick Place South (Level 4)

Unmasking Resistance: Deciphering Mechanisms and Charting New Frontiers in Cancer Therapies

Chair: Alice T. Shaw, Boston, MA

- 10:15 a.m. Introduction.** Alice T. Shaw, Boston, MA
- 10:20 a.m. Mutational processes and therapy resistance in breast cancer.** Sarat Chandarlapaty, New York, NY
- 10:40 a.m. SY13-01 Targeting the metabolic basis of resistance to Kras signaling inhibition in pancreatic cancer.** Pankaj Kumar Singh, Oklahoma City, OK
- 11:00 a.m. A genome-derived non-coding reporter of dynamic cancer cell state permits dissection and control of intratumoral heterogeneity and chemoresistance.** Adam D. Durbin, Memphis, TN
- 11:20 a.m. Emerging combination therapies to tackle drug resistance in KRAS mutant lung cancers.** Alice T. Shaw, Boston, MA

SPECIAL SESSION

10:15 a.m.–11:45 a.m.

NOT ELIGIBLE FOR CME CREDIT

Room S406 (Vista Ballroom) - McCormick Place South (Level 4)

New Drugs on the Horizon: Part 3

Cochairs: Mary M. Mader, Indianapolis, IN; Frederic Zecri, Cambridge, MA

- 10:15 a.m. Chair Introduction.** Frederic Zecri, Cambridge, MA
- 10:20 a.m. ND09 BAY 3547926: Novel targeted radionuclide therapy for hepatocellular carcinoma.** Jenny Karlsson, Oslo, Norway
- 10:40 a.m. ND10 An innovative and reversible WRN helicase inhibitor, GSK4418959 (IDE275), emerges as a promising clinical candidate for MSI-H cancers.** Yanhua Rao, Upper Providence, PA

11:00 a.m. ND11 AZD0022: a potent, oral KRASG12D-selective inhibitor that drives robust pathway inhibition and anti-tumor activity in KRASG12D models. Carla P. Martins, Cambridge, United Kingdom

11:20 a.m. ND12 M0324, a novel MUC-1 conditional CD40 agonist for selective immune activation in MUC-1 overexpressing tumors. Weixiao Sha, Darmstadt, Germany

11:40 a.m. Closing Remarks. Mary M. Mader, Indianapolis, IN



MAJOR SYMPOSIUM
10:15 a.m.–12:00 p.m.

Room S105 - McCormick Place South (Level 1)

Presidential Select Symposium: Leveraging Science to Reduce the Cancer Burden Worldwide

Chair: Robert G. Bristow, Manchester, United Kingdom

- 10:15 a.m. Introduction.** Patricia M. LoRusso, New Haven, CT
- 10:18 a.m. Introduction.** Robert G. Bristow, Manchester
- 10:23 a.m. Achieving global consensus in cancer: Why it matters.** André Ilbawi, Geneva, Switzerland
- 10:38 a.m. State of the science on single-dose HPV vaccination.** Aimée R. Kreimer, Bethesda, MD
- 10:53 a.m. Inviting Malawians into cancer clinical research.** Satish Gopal, Rockville, MD
- 11:08 a.m. Panel Discussion**

Moderators: Chyke A. Doubeni, Columbus, OH; Robert G. Bristow, Manchester, United Kingdom

Panelists: André Ilbawi, Geneva, Switzerland; Aimée R. Kreimer, Bethesda, MD; Satish Gopal, Rockville, MD; Frank George Njoroge, Nairobi, Kenya; C.S. Pramesh, Parel Mumbai, Maharashtra, India; Vanessa M. Hayes, Camperdown NSW, Australia; Sok Ching Cheong, Subang Jaya, Malaysia



CLINICAL TRIALS PLENARY SESSION

10:15 a.m.–12:15 p.m.

Arie Crown Theater - McCormick Lakeside Center (Level 2)

Therapeutic Advances in Non-Small Cell Lung Cancer

Cochairs: Stephen V. Liu, Bethesda, MD; Everett E. Vokes, Chicago, IL

- 10:15 a.m. CT050 Zongertinib in patients with pretreated HER2-mutant advanced NSCLC: Beamion LUNG-1.**
John V. Heymach, Houston, TX
- 10:30 a.m. Discussant.** Charles M. Rudin, New York, NY
- 10:45 a.m. CT051 SKYSCRAPER-01: A phase III, randomized trial of tiragolumab (tira) + atezolizumab (atezo) versus placebo (pbo) + atezo in patients (pts) with previously-untreated PD-L1-high, locally advanced unresectable/metastatic NSCLC.** Solange Peters, Lausanne, Switzerland
- 11:00 a.m. Discussant.** Ramaswamy Govindan, Saint Louis, MO
- 11:15 a.m. CT052 A highly selective, brain-penetrant and overcoming G2032R resistance ROS1 inhibitor JYP0322 in NSCLC patients with ROS1 fusion.**
Hongyun Zhao, Guangzhou, China
- 11:30 a.m. CT053 Aumolertinib with or without chemotherapy as first line treatment in locally advanced or metastatic NSCLC with sensitizing EGFR mutations (AENEAS2).** Shun Lu, Shanghai, China
- 11:45 a.m. Discussant.** Pasi A. Jänne, Boston, MA

MEET AND GREET SESSION

10:30 a.m.–11:30 a.m.

NOT ELIGIBLE FOR CME CREDIT

AACR Publications Booth 2615 - South Halls A1-2

Meet the Editors-in-Chief of *Cancer Immunology*

Research: Robert D. Schreiber and Philip D. Greenberg

MEET AND GREET SESSION

11:30 a.m.–12:30 p.m.

NOT ELIGIBLE FOR CME CREDIT

AACR Publications Booth 2615 - South Halls A1-2

Meet the Editor-in-Chief of *Molecular Cancer Research*: Massimo Loda

SPECIAL SESSION

12:30 p.m.–1:45 p.m.

NOT ELIGIBLE FOR CME CREDIT

Room S106 - McCormick Place South (Level 1)

AACR Annual Business Meeting of Members

AACR Chief Executive Officer. Margaret Foti, Philadelphia, PA

AACR President. Patricia M. LoRusso, New Haven, CT

AACR Past President. Philip D. Greenberg, Seattle, WA

AACR Treasurer. William N. Hait, New Brunswick, NJ

AACR President-Elect. Lillian L. Siu, Toronto, ON, Canada

AACR Treasurer-Elect. Michael A. Caligiuri, Duarte, CA



ADVANCES IN DIAGNOSTICS AND THERAPEUTICS

12:30 p.m.–2:00 p.m.

Arie Crown Theater - McCormick Lakeside Center (Level 2)

Challenges and Opportunities in the Development of Next Generation Antibody Drug Conjugates

Chair: Giuseppe Curigliano, Milan, Italy

12:30 p.m. Chair Introduction. Giuseppe Curigliano, Milan, Italy

12:35 p.m. Next generation ADCs: new targets and new payload. Giuseppe Curigliano, Milan, Italy

1:00 p.m. Biomarkers and prediction of activity. Sara A. Hurvitz, Seattle, WA

1:25 p.m. Managing and predicting toxicities from new and emerging ADCs. Hope S. Rugo, San Francisco, CA



ADVANCES IN EARLY DETECTION AND INTERCEPTION

12:30 p.m.–2:00 p.m.

Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)

Dharma Master Jiantai Advances in Biomarkers: Finding the Needles in the Haystack—Novel Technologies that Leverage the Cancer Genome, Epigenome, Repeatome and Proteome for Cancer Detection

Chair: Daniel D. De Carvalho, Toronto, ON, Canada

12:30 p.m. Chair Introduction. Daniel D. De Carvalho, Toronto, ON, Canada

12:35 p.m. Ultrasensitive MRD detection: Results from TRACERx. Charles Swanton, London, United Kingdom

1:00 p.m. Tissue-naïve tumor detection using plasma cell-free DNA methylomes. Daniel D. De Carvalho, Toronto, ON, Canada

1:25 p.m. LINE-1 ORF1p for multi-cancer detection. Kathleen H. Burns, Boston, MA



ADVANCES IN HEMATOLOGIC MALIGNANCIES

12:30 p.m.–2:00 p.m.

Room S401 - McCormick Place South (Level 4)

Dissecting and Engaging the Lymphoma Tumor Microenvironment

Chair: Christian Steidl, Vancouver, BC, Canada

12:30 p.m. Chair Introduction. Gilles Salles, New York, NY

12:31 p.m. How to enhance immunotherapies against lymphoma. Wendy Béguelin, New York, NY

12:51 p.m. The spatial organization of lymphoma cells with MYC-BCL2 co-expression shapes the immune microenvironment and determines survival after chemoimmunotherapy. Anand Devaprasath Jeyasekharan, Singapore, Singapore

1:11 p.m. Towards a new molecular taxonomy of classic Hodgkin lymphoma. Tomohiro Aoki, Toronto, ON, Canada

1:31 p.m. Bispecific antibodies in lymphoma: Optimizing response and overcoming resistance. Gilles Salles, New York, NY



ADVANCES IN ORGAN SITE RESEARCH

12:30 p.m.–2:00 p.m.

Room S103 - McCormick Place South (Level 1)

New Findings in Invasive Lobular Breast Cancer: Histology Matters

Chair: Steffi Oesterreich, Pittsburgh, PA

12:30 p.m. Chair Introduction. Steffi Oesterreich, Pittsburgh, PA

12:35 p.m. Role of E-cadherin loss in ILC. Steffi Oesterreich, Pittsburgh, PA

1:00 p.m. Is lobular breast cancer a new paradigm for DNA repair dysfunction and synthetic lethality? Matthew J. Sikora, Aurora, CO

1:25 p.m. Genomic and microenvironmental drivers of lobular breast cancer. Christina Curtis, Stanford, CA

Room S404 - McCormick Place South (Level 4)

Rare Cancers: Role of Precision Genomics, Immunotherapy, and Novel Molecular/Clinical Trial Approaches

Chair: Razelle Kurzrock, La Jolla, CA

- 12:30 p.m. Chair Introduction.** Razelle Kurzrock, La Jolla, CA
- 12:35 p.m. Rare to ultra-rare to N-of-1: How the approach to rare cancers can inform the strategy for all cancers.** Razelle Kurzrock, La Jolla, CA
- 1:00 p.m. DART: A national NCI/SWOG platform trial for immunotherapy in rare cancers.** Young Kwang Chae, Chicago, IL
- 1:25 p.m. Precision oncology and rare cancers: The view from India.** Sewanti Limaye, Mumbai, India



ADVANCES IN PREVENTION RESEARCH

12:30 p.m.–2:00 p.m.

Room E350 - McCormick Lakeside Center (Level 3)

Epstein-Barr Virus Associated Oncogenesis

Chair: Erle S. Robertson, Philadelphia, PA

- 12:30 p.m. Chair Introduction.** Erle S. Robertson, Philadelphia, PA
- 12:35 p.m. Measuring EBV DNA for the detection of cancer in high-risk populations.** Richard F. Ambinder, Baltimore, MD
- 1:00 p.m. The Oncovirus EBV rewires DNA repair via STAT3 exposing synthetic lethal vulnerabilities.** Sumita Bhaduri-McIntosh, Gainesville, FL
- 1:25 p.m. EBV reprogramming of the kinome for oncogenesis.** Erle S. Robertson, Philadelphia, PA



ADVANCES IN THE SCIENCE OF CANCER DISPARITIES

12:30 p.m.–2:00 p.m.

Room E351 - McCormick Lakeside Center (Level 3)

Health Disparities across the Cancer Clinical Research Continuum: Emerging Opportunities and Challenges

Chair: Chyke A. Doubeni, Columbus, OH

- 12:30 p.m. Chair Introduction.** Chyke A. Doubeni, Columbus, OH
- 12:35 p.m. Opportunities and challenges for disparities research across the clinical research continuum.** Chyke A. Doubeni, Columbus, OH
- 12:55 p.m. Understanding population differences in right-sided colorectal cancer: insights from a preclinical model.** Bianca N. Islam, Cleveland, OH
- 1:10 p.m. Influence of social, environmental, and genetic factors on tumor biology as contributor to cancer outcome disparities.** Stefan Ambs, Bethesda, MD
- 1:30 p.m. Implementing lung cancer screening using person-centered and community-engaged approaches to mitigate disparities.** Jamie L. Studts, Aurora, CO



MAJOR SYMPOSIA

12:30 p.m.–2:00 p.m.

Room S406 (Vista Ballroom) - McCormick Place South (Level 4)

Application of Systems Biology, Functional Clinical Proteomics and Multi-Omic Approaches for Precision Oncology at the Bedside

Chair: Emanuel Frank Petricoin, Manassas, VA

- 12:30 p.m. Introduction.** Emanuel Frank Petricoin, Manassas, VA
- 12:35 p.m. Using multiplexed spatial methods to study primary cancers and develop biomarkers of high-risk tumors.** Peter K. Sorger, Boston, MA
- 12:55 p.m. SY04-01 Mapping the functional microproteome in cancer.** John R. Prensner, Ann Arbor, MI
- 1:15 p.m. SY04-02 Clinical applications of cancer digital twins.** Jasmin Fisher, London, United Kingdom

1:35 p.m. **Clinical applications of CLIA-based functional drug target mapping and protein network profiling: Synergies for multi-omic rationalized precision therapy.** Emanuel Frank Petricoin, Manassas, VA

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)

Developments in RAS Signaling Inhibition: Bench to Bedside

Chair: Frank McCormick, San Francisco, CA

12:30 p.m. **Introduction.** Frank McCormick, San Francisco, CA

12:35 p.m. **The end of KRAS cancers?** Frank McCormick, San Francisco, CA

1:00 p.m. **Novel molecular mechanisms for KRAS inhibition.** Piro Lito, New York, NY

1:25 p.m. **Mechanism of response and resistance to RAS inhibition in solid tumors.** Sandra Misale, Baltimore, MD

Room E450 B - McCormick Lakeside Center (Level 4)

Imaging the Cell Cycle

Chair: Sabrina L. Spencer, Boulder, CO

12:30 p.m. **Introduction.** Sabrina L. Spencer, Boulder, CO

12:35 p.m. **SY22-01 States of cell-cycle withdrawal.** Sabrina L. Spencer, Boulder, CO

1:00 p.m. **SY22-02 Cell cycle plasticity drives tumor progression and drug resistance.** Wayne Stallaert, Pittsburgh, PA

1:25 p.m. **SY22-03 Multifaceted mitochondria in the regulation of chromosome inheritance.** Maria J. Rodriguez Colman, Utrecht, Netherlands

Room S105 - McCormick Place South (Level 1)

Immunometabolism and Metabolic Fitness in Tumors

Chair: Jeffrey C. Rathmell, Nashville, TN

12:30 p.m. **Introduction.** Jeffrey C. Rathmell, Nashville, TN

12:35 p.m. **SY21-01 Inflammatory drivers of the obesity-cancer connection.** Jeffrey C. Rathmell, Nashville, TN

12:55 p.m. **Enhancing antitumor T cell metabolism through REXO2: Unleashing the full potential of adoptive cell therapy.** Chrystal M. Paulos, Atlanta, GA

1:15 p.m. **SY21-01 Reprogramming the tumor microenvironment with a single punch- our journey from bench to bedside.** Ping-Chih Ho, Lausanne, Switzerland

1:35 p.m. **Dark lipid kinase PI5P4K is a molecular checkpoint of anti-tumor immunity.** Karen Dixon, Basel, Switzerland

Room E451 - McCormick Lakeside Center (Level 4)

Overcoming the Tumor Suppressive Role of the Innate Immune System within the Tumor Microenvironment

Chair: Ignacio Melero, Pamplona, Spain

12:30 p.m. **Introduction.** Ignacio Melero, Pamplona, Spain

12:35 p.m. **Harnessing neutrophil to overcome resistance to immune based therapies.** Taha Merghoub, Jersey City, NJ

1:00 p.m. **The COX-2/PGE2 axis: a dominant pathway underlying cancer immune evasion.** Santiago Zelenay, Manchester, United Kingdom

1:25 p.m. **TNF as a targetable orchestrator of an immunosuppressive tumor microenvironment.** Ignacio Melero, Pamplona, Spain

Room E353 C - McCormick Lakeside Center (Level 3)

Redefining Cancer Survivorship for People Living with Advanced and Metastatic Cancers

Chair: Areej El-Jawahri, Boston, MA

12:30 p.m. **Chair Introduction.** Areej El-Jawahri, Boston, MA

12:34 p.m. **Balancing on the edge: The lived experience of survivorship with advanced cancer.** Jill Feldman, Deerfield, IL

12:57 p.m. **SY32-01 Beyond diagnosis: Survivorship research for people living with advanced and metastatic cancers.** Michelle Mollica, Gaithersburg, MD

1:20 p.m. **The art of not knowing: Prognostic uncertainty and living meaningfully with advanced cancer.** Areej R. El-Jawahri, Boston, MA

Room E450 A - McCormick Lakeside Center (Level 4)

Synthetic Lethality: What Next?

Chair: Johann S. de Bono, Sutton, United Kingdom

- 12:30 p.m.** **Introduction.** Johann S. de Bono, Sutton, United Kingdom
- 12:35 p.m.** **Synthetic lethality and cancer care.** Johann S. de Bono, Sutton, United Kingdom
- 12:55 p.m.** **SY14-01 AI inferred spatial transcriptomics unlocks cancer biomarker discovery from histopathology.** Eytan Rupp, Bethesda, MD
- 1:15 p.m.** **SY14-02 Mapping synthetic lethal interactions at scale: A functional genomics approach to cancer therapeutic discovery.** Francisca Vazquez, Cambridge, MA
- 1:35 p.m.** **SY14-03 Exploiting dysregulated ribosomal homeostasis in chromosome 9p21.3 deleted cancers and microsatellite unstable cancers.** Edmond M. Chan, New York, NY

Room S102 - McCormick Place South (Level 1)

Understanding Organ-tropic Metastasis

Chair: Yibin Kang, Princeton, NJ

- 12:30 p.m.** **Introduction.** Yibin Kang, Princeton, NJ
- 12:35 p.m.** **Metastasis initiating cells and ecosystems.** Joan Massagué, New York, NY
- 1:00 p.m.** **Stromal and immune plasticity shape the metastatic microenvironment.** Neta Erez, Tel Aviv, Israel
- 1:25 p.m.** **Unraveling the metastatic niche: Mechanisms and systemic complications.** Yibin Kang, Princeton, NJ

MEET AND GREET SESSIONS

2:00 p.m.–3:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

AACR Publications Booth 2615 - South Halls A1-2

Meet the New Editor-in-Chief of *Clinical Cancer Research*: Timothy A. Yap

Room E353 A - McCormick Lakeside Center (Level 3)

Meet the Research Grant Reviewers

- 2:30 p.m.** Sandra W. Ryeom, New York, NY
- 2:53 p.m.** James M. Cleary, Boston, MA

POSTER SESSION

2:00 p.m.–5:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Halls A1-2, McCormick Place South

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

Tumor Biology

- Section 1 Advanced Nanotechnology and Imaging
- Section 2 Aging and Senescence in the Tumor Microenvironment
- Section 3 CAFs and Beyond: A Central Role for the Tumor Microenvironment in Cancer
- Section 4 Developmental Origins and Drivers of Pediatric Cancers
- Section 5 Invasion and Migration
- Section 6 Microenvironment-Driven Cancer Evolution
- Section 7 Targeting the Tumor Microenvironment: A Brave New World

Molecular/Cellular Biology and Genetics

- Section 9 Epigenetic Mechanisms and Therapeutic Implications in Cancer
- Section 10 Epigenetic Mechanisms of Cancer Resistance and Progression
- Section 11 Functional Genomics / Large-Scale Approaches to Cancer Gene Discovery
- Section 12 microRNAs and Other Noncoding RNAs 2
- Section 13 Non-Apoptotic Cell Death
- Section 14 Origins and Mechanisms of Genomic Instability

Experimental and Molecular Therapeutics

- Section 15 Antibody-Based Cancer Therapeutics 2
- Section 16 DNA Damage Response and Modulation of DNA Repair 1
- Section 17 Growth Factor Receptors and Other Surface Antigens as Targets for Therapy 1
- Section 18 Growth Factor Receptors and Other Surface Antigens as Targets for Therapy 2
- Section 19 Identification of Molecular Targets 1
- Section 20 Kinase and Phosphatase Inhibitors 2
- Section 21 Novel Antitumor Agents 2
- Section 22 Novel Drug Resistance Mechanisms
- Section 23 The Microenvironment in Therapeutic Response
- Section 24 Therapeutic Approaches to Attack the Tumor Microenvironment
- Section 54 Late-Breaking Research: Experimental and Molecular Therapeutics 2

Chemistry

- Section 25 High-Throughput Screening Assays and Libraries
- Section 52 Late-Breaking Research: Chemistry

Clinical Research

- Section 27 Adoptive Cell Therapy 1
- Section 28 Immune Checkpoints
- Section 29 Liquid Biopsy: Circulating Nucleic Acids 1
- Section 30 Modifiers of the Tumor Microenvironment
- Section 31 Predictive Biomarkers 4
- Section 32 Prognostic Biomarkers 2
- Section 33 Real-World Data and Real-World Evidence: Clinical Informatics and Data Science 1
- Section 34 Real-World Data and Real-World Evidence: Clinico-Genomics
- Section 53 Late-Breaking Research: Clinical Research 1

Clinical Trials

- Section 49 First-in-Human Phase I Clinical Trials 1
- Section 50 Phase II and Phase III Clinical Trials
- Section 51 Phase I Clinical Trials in Progress 1

Immunology

- Section 35 Enhanced Antibodies, TCR Constructs, Cytokines and Chimeric Proteins
- Section 36 Inflammation and Cancer: Tumor Initiation and Progression / Metastasis
- Section 37 Local Treatments, Novel Tools, and Delivery Systems to Manipulate Tumor Immunity
- Section 38 T Cell Engagers
- Section 39 Vaccines, In Situ Vaccines, and Vaccine Combinations

Science and Health Policy

- Section 40 Cancer Disparities and Costs of Care / Grant Peer Review

Survivorship

- Section 41 Advocates Poster Session 1
- Section 42 Advocates Poster Session 2

Population Sciences

- Section 43 Cancer Disparities: Environmental, Microbiome, and Tumor Biology
- Section 44 Environmental, Immunological, and Tumor Microenvironment Drivers of Cancer Disparities

Bioinformatics, Computational Biology, Systems Biology, and Convergent Science

- Section 45 Artificial Intelligence and Machine Learning for Therapeutic Election and Discovery
- Section 46 Convergence Science Diagnostic and Predictive Approaches
- Section 47 Molecular and Cellular Modeling and Engineering

Prevention, Early Detection, and Interception

- Section 48 The Role of Physical Activity, Diet, Microbiome, Obesity, and Energy Balance in the Cancer Continuum

SPECIAL SESSION**2:30 p.m.–4:00 p.m.****NOT ELIGIBLE FOR CME CREDIT**

Room E353 C - McCormick Lakeside Center (Level 3)

Advances in the Detection and Treatment of Gastrointestinal Cancers: SU2C Open Scientific Session**Chair:** William G. Nelson, Baltimore, MD

- 2:32 p.m.** **Early detection and interception of diffuse and intestinal gastric cancer.** Andrew T. Chan, Boston, MA
- 2:37 p.m.** **Early detection and interception of diffuse and intestinal gastric cancer.** David A. Drew, Boston, MA
- 2:54 p.m.** **Theranostic in pancreatic cancer: Detection and Treatment.** Julie L. Sutcliffe, Windsor, CA
- 3:16 p.m.** **Therapeutic implications of selective bacterial colonization of colorectal cancer.** Florencia McAllister, Houston, TX
- 3:38 p.m.** **Circulating tumor DNA-based methods for early detection, treatment guidance, and monitoring of minimal residual disease in colorectal cancer.** Ryan B. Corcoran, Boston, MA

**MINISYMPOSIA****2:30 p.m.–4:15 p.m.**

Room E350 - McCormick Lakeside Center (Level 3)

Multidisciplinary**Advancing Cancer Research Through an International Cancer Registry: AACR Project GENIE Use Cases****Chair:** Kenneth L. Kehl, Boston, MA

- 2:30 p.m.** **Introduction.** Kenneth L. Kehl, Boston, MA
- 2:35 p.m.** **3742 Multi-omics analysis of MYC gene and WNT signaling pathway alterations in early-onset colorectal cancer in Hispanic/Latino patients, enhanced with spatial transcriptomics approaches.** Francisco Gutierrez Carranza, Duarte, CA
- 2:50 p.m.** **3744 Learning the language of somatic mutations: A large language model approach to precision oncology.** John-William Sidhom, New York, NY
- 3:05 p.m.** **3745 Allele-specific HLA LOH frequencies and survival outcomes in cancer: a real-world analysis.** Michael Gormally, New York, NY
- 3:20 p.m.** **3746 Genomic landscape in metaplastic breast cancer: Results from the AACR GENIE Database.** Blessie Elizabeth Nelson, Houston, TX
- 3:35 p.m.** **3747 Long-read whole genome sequencing identifies genes for targeted therapy to treat cervical cancer.** Michael C. Dean, Rockville, MD
- 3:50 p.m.** **3748 U2AF1 mutations rescue deleterious exon skipping induced by KRAS mutations.** David M. Walter, Boston, MA
- 4:05 p.m.** **Closing Remarks.** Kenneth L. Kehl, Boston, MA

Arie Crown Theater - McCormick Lakeside Center (Level 2)

Clinical Research**Innovations in Immunotherapy****Cochairs:** Elise Alspach, St. Louis, MO; David L. Bajor, Cleveland, OH

- 2:30 p.m.** **Introduction.** Elise Alspach, St. Louis, MO
- 2:40 p.m.** **3763 Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency.** Alexander Biederstädt, Houston, TX
- 2:55 p.m.** **3764 Mapping the tumor-sentinel node immune migratome demonstrates a key role for CCR7+ dendritic cells in the successful response to immunoradiotherapy.** Robert Saddawi-Konefka, La Jolla, CA
- 3:10 p.m.** **3765 Combined silencing of MED12 and activation of IL2 by epigenetic editing enhances CAR T antitumor potency.** Frank Lin, Stanford, CA
- 3:25 p.m.** **3766 Low T cell diversity is associated with poor outcome in bladder cancer: A comprehensive longitudinal analysis of the T cell receptor repertoire.** Nanna Kristjansdottir, Aarhus, Denmark
- 3:40 p.m.** **3768 Development of novel MHC-II-restricted TCR-STEM CD4+ T cell immunotherapy for solid cancers.** Jiayi Zhang, Los Angeles, CA
- 3:55 p.m.** **3769 Targeting TAK1 kinase triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade.** Sapana P. Bansod, St. Louis, MO
- 4:10 p.m.** **Closing Remarks.** David L. Bajor, Cleveland, OH



CLINICAL TRIALS MINISYMPOSIUM

2:30 p.m.–4:30 p.m.

Room S406 (Vista Ballroom) - McCormick Place South (Level 4)

Aiming for Cure: Adjuvant and Neoadjuvant Approaches

Cochairs: Robert G. Maki, Philadelphia, PA; Aparna Parikh, Boston, MA

- 2:30 p.m.** **Chair Introduction.** Robert G. Maki, Philadelphia, PA
- 2:35 p.m.** **CT126** Aumolertinib as adjuvant therapy in patients with stage II-IIIB EGFR-mutated NSCLC after complete tumor resection: A randomized, double-blind, placebo-controlled, phase 3 trial (ARTS). Ying Cheng, Changchun, China
- 2:50 p.m.** **CT127** Pre-operative abemaciclib in localized cisplatin-ineligible MIBC with tissue and ctDNA molecular response validation (CLONEVO). Bishoy M. Faltas, New York, NY
- 3:05 p.m.** **CT128** RADIANT: A window of opportunity trial exploring preoperative immunomodulatory radiotherapy and durvalumab prior to radical cystectomy in patients with cisplatin-ineligible muscle-invasive bladder carcinoma. Michael Ong, Ottawa, ON, Canada
- 3:20 p.m.** **CT129** Immunity induction with atezolizumab, EIK1001, and radiotherapy in virus-associated tumors: Results of the AGADIR Trial. Antoine Italiano, Bordeaux, France
- 3:35 p.m.** **CT130** Neoadjuvant botensilimab plus balstilimab in MMR proficient and deficient early stage cancers: First results of the pan-cancer NEOASIS study. Myriam Chalabi, Amsterdam, Netherlands
- 3:50 p.m.** **CT131** A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): The ALTAIR Study. Hideaki Bando, Kashiwa, Japan
- 4:05 p.m.** **CT132** Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA) as a personalized biomarker. Chad Tang, Houston, TX
- 4:20 p.m.** **Closing Remarks.** Aparna Parikh, Boston, MA



MINISYMPOSIA

2:30 p.m.–4:30 p.m.

Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)

Bioinformatics, Computational Biology, Systems Biology, and Convergent Science

Characterizing Tumor as Complex Systems with Bioinformatics and Computational Biology

Cochairs: Laura M. Heiser, Portland, OR; Olivier Gevaert, Stanford, CA

- 2:30 p.m.** **Introduction.** Laura M. Heiser, Portland, OR
- 2:35 p.m.** **3749** Multi-omic characterization of treatment-naïve acute myeloid leukemia reveals subtype-specific features and biomarkers of drug response. Yi Hsiao, Ann Arbor, MI
- 2:50 p.m.** **3750** Spatial crosstalk modeling of the tumor microenvironment uncovers CCR5-mediated glia-to-glia signaling as a key regulator of brain metastases. Ju Young Ahn, Houston, TX
- 3:05 p.m.** **3751** A pan-cancer intracellular tumor antigen atlas. Guangyuan Li, New York, NY
- 3:20 p.m.** **3752** Single-cell-guided identification of logic-gated combinatorial antigens for effective and safe CAR therapy design. Sanna Madan, Bethesda, MD
- 3:35 p.m.** **3753** Differential roles of Wnt pathway mutations in colorectal cancer. Yoshikage Inoue, Kyoto, Japan
- 3:50 p.m.** **3754** ecDNAInspector nominates high-confidence structural predictions of extrachromosomal DNA for downstream analysis. Sophia J. Pribus, Stanford, CA
- 4:05 p.m.** **3755** AmpliconSuite enables discovery of extrachromosomal DNA in tumor genomes. Jens Luebeck, La Jolla, CA
- 4:20 p.m.** **Closing Remarks.** Olivier Gevaert, Stanford, CA

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)

Chemistry

Innovative Approaches in Drug Discovery: Novel Leads, Degraders, and AI-Driven Solutions

NOT ELIGIBLE FOR CME CREDIT

Cochairs: Zaneta Nikolovska-Coleska, Ann Arbor, MI; Joaquina Celebre Baranda, Lenexa, KS

- 2:30 p.m. Introduction.** Joaquina Celebre Baranda, Lenexa, KS
- 2:35 p.m. 3756 Optimization of the LIPA targeting agent for the treatment of ovarian cancer.** Ratna K. Vadlamudi, San Antonio, TX
- 2:50 p.m. 3757 Development of potent orally bioavailable inhibitors of nicotinamide N-methyl transferase.** Samarjit Patnaik, Rockville, MD
- 3:05 p.m. 3758 Discovery of a bridged proteolysis targeting chimera (PROTAC) recruiting the SPOP E3 ubiquitin ligase for targeted protein degradation.** Jerrel Lewis Catlett, New York, NY
- 3:20 p.m. 3759 Single cell transcriptomics on a bioprinted 3D neurovascular unit glioblastoma model identifies pharmacological interventions that selectively target tumor cells.** Yen-Ting Tung, Bethesda, MD
- 3:35 p.m. 3760 Local activation of immune cells and depletion of Tregs by tumor collagen-binding checkpoint immunotherapy.** Jun Ishihara, London, United Kingdom
- 3:50 p.m. 3761 AI-GPT-driven design of novel lipid nanoparticles for targeted and safe mRNA-based cancer immunotherapy.** Dong Shen, Baltimore, MD
- 4:05 p.m. 3762 DEL-AI: Proteome-wide in silico screening of multi-billion compound libraries using machine learning foundation models.** Paul Novick, San Francisco, CA
- 4:20 p.m. Closing Remarks.** Zaneta Nikolovska-Coleska, Ann Arbor, MI

Room S105 - McCormick Place South (Level 1)

Clinical Research

Liquid Biopsy: Circulating Nucleic Acids

Cochairs: Lars Dyrskjød, Aarhus, Denmark; Rodrigo Toledo, Barcelona, Spain

- 2:30 p.m. Introduction.** Lars Dyrskjød, Aarhus, Denmark
- 2:35 p.m. 3770 Comparison of ctDNA detection methods for monitoring minimal residual disease in patients with bladder cancer: Insights from the TOMBOLA Trial.** Iver Nordentoft, Aarhus, Denmark
- 2:50 p.m. 3771 Non invasive monitoring of relapsed SCLC using cell free fragmentomes and peripheral blood immunophenotyping.** Chirayu Mohindroo, Rockville, MD
- 3:05 p.m. 3772 Leveraging the cfDNA fragmentome to predict immunotherapy response.** Valsamo (Elsa) K. Anagnostou, Baltimore, MD
- 3:20 p.m. 3773 Urine cell-free RNA analysis for bladder cancer detection and monitoring.** Kevin J. Liu, Stanford, CA
- 3:35 p.m. 3774 Detection of post-surgical minimal residual disease (MRD) in colorectal cancer; preliminary results from the VICTORI study.** Emma Titmuss, Vancouver, BC, Canada
- 3:50 p.m. 3775 Liquid biopsy for therapy planning in clinically NO head and neck cancer (LiCOHN) - A personalized cell-free tumor DNA analysis for patients with HNSCC.** Susanne Flach, Munich, Germany
- 4:05 p.m. 3776 Association of baseline ctDNA EGFR mutation detection with clinical outcome in the phase II RAMOSE trial assessing ramucirumab plus osimertinib versus osimertinib in EGFR mutant non-small cell lung cancer.** Simon Heeke, Houston, TX
- 4:20 p.m. Closing Remarks.** Rodrigo Toledo, Barcelona, Spain

Room E451 - McCormick Lakeside Center (Level 4)

Experimental Therapeutics

Continuum of Innovation: Biological Therapeutic Agents

NOT ELIGIBLE FOR CME CREDIT

Cochairs: Elizabeth Fox, Memphis, TN; Andrew Z. Wang, Dallas, TX

- 2:30 p.m. Introduction.** Elizabeth Fox, Memphis, TN
- 2:35 p.m. 3777 Development of potent FGFR4-targeted antibody-drug conjugate therapies for rhabdomyosarcoma and other cancers expressing FGFR4.** Meijie Tian, Bethesda, MD
- 2:50 p.m. 3778 Preclinical evaluation of BG-C137, a potential first-in-class FGFR2b-targeting ADC, for the treatment of FGFR2b-expressing cancer.** Yibin Xu, Shanghai, China
- 3:05 p.m. 3779 LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitors.** Nathan A. Brooks, Indianapolis, IN
- 3:20 p.m. 3780 TP53 mutant human acute myeloid leukemia stem cells rely on the NFkB pathway for self-renewal and are sensitive to proteasome inhibitors.** Zohar Sachs, Minneapolis, MN
- 3:35 p.m. 3781 Kinase fusion landscape of pancreatic cancer.** Ravi Chakra Turaga, Chandler, AZ
- 3:50 p.m. 3782 Nuclear expulsion-derived extracellular vimentin accelerates CD8+ T cell dysfunction and enhances treatment resistance.** Woo-Yong Park, Bethesda, MD
- 4:05 p.m. 3783 Niche driven inflammatory regulation in the pathogenesis and treatment of myeloid malignancies.** Pallavi Budgude, New York, NY
- 4:20 p.m. Closing Remarks.** Andrew Z. Wang, Dallas, TX

Room S102 - McCormick Place South (Level 1)

Immunology

Antigens, Antibodies, BiTEs, and Vaccines

NOT ELIGIBLE FOR CME CREDIT

Cochairs: Cristina Puig Saus, Los Angeles, CA; Brian J. Czerniecki, Tampa, FL

- 2:30 p.m. Introduction.** Cristina Puig Saus, Los Angeles, CA
- 2:35 p.m. 3791 Tumor cells surviving DNA damage acquire antigen presenting functions to stimulate anti-tumor immunity.** Tiffany R. Emmons, Cambridge, MA
- 2:50 p.m. 3792 Antigen and therapeutically relevant T cell molecular checkpoints control B cell heterogeneity and function to deliver anti-tumor immunity.** Daniel P. Hollern, La Jolla, CA
- 3:05 p.m. 3793 Advancing GPC3-positive solid tumor therapy with AZD9793, a novel CD8-guided T cell engager with potent pre-clinical efficacy and superior therapeutic index over GPC3 x CD3 formats.** Cristina Bergamaschi, Gaithersburg, MD
- 3:20 p.m. 3794 Developing an mRNA nanomedicine platform to democratise therapeutic antibodies.** Louise S. Brackenbury, Bristol, United Kingdom
- 3:35 p.m. 3795 Cross-HLA targeting of synthetic neoepitopes with T cell engagers to eradicate sotorasib-resistant, KRAS-G12C mutant cancer.** Lauren Stopfer, Long Island City, NY
- 3:50 p.m. 3796 CAR-T cells secreting anti-PD1/anti-CTLA4 bispecific antibody exhibit superior antitumor efficacy for ccRCC treatment.** Nithyassree Murugan, Boston, MA
- 4:05 p.m. 3797 Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of CD3-bispecifics and mitigate T cell exhaustion.** Latifa Zekri, Tuebingen, Germany
- 4:20 p.m. Closing Remarks.** Brian J. Czerniecki, Tampa, FL

Room E450 B - McCormick Lakeside Center (Level 4)

Molecular/Cellular Biology and Genetics

Metabolic Frontiers in Cancer: Amino Acids, Nutrient Dependencies, and Therapeutic Opportunities

Cochairs: Cosimo Commisso, La Jolla, CA; Boyi Gan, Houston, TX

- 2:30 p.m.** **Introduction.** Cosimo Commisso, La Jolla, CA
- 2:35 p.m.** **3798 Branched-chain amino acid metabolism and histone propionylation in pancreatic cancer.** Christina Demetriadou, Philadelphia, PA
- 2:50 p.m.** **3799 CDKN2A Low cancer cells outcompete macrophages for microenvironmental zinc to drive immunotherapy resistance.** Aidan R. Cole, Pittsburgh, PA
- 3:05 p.m.** **3800 Physiological nutrient levels reveal nucleotide salvage as a dependency in B-cell acute lymphoblastic leukemia.** Ryan Elbashir, Cambridge, MA
- 3:20 p.m.** **3801 Serine starvation inhibits SRSF protein expression and modulates RNA splicing in breast cancer cells.** Philippa Burns, Chicago, IL
- 3:35 p.m.** **3802 Isoleucine and valine promote prostate cancer progression via propionyl-CoA-mediated cholesterol metabolism.** Zhongchi Li, New York, NY
- 3:50 p.m.** **3803 CRISPR screening identifies methionine synthase as a potential therapeutic target in KRAS-driven NSCLC.** Jessie Yanxiang Guo, New Brunswick, NJ
- 4:05 p.m.** **3804 Accumulation of branched chain keto acids promotes immunosuppression and neurodegeneration in leptomenigeal disease.** Mariam Lotfy Khaled, Tampa, FL
- 4:20 p.m.** **Closing Remarks.** Boyi Gan, Houston, TX

Room S402 - McCormick Place South (Level 4)

Multidisciplinary

Cutting-Edge Advances in Hematology: CAR-T Therapy, B-cell Transformation, Leukemia Mechanisms, and Targeted Drug Development

Cochairs: Sarwish Rafiq, Brookhaven, GA; Stephen Gottschalk, Memphis, TN

- 2:30 p.m.** **Introduction.** Sarwish Rafiq, Atlanta, GA

- 2:35 p.m.** **3805 Loss of NSD2 induces acquired resistance to EZH2 inhibitors in B-cell lymphoma by disrupting enhancer function.** Daniel Angelov, Dublin, Ireland
- 2:50 p.m.** **3806 Single-cell transcriptional mapping reveals genetic and non-genetic determinants of aberrant differentiation in AML.** Andy G. Zeng, Toronto, ON, Canada
- 3:05 p.m.** **3807 Validation of a functional genomics screen based on lentiviral integration site analysis reveals single-gene disruptions enhancing CAR19 T-cell effectiveness in preclinical models.** Beatriz Coutinho de Oliveira, Cleveland, OH
- 3:20 p.m.** **3808 Bidirectional glutamine transport prevents mitochondrial stress in B-cell transformation.** Ruifeng Sun, New Haven, CT
- 3:35 p.m.** **3809 Pan-RAS inhibitor RMC-7977 overcomes oncogenic RAS signaling and exerts antileukemic effects in CMML/AML cells.** Tessa Seale, Baltimore, MD
- 3:50 p.m.** **3810 Targeting the ADAR1/PKR pathway in TP53-mutant acute myeloid leukemia.** Yara Rodriguez, Boston, MA
- 4:05 p.m.** **3811 Drug discovery of potent and specific CDK9 protein degraders for the treatment of refractory lymphomas.** Jia Zhou, Galveston, TX
- 4:20 p.m.** **Closing Remarks.** Stephen Gottschalk, Memphis, TN

Room S404 - McCormick Place South (Level 4)

Population Sciences

Genomic Breakthroughs and Biomarker Innovations in Precision Cancer Medicine

Cochairs: Laura Fejerman, Davis, CA; Marcela Mazo-Canola, San Antonio, TX

- 2:30 p.m.** **Introduction.** Laura Fejerman, Davis, CA
- 2:35 p.m.** **3812 Characterization of cancer predisposition among germline variant carriers.** Jie Liu, St. Louis, MO
- 2:50 p.m.** **3813 Multipronged approach identifying new hallmarks of antibiotics-mediated immunosuppression in a prospective trial of cancer immunotherapy.** Carolina Alves Costa Silva, Villejuif, France

- 3:05 p.m.** **3814 Proteomics and overall mortality, imminent death, death at younger age, and cancer death.** Karl Smith-Byrne, Oxford, United Kingdom
- 3:20 p.m.** **3815 High-penetrance rare variants underlying familial lung cancer risk: Insights from the Genetic Epidemiology of Lung Cancer Consortium.** Yanhong Liu, Houston, TX
- 3:35 p.m.** **3816 Fine-mapping candidate causal cell types in solid cancers using cis-regulatory elements.** Peter Kraft, Rockville, MD
- 3:50 p.m.** **3817 Using gene-environment interactions to explore pathways for colorectal cancer risk.** Emmanouil Bouras, London, United Kingdom
- 4:05 p.m.** **3818 Climate stressors and oncology care: awareness of healthcare professionals in Puerto Rico.** Jessica Hernandez Marrero, San Juan, Puerto Rico
- 4:20 p.m.** **Closing Remarks.** Marcela Mazo-Canola, San Antonio, TX

Room S401 - McCormick Place South (Level 4)

Tumor Biology

Cancer Models: Mechanisms and Therapies

Cochairs: Sergei I. Grivennikov, Los Angeles, CA; Kwon-Sik Park, Charlottesville, VA

- 2:30 p.m.** **Introduction.** Sergei I. Grivennikov, Los Angeles, CA
- 2:35 p.m.** **3819 Modeling T cell and cancer cell interactions to examine immune checkpoint inhibition resistance in pancreatic cancer.** Aji Istadi, Darlinghurst, Australia
- 2:50 p.m.** **3820 CancerModels.Org: A comprehensive resource for advancing precision medicine in cancer research.** Zinaida Perova, Cambridge, United Kingdom
- 3:05 p.m.** **3821 Epigenetic mechanisms in early-onset hereditary cancer: Insights from a new Brca1 mouse model.** Carman Li, Boston, MA
- 3:20 p.m.** **3822 Development and characterization of mouse models of epithelioid sarcoma.** Ryo Miyamoto, Toronto, ON, Canada
- 3:35 p.m.** **3823 Triple negative breast cancer (TNBC) PDX models for preclinical investigation of novel therapies.** Jens Hoffmann, Berlin, Germany

- 3:50 p.m.** **3824 Investigating the role of allelic imbalance in pancreatic cancer aggressiveness, survival, and therapeutic resistance.** Enrico Gurreri, Houston, TX
- 4:05 p.m.** **3825 Divergent evolution of FOXA1 mutations drive prostate tumorigenesis or therapy-resistant intraluminal plasticity.** Sanjana Eyunni, Ann Arbor, MI
- 4:20 p.m.** **Closing Remarks.** Kwon-Sik Park, Charlottesville, VA

Room E450 A - McCormick Lakeside Center (Level 4)

Tumor Biology

Molecular Underpinnings of Metastasis

Cochairs: Lalita Shevde-Samant, Birmingham, AL; Adam I. Marcus, Atlanta, GA

- 2:30 p.m.** **Introduction.** Lalita Shevde-Samant, Birmingham, AL
- 2:35 p.m.** **3826 Awakened dormant cancer cells undergo highly mesenchymal to quasi-mesenchymal transition and acquire stemness.** Jingwei Zhang, Cambridge, MA
- 2:50 p.m.** **3827 Chronic alcohol consumption promotes pancreatic cancer liver metastasis in mice through PAD4-mediated pre-metastatic niche formation.** Jieun Kim, Los Angeles, CA
- 3:05 p.m.** **3828 Understanding the molecular underpinnings of breast cancer brain metastases: implications for early detection and treatment.** Melanie Spears, Toronto, ON, Canada
- 3:20 p.m.** **3829 Dissecting the role of chemotherapy-induced host responses in post-therapy metastatic relapse of breast cancer.** Chaojia Chen, Bar Harbor, ME
- 3:35 p.m.** **3830 The enhanced formation of neutrophil extracellular traps (NETs) contributes to peritoneal and hepatic metastasis in diabetic conditions.** Rei Takahashi, Tochigi, Japan
- 3:50 p.m.** **3831 A molecular landscape of epithelial to mesenchymal transition reveals dependencies on lysosomes and nutrient scavenging.** Michal J. Nagiec, New York, NY
- 4:05 p.m.** **3832 Modeling metastatic ER+ breast cancer in rats.** Carstyn F. Joiner, Madison, WI
- 4:20 p.m.** **Closing Remarks.** Adam I. Marcus, Atlanta, GA

**SPECIAL SESSION****2:30 p.m.–4:30 p.m.**

Room E352 - McCormick Lakeside Center (Level 3)

AACR-JCA Joint Session: Aberrant Neural Mechanisms in Brain Tumor Development and Therapy**Cochairs:** Annie A. Huang, Toronto, ON, Canada; Hiromichi Suzuki, Tokyo, Japan

- 2:30 p.m. Introduction.** Annie A. Huang, Toronto, ON, Canada
- 2:34 p.m. Interrogation of the repetitive genome yields novel insights into MB development.** Hiromichi Suzuki, Tokyo, Japan
- 3:02 p.m. Unraveling cancer-specific epigenome to delineate targetable neural mechanisms in SHH-medulloblastoma.** Daisuke Kawauchi, Nagoya, Japan
- 3:30 p.m. Mechanisms of neuronal diversity and cellular heterogeneity in ETMRs.** Annie A. Huang, Toronto, ON, Canada
- 3:58 p.m. Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells.** Sheila K. Singh, Hamilton, ON, Canada
- 4:26 p.m. Closing Remarks.** Hiromichi Suzuki, Tokyo, Japan

MINISYMPOSIUM**2:30 p.m.–4:45 p.m.****NOT ELIGIBLE FOR CME CREDIT**

Room S103 - McCormick Place South (Level 1)

**Experimental Therapeutics
Novel Antitumor Agents****Cochairs:** Richard C. Marcellus, Toronto, ON, Canada; Derek R. Duckett, Tampa, FL

- 2:30 p.m. Introduction.** Derek R. Duckett, Tampa, FL

- 2:40 p.m. 3784 Activity of the novel KIF18A inhibitor, ATX-295, is enriched in whole genome doubled ovarian cancer pre-clinical models.** Maureen M. Lynes, Lexington, MA
- 2:55 p.m. 3785 CFON-026 is a macrocycle that disrupts the BTK protein scaffold thereby inhibiting all clinically relevant BTK resistance mutations.** Jos de Man, Oss, Netherlands
- 3:10 p.m. 3786 Combination of MTA-cooperative PRMT5 inhibitor BMS-986504 and KRAS inhibitors for the treatment of MTAP-deleted KRAS-mutant pancreatic cancer.** Kristina Drizyte-Miller, Chapel Hill, NC
- 3:25 p.m. 3787 Restoring the function of the guardian of the genome: FMC-220 a highly potent and selective covalent activator of p53 Y220C.** Kevin R. Webster, Boston, MA
- 3:40 p.m. 3788 BBO-8520, a first-in-class direct dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C, exhibits robust efficacy in non-small cell lung cancer preclinical models.** James P. Stice, South San Francisco, CA
- 3:55 p.m. 3789 INCB177054: A novel, potent, orally bioavailable DGK α/ζ dual inhibitor enhances T-cell function and demonstrates potent antitumor activity.** Xiaodi Ren, Wilmington, DE
- 4:10 p.m. 3790 Preclinical assessment of valemetostat, a dual inhibitor of EZH2 and EZH1, combined with trastuzumab deruxtecan and datopotamab deruxtecan for multiple solid tumors.** Daisuke Honma, Tokyo, Japan
- 4:25 p.m. 6370 Farnesyl transferase inhibitor KO-2806 enhances the antitumor activity of cabozantinib in ccRCC tumors that progress on anti-VEGFR agents.** Jovelyn G. Gasendo, San Diego, CA
- 2:30 p.m. Closing Remarks.** Richard C. Marcellus, Toronto, ON, Canada

**AWARD LECTURE****3:00 p.m.–3:45 p.m.**

Room E351 - McCormick Lakeside Center (Level 3)

**AACR-Minorities in Cancer Research
Jane Cooke Wright Lectureship****Chair:** Jose G. Trevino, Richmond, VA**Funder Remarks:** Jamal Sims, Foster City, CA**Addressing disparities in lymphoma outcomes.** Christopher R. Flowers, Houston, TX**MAJOR SYMPOSIUM****3:00 p.m.–4:30 p.m.**

Room S106 - McCormick Place South (Level 1)

**Regulatory Science and Policy Session
Molecular Tumor Profiling for Pediatric Oncology****NOT ELIGIBLE FOR CME CREDIT****Chair:** Alejandro Sweet-Cordero, San Francisco, CA**Speakers:** Alanna Joyce Church, Boston, MA; Katherine A. Janeway, Boston, MA; Elaine R. Mardis, Columbus, OH**AWARD LECTURE****4:15 p.m.–5:00 p.m.****NOT ELIGIBLE FOR CME CREDIT**

Room E351 - McCormick Lakeside Center (Level 3)

**AACR-Margaret Foti Award for Leadership and
Extraordinary Achievements in Cancer Research****Chair:** Michael A. Caligiuri, Duarte, CA**From academia to industry: An incredible journey in innovation.**
William N. Hait, New Brunswick, NJ**SPECIAL SESSION****4:45 p.m.–6:15 p.m.**

Room E450 A - McCormick Lakeside Center (Level 4)

**AACR-ASCO Joint Session: Challenges and
Opportunities of Theranostics****Cochairs:** Patricia M. LoRusso, New Haven, CT; Robin Zon, Cincinnati, OH**4:45 p.m. Introduction from the AACR President.** Patricia M. LoRusso, New Haven, CT**4:46 p.m. Introduction from the ASCO President.** Robin Zon, Cincinnati, OH**4:47 p.m. Molecular imaging, theranostics, and cancer drug development.** E.G. Elisabeth de Vries, Groningen, Netherlands**5:07 p.m. Role of dosimetry in personalizing radiopharmaceutical therapy.** Ravi B. Patel, Pittsburgh, PA**5:27 p.m. Enhancing global access to innovative radiopharmaceuticals and technologies.** Mike Sathekge, Pretoria, South Africa**5:47 p.m. Panel Discussion****AWARD LECTURES****5:00 p.m.–5:45 p.m.**

Room S103 - McCormick Place South (Level 1)

**AACR Award for Outstanding Achievement
in Chemistry in Cancer Research****NOT ELIGIBLE FOR CME CREDIT****Chair:** Danette L. Daniels, Cambridge, MA**Targeted therapies in cancer: The past, present and future.**
Shiva Malek, Cambridge, MA

Room S401 - McCormick Place South (Level 4)

AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research

NOT ELIGIBLE FOR CME CREDIT

Chair: Frederick R. Appelbaum, Seattle, WA

From breakthrough to benchmark: Generational leaps in targeted therapies. Alice T. Shaw, Boston, MA

Room S106 - McCormick Place South (Level 1)

AACR-St. Baldrick's Foundation Award for Outstanding Achievement in Pediatric Cancer Research

Chair: Jason T. Yustein, Atlanta, GA

Dissecting the genome of acute lymphoblastic leukemia. Charles G. Mullighan, Memphis, TN



MEET-THE-EXPERT SESSIONS **5:00 p.m.-5:45 p.m.**

Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)

Beyond Immune Checkpoint Blockade: Emerging Strategies

Tak W. Mak, Toronto, ON, Canada

Room S102 - McCormick Place South (Level 1)

Molecular Epidemiology to Identify Cancer Mechanisms and Prevention Strategies

Elizabeth A. Platz, Baltimore, MD

Room E450 B - McCormick Lakeside Center (Level 4)

Multigene Sequencing for Treatment Decisions: What Did We Learn?

Fabrice Andre, Villejuif, France

Room S105 - McCormick Place South (Level 1)

Studying Metastasis in Small Cell Lung Cancer

Caroline Dive, Manchester, United Kingdom



FORUMS

5:00 p.m.-6:30 p.m.

Room E451 - McCormick Lakeside Center (Level 4)

Advances in Tumor-infiltrating Lymphocyte (TIL) and CAR T Therapies

Chair: Inge Marie Svane, Copenhagen, Denmark

5:00 p.m. Chair Introduction. Inge Marie Svane, Copenhagen, Denmark

5:01 p.m. Is neoantigen dissection needed to advance TIL ACT? Inge Marie Svane, Copenhagen, Denmark

5:20 p.m. TCRs and TIME what's Kras got to do with it? Robert H. Vonderheide, Philadelphia, PA

5:40 p.m. Unveiling the mechanisms of TIL therapy: Toward next-generation. Alexandre Harari, Lausanne, Switzerland

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)
Intra-tumor Heterogeneity of Cancer Models: Towards More Realistic Models for Therapy

Chair: Carlo C. Maley, Tempe, AZ

5:00 p.m. Chair Introduction. Carlo C. Maley, Tempe, AZ

5:05 p.m. The problem of intra-tumor homogeneity in pre-clinical models. Carlo C. Maley, Tempe, AZ

5:20 p.m. Preclinical models of heterogeneous breast cancer. Kornelia Polyak, Brookline, MA

5:40 p.m. Breast cancer patient-derived xenografts to model tumor ecosystems. Carlos M. Caldas, Cambridge, MA

Room E352 - McCormick Lakeside Center (Level 3)

The Role of Surgery in Modern Cancer Treatment: Opportunity for Patient-derived Models or Simply an Art of Diminishing Return

Chair: Jonathan Hernandez, Bethesda, MD

5:00 p.m. Chair Introduction. Jonathan Hernandez, Bethesda, MD

5:05 p.m. Liver metastases. Jonathan Hernandez, Bethesda, MD

5:20 p.m. Colorectal cancer. Jesse Joshua Smith, New York, NY

5:40 p.m. Pancreatic cancer. Jen Jen Yeh, Chapel Hill, NC

Room E353 C - McCormick Lakeside Center (Level 3)

Significance, Innovation, and Challenges of Biostatistics in Preclinical Studies, Clinical Trials, and Beyond

Chair: J. Jack Lee, Houston, TX

5:00 p.m. Chair Introduction. J. Jack Lee, Houston, TX

5:05 p.m. Foundation of biostatistics in preclinical studies.
J. Jack Lee, Houston, TX

5:25 p.m. Critical roles of biostatisticians in clinical trials.
Lindsay A. Renfro, Los Angeles, CA

5:45 p.m. From data to discovery: How biostatistics, bioinformatics, and AI advance cancer research.
Yu Shyr, Nashville, TN



SPECIAL SESSION

5:00 p.m.–6:30 p.m.

Room E350 - McCormick Lakeside Center (Level 3)

Using Communication Effectively to Foster Trust in Science, Cultivate Engagement, and Improve Clinical Trial Participation

Chair: William S. Dalton, Tampa, FL

5:00 p.m. Opening remarks. William S. Dalton, Tampa, FL

5:10 p.m. Building trust through community-centered clinical trials. Robert A. Winn, Richmond, VA

5:28 p.m. The patient's perspective: Building trust through engagement and communication. Deborah E. Collyar, Danville, CA

5:46 p.m. Science for everyone: Countering misinformation and building public trust. K. Vish Viswanath, Boston, MA



AWARD LECTURES

5:30 p.m.–6:15 p.m.

Room E351 - McCormick Lakeside Center (Level 3)

AACR Award for Outstanding Achievement in Basic Cancer Research

Chair: Kristin A. Altwegg, Rockville, MD

Fill the gap between big cancer data and cancer medicine.
Han Liang, Houston, TX

Room S404 - McCormick Place South (Level 4)

AACR-G.H.A. Clowes Award for Outstanding Basic Cancer Research

Chair: J. Alan Diehl, Pepper Pike, OH

Funder Remarks: Kristin Bedard, South San Francisco, CA

Metabolic control of cancer progression. Karen H. Vousden, London, United Kingdom

PROFESSIONAL DEVELOPMENT SESSION

5:30 p.m.–7:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Regency CDE - Hyatt Regency McCormick Place

Productive Peer Review: Improving Science While Avoiding Common Pitfalls

Moderators: Christine A. Iacobuzio-Donahue, New York, NY;
Christine M. Lovly, Nashville, TN

TOWN HALL MEETING**5:30 p.m.–7:00 p.m.****NOT ELIGIBLE FOR CME CREDIT**

Great Lakes AB - Marriott Marquis Chicago

Minorities in Cancer Research Town Hall Meeting**Chair:** Melissa B. Davis, Atlanta, GA**TOWN HALL MEETINGS****6:30 p.m.–8:30 p.m.****NOT ELIGIBLE FOR CME CREDIT**

Room S102 - McCormick Place South (Level 1)

Biomarker Discovery, Validation, and Clinical Implementation for Cancer Prevention: Success Stories and Lessons Learned—A Cancer Prevention Working Group Town Hall Meeting**Cochairs:** Marcia R. Cruz-Correa, San Juan, PR; Adriana Albini, Milano, Italy**Panelists:** Anirban Maitra, Houston, TX; Andrea De Censi, Genova, Italy; Sara A. Hurvitz, Seattle, WA

Room S103 - McCormick Place South (Level 1)

Charting the Course: Innovating Cancer Drug Discovery in a Challenging Landscape—A Chemistry in Cancer Research Working Group Town Hall Meeting**Cochairs:** Lori S. Friedman, South San Francisco, CA; Mary M. Mader, Indianapolis, IN**Moderator:** Daniel K. Nomura, Berkeley, CA**Panelists:** Gwenn Hansen, San Francisco, CA; Shiva Malek, Cambridge, MA; Joseph Pearlberg, New York, NY; Ryan Schoenfeld, New York, NY

Room S101 - McCormick Place South (Level 1)

Critical Dependencies in Hematologic Malignancies: A Hematologic Malignancies Working Group Town Hall Meeting**Chair:** Kenneth C. Anderson, Wellesley, MA**Panelists:** Maria E. Figueroa, Miami, FL; Lucy A. Godley, Chicago, IL; Kimberly Stegmaier, Boston, MA

Room S105 - McCormick Place South (Level 1)

Functional Consequences of Cellular and Molecular Heterogeneity in the Tumor Microenvironment: A Tumor Microenvironment Working Group Town Hall Meeting**Cochairs:** Edna Cukierman, Philadelphia, PA; Mikala Egeblad, Baltimore, MD**Panelists:** Jose M. Adrover, London, United Kingdom; Saumya Maru, Baltimore, MD; Maayan Pour, New York, NY

Room S104 - McCormick Place South (Level 1)

Is Cancer Evolution Driven by Evolutionary Genomic, Epigenomic Alterations or the Microenvironment? A Cancer Evolution Working Group Town Hall Meeting**Cochairs:** Anna D. Barker, Los Angeles, CA; Jeffrey P. Townsend, New Haven, CT**Panelists:** Mathieu Lupien, Toronto, ON, Canada; Andriy Marusyk, Tampa, FL; J. Nicholas Fisk, Kingston, RI**PROFESSIONAL DEVELOPMENT SESSION****7:00 p.m.–9:00 p.m.****NOT ELIGIBLE FOR CME CREDIT**

Hall C - McCormick Place North (Level 1)

Navigating the Path to a Successful Career in Cancer Research**Cochairs:** Brian M. Rivers, Atlanta, GA; Carmen E. Guerra, Philadelphia, PA; Luz Maria Rodriguez, Rockville, MD; Pablo A. Sanchis, Buenos Aires, Argentina



PLENARY SESSION

8:00 a.m.–10:00 a.m.

Hall B1 - McCormick Place North (Level 3)

Targeting the Cancer Ecosystem

Chair: Mara H. Sherman, New York, NY

8:00 a.m. Chair Introduction. Mara H. Sherman, New York, NY

8:05 a.m. PL04-01 The various layers of intratumor heterogeneity and their impact on tumor immunity.
Yardena Samuels, Rehovot, Israel

8:32 a.m. Leveraging tumor immune archetypes in treating cancer. Matthew F. Krummel, San Francisco, CA

8:59 a.m. Decoding the role of spatial tumor-immune cell interactions in cancer progression and treatment sensitivity. Kurt A. Schalper, New Haven, CT

9:26 a.m. Metastatic dissemination from the perspective of the cancer cell, its microenvironment, and the host.
Mariam Jamal-Hanjani, London, United Kingdom

9:53 a.m. Wrap-up and opportunities for the future. Mara H. Sherman, New York, NY

PROFESSIONAL DEVELOPMENT SESSION

8:30 a.m.–2:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Hall C - McCormick Place North (Level 1)

Special Program for High School Students: The Conquest of Cancer and the Next Generation of Cancer Researchers

Chair: Brian M. Rivers, Atlanta, GA

POSTER SESSION

9:00 a.m.–12:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Halls A1-2, McCormick Place South

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

Tumor Biology

- Section 1 Angiogenesis
- Section 2 Approaches for Metastasis Inhibition
- Section 3 Cancer Cell Heterogeneity, Evolution, and Trajectory Profiling
- Section 4 Mouse and Other Models
- Section 5 Pediatric Cancer Models
- Section 6 The Tumor Immune Interplay as a Driver of Progression
- Section 7 Tumoroids, Organoids, and Cell Culture

Science and Health Policy

- Section 8 Cancer Survivorship and Patient Communication / Patient Advocacy and Engagement

Molecular/Cellular Biology and Genetics

- Section 9 Gene Regulation and Transcription Factors 1
- Section 10 High-Throughput Sequencing / Microarrays / Next-Generation Sequencing
- Section 11 Integrating Chromatin, Oncogenes, DNA Repair, and Biomarkers for Therapeutic Advancements
- Section 12 Kinases/Phosphatases, Ubiquitin, and Ubiquitin-like Proteins
- Section 13 Metabolic Pathways
- Section 53 Late-Breaking Research: Molecular/Cellular Biology and Genetics 2

Experimental and Molecular Therapeutics

- Section 15 DNA Damage Response and Modulation of DNA Repair 2
- Section 16 HDAC and Methyltransferase Inhibitors
- Section 17 New and Emerging Cancer Drug Targets
- Section 18 Novel Cancer Therapeutic Targets 1
- Section 19 Oncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy 1
- Section 20 Pharmacokinetics and Pharmacodynamics of Cancer Therapeutics
- Section 21 RAS Inhibitors
- Section 22 Regulation of Gene Expression in Drug Resistance
- Section 23 Reversal of Drug Resistance 2
- Section 52 Late-Breaking Research: Experimental and Molecular Therapeutics 3

Chemistry

- Section 25 Computational Drug Discovery, Nanotechnology, and Therapeutics
- Section 26 Proteomic Biomarkers and Therapeutics

Clinical Research

- Section 27 Biostatistics in Clinical Trials / Surgical Oncology
- Section 28 Immune Responses to Therapies Including Chemotherapy and Radiotherapy
- Section 29 Liquid Biopsy: Circulating Nucleic Acids 2
- Section 30 Molecular Diagnosis, Molecular Characterization and Theranostics of Tumors
- Section 31 Predictive Biomarkers 5
- Section 32 Prognostic Biomarkers 3
- Section 33 Radiation Sciences 1
- Section 34 Targeted Therapies and Combinations 2
- Section 51 Late-Breaking Research: Clinical Research 2 / Endocrinology

Clinical Trials

- Section 48 First-in-Human Phase I Clinical Trials 2
- Section 49 Phase II Clinical Trials 1
- Section 50 Phase I Clinical Trials in Progress 2

Endocrinology

- Section 35 Molecular, Preclinical, and Clinical Endocrinology
- Section 51 Late-Breaking Research: Clinical Research 2 / Endocrinology

Immunology

- Section 36 Antibodies and Antibody-Drug Conjugates
- Section 37 CAR-T Cells
- Section 38 Epigenetic Regulation of Tumor Immunity
- Section 39 Immune Fitness and Metabolic Regulation of Cancer Immunity
- Section 40 Modulation of Tumor Microenvironment: Modulation of Lymphocyte Influx

Population Sciences

- Section 41 Advancing Cancer Health Equity Through Screening, Diagnostics, Genetics, and Social Determinants
- Section 42 Environmental, Social, and Biological Determinants of Cancer Risk and Survival
- Section 54 Late-Breaking Research: Population Sciences

Prevention, Early Detection, and Interception

- Section 43 Health Disparities across the Cancer Continuum
- Section 44 Survivorship Research

Bioinformatics, Computational Biology, Systems Biology, and Convergent Science

- Section 45 Multi-modal Analysis and Multi-omics Characterization
- Section 46 Sequence Analysis and Genome Landscapes
- Section 47 Single-Cell and Spatial Molecular Analysis

MEET AND GREET SESSION**9:30 a.m.–10:30 a.m.****NOT ELIGIBLE FOR CME CREDIT**

AACR Publications Booth 2615 - South Halls A1-2

Meet the New Editor-in-Chief of *Molecular Cancer Therapeutics*: Daniel K. Nomura**ADVANCES IN DIAGNOSTICS AND THERAPEUTICS****10:15 a.m.–11:45 a.m.**

Room S102 - McCormick Place South (Level 1)

Next Generation Cell Cycle Inhibitors: Moving to Selective Inhibitors and Rationale Combinations**Chair:** Elizabeth Ruth Plummer, Newcastle Upon Tyne, United Kingdom

- 10:15 a.m. Chair Introduction.** Elizabeth Ruth Plummer, Newcastle Upon Tyne, United Kingdom
- 10:20 a.m. Novel selective cell cycle inhibitors.** Geoffrey I. Shapiro, Boston, MA
- 10:45 a.m. Mechanism and strategies for immunological combinations.** Gary K. Schwartz, Cleveland, OH
- 11:10 a.m. Emerging transcriptional cell cycle inhibitors.** Elizabeth Ruth Plummer, Newcastle Upon Tyne, United Kingdom

**ADVANCES IN EARLY DETECTION AND INTERCEPTION****10:15 a.m.–11:45 a.m.**

Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)

Opportunities in Cancer Early Detection Using Next Generation Liquid Biopsies**Chair:** Victor E. Velculescu, Baltimore, MD

- 10:15 a.m. Chair Introduction.** Victor E. Velculescu, Baltimore, MD
- 10:16 a.m. Circulating biomarkers for cancer risk assessment and early detection.** Sam M. Hanash, Houston, TX
- 10:41 a.m. Identification of early detection biomarkers through multiomic analysis of precursor lesions.** Ronny I. Drapkin, Philadelphia, PA
- 11:06 a.m. Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection.** Victor E. Velculescu, Baltimore, MD

**ADVANCES IN HEMATOLOGIC MALIGNANCIES****10:15 a.m.–11:45 a.m.**

Room S401 - McCormick Place South (Level 4)

Epigenetics and RNA Modification in Hematologic Malignancies**Chair:** Chuan He, Chicago, IL

- 10:15 a.m. Chromatin regulation by RNA methylation in leukemia.** Chuan He, Chicago, IL
- 10:40 a.m. Novel mechanisms driving acute myeloid leukemia.** Margaret A. Goodell, Houston, TX
- 11:05 a.m. Targeting the KMT2A: Menin complex in leukemia.** Scott A. Armstrong, Boston, MA



ADVANCES IN ORGAN SITE RESEARCH

10:15 a.m.–11:45 a.m.

Room E450 A - McCormick Lakeside Center (Level 4)

Optimizing and Moving beyond PSMA Based Radiopharmaceuticals for Prostate Cancer

Chair: Michael J. Morris, New York, NY

- 10:15 a.m.** **Chair Introduction.** Michael J. Morris, New York, NY
- 10:20 a.m.** **Leveraging biomarkers and new target development for radioligand therapy in prostate cancer.** Michael J. Morris, New York, NY
- 10:45 a.m.** **PSMA regulation in advanced prostate cancer and therapeutic implications.** Himisha Beltran, Boston, MA
- 11:10 a.m.** **Improving efficacy of radioligand therapy in prostate cancer: Novel combinations and new payloads.** Shahneen K. Sandhu, Parkville, Australia

Room S103 - McCormick Place South (Level 1)

Updates from SABCS 2024

Cochairs: Carlos L. Arteaga, Dallas, TX; Charles M. Perou, Chapel Hill, NC

- 10:15 a.m.** **Introduction.** Carlos L. Arteaga, Dallas, TX
- 10:20 a.m.** **Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2- metastatic breast cancer.** Pedram Razavi, New York, NY
- 10:40 a.m.** **APOBEC3 mutagenesis induces resistance-promoting genomic alterations in breast cancer.** Avantika Gupta, New York City, NY
- 11:00 a.m.** **Exploratory biomarker analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) efficacy in human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC) in DESTINY-Breast03 (DB-03).** William Jacot, Montpellier, France
- 11:20 a.m.** **Paired DNA and RNA analysis of CALGB 40603 (Alliance) reveals insights into the molecular and prognostic landscape of stage II-III triple-negative breast cancer.** Brooke Felsheim, Chapel Hill, NC
- 11:40 a.m.** **Closing Remarks.** Charles M. Perou, Chapel Hill, NC



ADVANCES IN POPULATION SCIENCES

10:15 a.m.–11:45 a.m.

Room E352 - McCormick Lakeside Center (Level 3)

Sustaining Cancer Prevention and Control Programs in Diverse Communities: Model Community-Living Learning Health Systems

Chair: Folakemi T. Odedina, Jacksonville, FL

- 10:15 a.m.** **Chair Introduction.** Folakemi T. Odedina, Jacksonville, FL
- 10:20 a.m.** **Community embedded interventions to address disparities in prostate cancer outcomes.** Ernest Kaninjing, Milledgeville, GA
- 10:45 a.m.** **Community-based approach to cancer prevention and control: The African tale.** Catherine Adebukola Oladoyinbo, Lagos, Nigeria
- 11:10 a.m.** **Community embedded interventions to address human papilloma virus disease awareness.** Marc T. Goodman, Los Angeles, CA



ADVANCES IN PREVENTION RESEARCH

10:15 a.m.–11:45 a.m.

Room S105 - McCormick Place South (Level 1)

New Game Plan for Cancer Prevention: Tackling Neoplasms by Intercepting the Host Microenvironment

Chair: Edna Cukierman, Philadelphia, PA

- 10:15 a.m.** **Chair Introduction.** Edna Cukierman, Philadelphia, PA
- 10:20 a.m.** **Targeting age-associated ovarian fibrosis to reduce cancer risk.** Barbara Vanderhyden, ON, Canada
- 10:45 a.m.** **Modeling the progression to pancreatic tumor invasion from in silico to human fibroblast-epithelial interactions.** Elana Judith Fertig, Baltimore, MD
- 11:10 a.m.** **Intercepting pancreatic cancer by targeting its predisposed TME.** Edna Cukierman, Philadelphia, PA



ADVANCES IN TECHNOLOGIES

10:15 a.m.–11:45 a.m.

Room S404 - McCormick Place South (Level 4)

Emerging Concepts and Technologies to Enable the Discovery of Allosteric Inhibitors

NOT ELIGIBLE FOR CME CREDIT

Chair: Brian Liao, Cambridge, United Kingdom

- 10:15 a.m. Chair Introduction.** Brian Liao, Cambridge, United Kingdom
- 10:20 a.m. Leveraging large-scale mutational scanning to identify candidate allosteric sites.** Brian Liao, Cambridge, United Kingdom
- 10:40 a.m. The allosteric mechanism of the anti-cancer drug Selinexor in XPO1 degradation.** Yuh Min Chook, Dallas, TX
- 11:00 a.m. Large library docking against AlphaFold models: unlocking novel chemotypes to potentiate allosteric modulator discovery.** Jiankun Lyu, New York, NY

Room S406 (Vista Ballroom) - McCormick Place South (Level 4)

Reality Check: AI in Drug Discovery

Chair: Bissan Al-Lazikani, Houston, TX

- 10:15 a.m. Chair Introduction.** Bissan Al-Lazikani, Houston, TX
- 10:17 a.m. Catching cancer early: AI for risk prediction, blood test, clinical screening.** Chris Sander, Boston, MA
- 10:42 a.m. Reminiscing about the future of AI in drug discovery.** Alexander Tropsha, Chapel Hill, NC
- 11:07 a.m. From and to the patient: Forward and reverse transition in drug discovery.** Bissan Al-Lazikani, Houston, TX



MAJOR SYMPOSIA

10:15 a.m.–11:45 a.m.

Room E451 - McCormick Lakeside Center (Level 4)

Advances in Cancer Vaccines

Chair: Darrell J. Irvine, La Jolla, CA

- 10:15 a.m. Introduction.** Darrell J. Irvine, La Jolla, CA
- 10:20 a.m. Identification and functional validation of neoantigen-specific TCRs from PBMC in low mutational burden cancer patients.** Stephen P. Schoenberger, La Jolla, CA
- 10:45 a.m. RNA vaccines for pancreatic cancer.** Vinod P. Balachandran, New York, NY
- 11:10 a.m. Enhancing cancer vaccines through lymph node targeting.** Darrell J. Irvine, La Jolla, CA

Room E353 C - McCormick Lakeside Center (Level 3)

Cardio-Oncology: A Novel Platform for Investigation

Chair: Javid J. Moslehi, San Francisco, CA

- 10:15 a.m. Introduction.** Javid J. Moslehi, San Francisco, CA
- 10:20 a.m. The endothelium as a source of cardiovascular toxicity from cancer therapy.** Iris Jaffe, Medford, MA
- 10:45 a.m. Endothelial cell apoptosis as a mechanism of cancer therapy-induced cardiovascular toxicity.** Kristopher A. Sarosiek, Boston, MA
- 11:10 a.m. Immune checkpoint inhibitors and cardiac toxicity: From mice to humans.** Javid J. Moslehi, San Francisco, CA

Room S106 - McCormick Place South (Level 1)

**Regulatory Science and Policy Session
Implementing Multi-Regional Clinical Trials (MRCTs)
for Cancer Research in an Evolving World**

NOT ELIGIBLE FOR CME CREDIT

Moderator: Harpreet Singh, Frederick, MD

Panelists: Andy Kinley, Frederick, MD; Guilin Huang, Boston, MA;
Raymond U. Osarogiagbon, Memphis, TN; Stacey Bledsoe,
Foster City, CA

Room E350 - McCormick Lakeside Center (Level 3)

**Minorities in Cancer Research Scientific Symposium:
Using Self-identified Race/Ethnic Categories in
Cancer Disparities Research in the Era of Precision
Medicine**

Cochairs: Carmen E. Guerra, Philadelphia, PA; Camille C. R. Ragin,
Philadelphia, PA

Speakers: Chanita Hughes Halbert, Los Angeles, CA; Rodney C.
Haring, Buffalo, NY; Scarlett L. Gomez, San Francisco, CA

Room E351 - McCormick Lakeside Center (Level 3)

**Novel Classes of Human Cancer Rejection Antigens:
Beyond Point Mutations**

NOT ELIGIBLE FOR CME CREDIT

Chair: Christopher A. Klebanoff, New York, NY

10:15 a.m. Introduction. Christopher A. Klebanoff, New York, NY

**10:20 a.m. Therapeutic targeting of public neoantigens
resulting from recurrent gene fusions and mRNA
mis-splicing events.** Christopher A. Klebanoff,
New York, NY

**10:45 a.m. Tumor-wide RNA splicing aberrations generate
therapeutically actionable public neoantigens.**
Hideho Okada, San Francisco, CA

**11:10 a.m. Dark genome antigens as targets for
immunotherapies.** Sebastian Amigorena, Paris,
France

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)

**The Influence of Diet and Metabolism on
Cancer Cell State**

Chair: Lydia W.S. Finley, New York, NY

10:15 a.m. Introduction. Lydia W.S. Finley, New York, NY

**10:20 a.m. Identifying and exploiting cell-state dependent
metabolic vulnerabilities.** Lydia W.S. Finley,
New York, NY

10:45 a.m. A role for ROS in pancreas cancer progression.
Karen H. Vousden, London, United Kingdom

**11:10 a.m. Dietary control of intestinal stem cells in physiology
and cancer.** Omer H. Yilmaz, Cambridge, MA

Room E450 B - McCormick Lakeside Center (Level 4)

**Unraveling the Mechanisms of Action for Combined
Immune-Radiation Therapy**

Chair: Sandra Demaria, New York, NY

10:15 a.m. Introduction. Sandra Demaria, New York, NY

**10:20 a.m. SY36-01 Harnessing the radiation-induced local
and systemic immune modulation to improve tumor
control.**
Tim Illidge, Manchester, United Kingdom

**10:45 a.m. SY36-02 Interrogating how the dialogue between
immune cells and fibroblasts impacts radiotherapy
outcomes.** Anna Wilkins, London, United Kingdom

**11:10 a.m. Novel radiation-immunotherapy combinations to
enhance antitumor efficacy.** Sandra Demaria,
New York, NY



CLINICAL TRIALS PLENARY SESSION

10:15 a.m.–12:15 p.m.

Arie Crown Theater - McCormick Lakeside Center (Level 2)

Biologics and T-cell Engagers

Cochairs: Crystal L. Mackall, Stanford, CA; Jedd D. Wolchok, New York, NY

10:15 a.m. CT203 Fc-optimized anti-CD40 agonist antibody 2141-V11 for BCG-unresponsive non-muscle invasive bladder cancer: Updates on phase 1 study clinical outcomes and biological correlatives. Juan C. Osorio, New York, NY

10:30 a.m. Discussant. Sangeeta Goswami, Houston, TX

10:45 a.m. CT204 Phase 1a/b study of runimotamab, a HER2 x CD3 T cell-engaging bispecific antibody, administered as a single agent and in combination with trastuzumab in patients with HER2-expressing breast cancer (BC). Shanu Modi, New York City, NY

11:00 a.m. Discussant. Hope S. Rugo, San Francisco, CA

11:15 a.m. CT205 Updated clinical results, recommended phase 2 dose (RP2D) determination and translational study results for START-001: A phase 1/2 trial of invikafusp alfa, a first-in-class TCR b chain-targeted bispecific antibody in patients with anti-PD(L)1-resistant, antigen-rich solid tumors. Ryan J. Sullivan, Boston, MA

11:30 a.m. Discussant. Jason J. Luke, Pittsburgh, PA

11:45 a.m. CT206 ICAM-1 directed chimeric antigen receptor (CAR) T cells (AIC100) in patients with advanced thyroid cancers: Clinical and translational data from the phase 1 dose escalation study. Samer A. Srour, Houston, TX

12:00 p.m. Discussant. Sandip Pravin Patel, Del Mar, CA

MEET AND GREET

11:30 a.m.–12:30 p.m.

NOT ELIGIBLE FOR CME CREDIT

AACR Publications Booth 2615 - South Halls A1-2

Meet the Editors-in-Chief of *Cancer Prevention Research*: Raymond N. DuBois and Nickolas Papadopoulos



AWARD LECTURE

12:00 p.m.–12:30 p.m.

Room S402 - McCormick Place South (Level 4)

AACR Gertrude B. Elion Cancer Research Award Lecture

Chair: Geeta Sharma, Baltimore, MD

Deconstructing benign-to-malignant transition in the colon. Peter M.K. Westcott, Cold Spring Harbor, NY



ADVANCES IN DIAGNOSTICS AND THERAPEUTICS

12:30 p.m.–2:00 p.m.

Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)

Bispecifics: The Case for Duality

Chair: Elena Garralda, Barcelona, Spain

12:30 p.m. Chair Introduction. Elena Garralda, Barcelona, Spain

12:35 p.m. Preclinical development of bispecific antibodies: Opportunities and challenges. Timothy Heffernan, Houston, TX

1:25 p.m. Clinical advances and future directions in T-cell engager therapies. James L. Gulley, Takoma Park, MD

1:00 p.m. Expanding the potential of bispecific antibodies: Beyond T-cell engagers. Elena Garralda, Barcelona, Spain



ADVANCES IN HEMATOLOGIC MALIGNANCIES

12:30 p.m.–2:00 p.m.

Room S401 - McCormick Place South (Level 4)

Myeloma as a Model for Early Interception

Cochairs: Omar Nadeem, Boston, MA; Gad Getz, Cambridge, MA

- 12:30 p.m. Chair Introduction.** Gad Getz, Cambridge, MA
- 12:35 p.m. Studying the progression of myeloma: From precursor conditions to overt myeloma.** Gad Getz, Cambridge, MA
- 1:00 p.m. Screening for monoclonal gammopathy of undetermined significance (MGUS): Opportunity for early intervention.** Sigurour Kristinnsson, Reykjavik, Iceland
- 1:25 p.m. Early therapeutic intervention to prevent multiple myeloma.** Omar Nadeem, Boston, MA

Room E450 A - McCormick Lakeside Center (Level 4)

Innovative Paradigms in Immunotherapy Combinations in Gastric/Gastroesophageal Cancer

Chair: Sun Young Rha, Seoul, Republic of Korea

- 12:30 p.m. Chair Introduction.** Sun Young Rha, Seoul, Republic of Korea
- 12:35 p.m. Building on the foundations of PD-1 in gastroesophageal cancer.** Samuel J. Klemperer, Boston, MA
- 1:00 p.m. Charting gastric cancer evolution through tumor ecosystems and metastatic pathways.** Raghav Sundar, New Haven, CT
- 1:25 p.m. Harnessing tumor microenvironment understanding for precision immunotherapy.** Sun Young Rha, Seoul, Republic of Korea



ADVANCES IN POPULATION SCIENCES

12:30 p.m.–2:00 p.m.



ADVANCES IN ORGAN SITE RESEARCH

12:30 p.m.–2:00 p.m.

Room E353 C - McCormick Lakeside Center (Level 3)

Emergence of Neuroendocrine Cancers as Resistance to Therapy: Dedicated to the Memory of Andrew Schally

Chair: Charles M. Rudin, New York, NY

- 12:30 p.m. Chair Introduction.** Charles M. Rudin, New York, NY
- 12:35 p.m. DLL3 as a diagnostic and therapeutic target in neuroendocrine cancer transformation.** John Thomas Poirier, New York, NY
- 1:00 p.m. Epigenetic drivers that constrain the small cell lung cancer (SCLC) neuroendocrine phenotype and promote SCLC histological transformation.** Matthew Gilbert Oser, Boston, MA
- 1:25 p.m. Insights into lineage plasticity from single cell analyses of pre- and post-transformation and mixed histology tumors.** Charles M. Rudin, New York, NY

Room S404 - McCormick Place South (Level 4)

Advancing Cancer Research in Understudied Populations by Engaging with Local and Global Communities

Chair: Maria Elena Martinez, San Diego, CA

- 12:30 p.m. Chair Introduction.** Maria Elena Martinez, San Diego, CA
- 12:35 p.m. Can community-based colorectal cancer screening programs be sustained long-term?** Maria Elena Martinez, San Diego, CA
- 1:00 p.m. From stress to cervical cancer risk: Investigating racial disparities through the vaginal microbiome, psychobiology, and community-engaged research.** Katherine Y. Tossas, Richmond, VA
- 1:25 p.m. How can global health research help us advance fighting cancer for everyone?** Luis G. Carvajal-Carmona, Davis, CA



ADVANCES IN PREVENTION RESEARCH

12:30 p.m.–2:00 p.m.

Room E350 - McCormick Lakeside Center (Level 3)

Advances in Prevention Research Towards the Elimination of Cervical Cancer in Low- and Middle-Income Countries

Chair: Julie Torode, London, United Kingdom

- 12:30 p.m. Chair Introduction.** Julie Torode, London, United Kingdom
- 12:35 p.m. The WHO cervical cancer elimination initiative five years in: How are we doing?** Julie Torode, London, United Kingdom
- 1:25 p.m. Research under-pinning global elimination ambitions: How is new technology contributing and experience in real-world implementation?** Karen Canfell, Sidney, Australia
- 1:00 p.m. The route to national elimination: Nigeria, a case study.** Zainab Shinkafi-Bagudu, Abuja, Nigeria



ADVANCES IN TECHNOLOGIES

12:30 p.m.–2:00 p.m.

Room S406 (Vista Ballroom) - McCormick Place South (Level 4)

Integrating Multi-Omics and Spatial Technologies for Discovery and Prediction

Chair: Benjamin Haibe-Kains, Toronto, ON, Canada

- 12:30 p.m. Chair Introduction.** Benjamin Haibe-Kains, Toronto, ON, Canada
- 12:35 p.m. Challenges and opportunities for multimodal, longitudinal analysis in clinical settings.** Benjamin Haibe-Kains, Toronto, ON, Canada
- 12:50 p.m. Single-cell spatial multi-omics for mapping cell organization, interactions, and functional niches.** Linghua Wang, Houston, TX
- 1:10 p.m. Decipher actionable tumor suppressor defects for personalized cancer medicine.** Di Zhao, Houston, TX
- 1:30 p.m. Explainable learning for biomedical discovery from spatial omics.** Jovan Tanevski, Heidelberg, Germany



ADVANCES IN THE SCIENCE OF CANCER DISPARITIES

12:30 p.m.–2:00 p.m.

Room E351 - McCormick Lakeside Center (Level 3)

Advances in the Science of Cancer Disparities: Molecular Taxonomy of Prostate Cancer

Chair: Timothy R. Rebbeck, Boston, MA

- 12:30 p.m. Chair Introduction.** Timothy R. Rebbeck, Boston, MA
- 12:35 p.m. Epigenomic profiling of localized prostate cancer in self-identified Black men.** Tamara L. Lotan, Baltimore, MD
- 12:55 p.m. Germline risk of prostate cancer in males of self-identified Black race/ethnicity.** Kara N. Maxwell, Philadelphia, PA
- 1:15 p.m. Molecular heterogeneity of prostate cancer genomics in men of African descent.** Timothy R. Rebbeck, Boston, MA



MAJOR SYMPOSIUM

12:30 p.m.–2:00 p.m.

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)

A New Frontier for Combination Therapy: Identification and Pharmacologic Targeting of Malignant Cell States

Chair: Alex K. Shalek, Cambridge, MA

- 12:30 p.m. Introduction.** Alex K. Shalek, Cambridge, MA
- 12:35 p.m. Defining, modeling, and targeting cell states in cancer.** Peter S. Winter, Cambridge, MA
- 1:00 p.m. Tracking and targeting dynamic cell states in therapy resistance.** Sydney Shaffer, Philadelphia, PA
- 1:25 p.m. Title to be announced.** Benjamin Izar, New York, NY

Room S103 - McCormick Place South (Level 1)

Adaptive Therapy from Board to Bench to Bedside and Back Again

Chair: Alexander R.A. Anderson, Tampa, FL

- 12:30 p.m. Introduction.** Alexander R.A. Anderson, Tampa, FL
- 12:35 p.m. Optimizing Adaptive therapy for clinical implementation.** Alexander R.A. Anderson, Tampa, FL
- 1:00 p.m. SY43-01 Translating adaptive therapy to ovarian cancer patients.** Michelle Lockley, London, United Kingdom
- 1:25 p.m. Comparing different adaptive therapy protocols for controlling acquired therapeutic resistance.** Carlo C. Maley, Tempe, AZ

Room S105 - McCormick Place South (Level 1)

Exploring the Intersection of Environmental Challenges and Oncology

Chair: Stefania Papatheodorou, Piscataway, NJ

- 12:30 p.m. Introduction.** Stefania Papatheodorou, Piscataway, NJ
- 12:35 p.m. The Impact of extreme weather events across the cancer control continuum: Research experiences from the US Caribbean.** Ana Patricia Ortiz-Martínez, San Juan, Puerto Rico
- 1:00 p.m. Prenatal exposure to climate related environmental hazards and risk of pediatric cancers.** Stefania Papatheodorou, Piscataway, NJ
- 1:25 p.m. Extreme weather events and exposure to cancer-causing substances.** Jaime Madrigano, Baltimore, MD

Room E450 B - McCormick Lakeside Center (Level 4)

Developmental Origins of Childhood Cancer

Chair: Corinne Mary Linardic, Durham, NC

- 12:30 p.m. Introduction.** Corinne Mary Linardic, Durham, NC
- 12:35 p.m. Dysregulated developmental signaling pathways in the childhood cancer rhabdomyosarcoma.** Corinne Mary Linardic, Durham, NC

- 1:00 p.m. Tracing the origins of childhood cancer using somatic mutations.** Tim Coorens, Cambridge, MA

- 1:25 p.m. Epidemiologic and genomic insights into the overlap between development and childhood cancer.** Philip J. Lupo, Atlanta, GA

Room S102 - McCormick Place South (Level 1)

Dharma Master Jiantai Symposium in Targeted Therapy: The Hippo Pathway in Cancer Development and Therapeutic Targeting

Chair: Kun-Liang Guan, La Jolla, CA

- 12:30 p.m. Introduction.** Kun-Liang Guan, La Jolla, CA
- 12:35 p.m. Hippo signaling in organ size control and cancer.** Kun-Liang Guan, La Jolla, CA
- 1:00 p.m. Using the cancer dependency map.** William C. Hahn, Boston, MA
- 1:25 p.m. SY28-01 The paradox of YAP/TAZ in cancer biology.** Georg Halder, Leuven, Belgium

Arie Crown Theater - McCormick Lakeside Center (Level 2)

Technical and Clinical Advances in Circulating Tumor DNA Minimal Residual Disease Detection

Chair: Maximilian Diehn, Stanford, CA

- 12:30 p.m. Introduction.** Maximilian Diehn, Stanford, CA
- 12:35 p.m. Advances in ctDNA MRD analysis for early stage cancers.** Maximilian Diehn, Stanford, CA
- 1:00 p.m. ctDNA MRD detection in colorectal cancer: From research to clinic utility.** Jeanne Tie, Melbourne, Australia
- 1:25 p.m. Modulating cfDNA biology to improve liquid biopsies.** Viktor Adalsteinsson, Wakefield, MA

Room E451 - McCormick Lakeside Center (Level 4)

Transcending Boundaries: Harnessing Induced Proximity Pharmacology for Next-Generation Anti-Cancer Therapies

Chair: Alessio Ciulli, Dundee, United Kingdom

12:30 p.m. Introduction. Alessio Ciulli, Dundee, United Kingdom

12:35 p.m. New insights and twists on PROTAC and molecular glue degraders design and mechanism. Alessio Ciulli, Dundee, United Kingdom

1:00 p.m. MrTAC: Methylarginine targeting chimeras for the lysosomal degradation of intracellular proteins. Lauren Albrecht, Irvine, CA

1:25 p.m. SY07-01 Gain-of-function small molecules to reprogram oncogenic transcription factors. Sai Gourisankar, Stanford, CA

MEET AND GREET SESSION

1:30 p.m.–2:30 p.m.

NOT ELIGIBLE FOR CME CREDIT

AACR Publications Booth 2615 - South Halls A1-2

Meet the Editor-in-Chief of *Cancer Epidemiology, Biomarkers & Prevention*: Elizabeth A. Platz

POSTER SESSION

2:00 p.m.–5:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Halls A1-2, McCormick Place South

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

Tumor Biology

- Section 1 A Role for the Tumor Microenvironment in Progression
- Section 2 Molecular Regulation of EMT
- Section 3 Mouse Models of Cancer and Mechanisms
- Section 4 Organoids
- Section 5 Shaping Tumor Stromal Interactions in Cancer
- Section 6 The Immune Microenvironment in Cancer
- Section 7 Tumor Microenvironment and Metastasis
- Section 8 Where's Waldo: Spatial Complexity of the Tumor Microenvironment 2

Molecular/Cellular Biology and Genetics

- Section 10 CDK Inhibitors
- Section 11 Genomic Profiling of Tumors 1
- Section 12 Metabolic Reprogramming
- Section 13 S/G2/M phase
- Section 14 Therapeutic Targets and Mitochondrial Function

Experimental and Molecular Therapeutics

- Section 15 Antibody-Based Cancer Therapeutics 3
- Section 16 Drug Discovery Assay Technologies
- Section 17 Drug Resistance in Molecular Targeted Therapies 3
- Section 18 Drug Resistance in Molecular Targeted Therapies 4
- Section 19 Identification of Molecular Targets 2
- Section 20 Kinase and Phosphatase Inhibitors 3
- Section 21 Novel Antitumor Agents 3
- Section 22 Novel Methods in Small Molecule and Biologics Drug Discovery
- Section 23 Oncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy 2
- Section 24 PARP Inhibitors

Chemistry

- Section 25 Drug Design, Synthesis, and Disposition
- Section 26 Multi-omics for the Cancer Proteome

Clinical Research

- Section 27 Functional and Molecular Imaging and Radiomics
- Section 28 Immune Response to Therapies
- Section 29 Immunomodulatory Agents and Interventions
- Section 30 Inflammation, Immunity, and Cancer
- Section 31 Liquid Biopsy: Circulating Nucleic Acids 3
- Section 32 Predictive Biomarkers 6 / Diagnostic Biomarkers 3
- Section 33 Real-World Data and Real-World Evidence: Clinical Informatics and Data Science 2
- Section 34 Targeted Therapies and Combinations 3
- Section 35 Therapeutic Antibodies, Including Engineered Antibodies 2
- Section 53 Late-Breaking Research: Clinical Research 3

Clinical Trials

- Section 50 Phase II Clinical Trials 2
- Section 51 Phase II and Phase III Clinical Trials in Progress

Immunology

- Section 36 Adaptive Immunity in Tumors / Oncogenic Pathway-Mediated Regulation of Inflammation and Tumor Immunity
- Section 37 Antibodies 3: Multi-Target Checkpoint Inhibitors and Immune Activators
- Section 38 CAR Therapies: Emerging Approaches and Combinations
- Section 39 Innate Immunity to Tumors
- Section 40 Interplay between Immune System and Radio-, Chemo- and Targeted Therapies 2
- Section 54 Late-Breaking Research: Immunology 3

Population Sciences

- Section 41 Breaking Barriers in Cancer Care: Addressing Disparities and Improving Outcomes
- Section 42 Health Disparities and Systemic Inequities: Lifestyle, Metabolism, and Disparities in Cancer Risk and Outcomes

Bioinformatics, Computational Biology, Systems Biology, and Convergent Science

- Section 44 Computational and Systems Biology Approaches
- Section 45 Computational Immunology and Tumor Microenvironment Characterization
- Section 46 New Software Tools and Machine Learning Methods
- Section 52 Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2

Prevention, Early Detection, and Interception

- Section 48 Development of Chemopreventive Agents and Preclinical Models



MINISYMPOSIA

2:30 p.m.–4:00 p.m.

Room E450 A - McCormick Lakeside Center (Level 4)

Bioinformatics, Computational Biology, Systems Biology, and Convergent Science

Convergence Science Approaches in Cancer Vulnerabilities Discovery and Treatment Optimization

Cochairs: Luciane Tsukamoto Kagohara, Baltimore, MD; Jeremy Mason, Los Angeles, CA

- 2:30 p.m.** **Introduction.** Luciane Tsukamoto Kagohara, Baltimore, MD
- 2:35 p.m.** **6353 Path2Space: An AI approach for cancer biomarker discovery via histopathology inferred spatial transcriptomics.** Eldad D. Shulman, Bethesda, MD
- 2:50 p.m.** **6355 Mapping the genetic, epigenetic, and microenvironmental evolution of HER2-positive breast cancer during neoadjuvant therapy.** Seongyeol Park, Stanford, CA
- 3:05 p.m.** **6356 Multiscale high-content imaging to identify molecular and morphological signatures in drug-resistant cancer cells.** Yang Liu, Urbana, IL
- 3:20 p.m.** **6358 Single cell transcriptional dynamics in the HCM1 cancer model collection.** Luca Zanella, New York, NY
- 3:35 p.m.** **6359 MUTE-Seq: An ultrasensitive method for detecting low-frequency mutations in cfDNA with engineered advanced-fidelity FnCas9.** Junseok W. Hur, Seoul, Republic of Korea
- 3:50 p.m.** **Closing Remarks.** Jeremy Mason, Los Angeles, CA

Room S102 - McCormick Place South (Level 1)

Experimental Therapeutics

Novel Cancer Therapeutic Targets

NOT ELIGIBLE FOR CME CREDIT

Cochairs: Bruce A. Chabner, Newton, MA; Hui Feng, Boston, MA

- 2:30 p.m.** **Introduction.** Bruce A. Chabner, Newton, MA

- 2:35 p.m.** **6388 Exploiting CTPS1 dependency for the treatment of breast and ovarian cancer.** Xiyin Wang, Rochester, MN
- 2:50 p.m.** **6389 Unveiling the potent anti-tumor activity and underlying mechanism of action of the novel pan-RAF inhibitor exarafenib in BRAF-mutated NSCLC.** Tadashi Manabe, San Francisco, CA
- 3:05 p.m.** **6390 Identification of novel pan-KRAS mutation inhibitor shows significant efficacy in pancreatic cancer with no toxicity, offering hope beyond current therapies.** Pinar Atalay, Houston, TX
- 3:20 p.m.** **6392 Next-generation ADCs: precise delivery of exatecan to tumor nuclei by targeting the tumor microenvironment with an anti-DNA cell-penetrating antibody.** Zaira Ianniello, New Haven, CT
- 3:35 p.m.** **6394 Patient-derived neuroblastoma models are sensitive to nucleolin-recognizing liposomal drugs.** Fabio Pastorino, Genoa, Italy
- 3:50 p.m.** **Closing Remarks.** Hui Feng, Boston, MA

Arie Crown Theater - McCormick Lakeside Center (Level 2)

Immunology

Adoptive Cell Therapies

Cochairs: Daniel J. Powell, Philadelphia, PA; Sidi Chen, West Haven, CT

- 2:30 p.m.** **Introduction.** Sidi Chen, West Haven, CT
- 2:35 p.m.** **6396 CREM is a regulatory checkpoint of CAR and IL-15 signaling in NK cells.** Hind Rafei, Houston, TX
- 2:50 p.m.** **6397 Overexpression of Serpin B9 in anti-tumor T cells restrains granzyme B mediated auto-destruction and improves the therapeutic effect of adoptive cell therapy in ovarian cancer.** Paulina Walczak, Chicago, IL
- 3:05 p.m.** **6398 Harnessing the conditional proteolytic activity of ADA.m.17 to generate autonomous regulatory mechanisms in CAR T cells.** Jeremy R. Bjelajac, Stanford, CA
- 3:20 p.m.** **6399 Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma.** Yifei Hu, Chicago, IL

3:35 p.m. **6400 Preclinical efficacy of combinatorial B7-H3 CAR T cell and ONC206 treatment in DIPG/DMG.** Andrea Timpanaro, Seattle, WA

3:50 p.m. **Closing Remarks.** Daniel J. Powell, Philadelphia, PA



MINISYMPOSIA

2:30 p.m.–4:15 p.m.

Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)

Clinical Research

Diagnostic and Predictive Biomarkers

Cochairs: Howard I. Scher, New York, NY; Manuela Ferracin, Bologna, Italy

2:30 p.m. **Introduction.** Manuela Ferracin, Bologna, Italy

2:35 p.m. **6360 A tumor agnostic composite gene expression signature identifies three groups of patients treated with immune checkpoint blockade with distinct clinical outcome.** Pierre Saintigny, Lyon, France

2:50 p.m. **6361 The vanguard study: An NCI cancer screening research network feasibility study.** Marie Wood, Aurora, CO

3:05 p.m. **6362 Characterization of therapeutic effects in glioblastoma through integrated spatial single-cell multiome profiling of longitudinal samples: Unveiling clinically relevant subtypes of pathological changes.** Frederik De Smet, Leuven, Belgium

3:20 p.m. **6363 Predicting resistance to cytotoxic chemotherapy.** Geoff Macintyre, Madrid, Spain

3:35 p.m. **6364 Serum proteomics analysis: Potential biomarkers and mechanisms of trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis (ILD).** Charles A. Powell, New York, NY

3:50 p.m. **6366 Pre-diagnostic circulating proteins and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).** Yahya Mahamat-saleh, Lyon, France

4:05 p.m. **Closing Remarks.** Howard I. Scher, New York, NY

Room E451 - McCormick Lakeside Center (Level 4)

Clinical Research

Targeted Therapies and Combinations

Cochairs: Srinivasan Yegnasubramanian, Baltimore, MD; Catherine Handy Marshall, Baltimore, MD

2:30 p.m. **Introduction.** Srinivasan Yegnasubramanian, Baltimore, MD

2:35 p.m. **6367 CHD1 loss hijacks SREBP2-mediated cholesterol biosynthesis to fuel SPOP-deficient prostate cancer and confers resistance to castration.** Feiyu Chen, Houston, TX

2:50 p.m. **6368 Correlative preclinical studies to elucidate mechanisms of synergy of the combination of the RAF/MEK clamp avutometinib and the FAK inhibitor defactinib in low grade serous ovarian cancer.** Udai Banerji, London, United Kingdom

3:05 p.m. **6369 Perivascular niche-resident alveolar macrophages confer interstitial pneumonitis related to trastuzumab deruxtecan.** Qing Wei, Hang Zhou, China

3:20 p.m. **6371 KLIPP: Precision targeting of fusions and amplified oncogenes using CRISPR.** Mats Ljungman, Ann Arbor, MI

3:35 p.m. **6372 Combined tissue and liquid biopsy improves outcomes in advanced solid tumors: an exploratory analysis of the ROME trial.** Paolo Marchetti, Rome, Italy

3:50 p.m. **6373 From genotype to phenotype: Adding phosphoproteomic analysis to molecularly-guided therapy recommendation in Cancer of Unknown Primary (CUP).** Maximilian Werner, Dresden, Germany

4:05 p.m. **Closing Remarks.** Catherine Handy Marshall, Baltimore, MD



MINISYMPOSIA

2:30 p.m.–4:30 p.m.

Room S404 - McCormick Place South (Level 4)

Experimental Therapeutics Degraders and Glues

NOT ELIGIBLE FOR CME CREDIT

Cochairs: Rima S. Al-awar, Toronto, ON, Canada; Norbert Kraut, Vienna, Austria

- 2:30 p.m.** **Introduction.** Rima S. Al-awar, Toronto, ON, Canada
- 2:40 p.m.** **6374 COuPLrs, a new class of cysteine-reactive compounds for modulating protein-protein interaction.** Diane Yang, Boston, MA
- 2:55 p.m.** **6375 Discovery and characterization of novel, potent and selective CDK2 molecular glue degrader against CCNE1-amplified tumors.** Leenus Martin, San Diego, CA
- 3:10 p.m.** **6376 KRASmultidegrader BPI-585725 displays potent anti-tumor activity in KRAS-driven preclinical models.** Quan Zhou, Hangzhou, China
- 3:25 p.m.** **6377 TEAD-targeting small molecules induce a cofactor switch to regulate the Hippo pathway.** Alissa D. Guarnaccia, South San Francisco, CA
- 3:40 p.m.** **6378 Brain-penetrant molecular glue degraders targeting ALK via a novel degron: a potential therapeutic approach for ALK-positive NSCLC.** Zheng Wang, San Diego, CA
- 3:55 p.m.** **6379 Identification of selective, orally bioavailable aurora A degraders for treatment of pediatric and adult cancers.** Ryan Rountree, San Francisco, CA
- 4:10 p.m.** **6380 PLX-4545, a selective IKZF2 degrader, reprograms suppressive Tregs leading to tumor growth inhibition and combination benefit with immune checkpoint therapy.** Peggy A. Thompson, San Diego, CA
- 4:25 p.m.** **Closing Remarks.** Norbert Kraut, Vienna, Austria

Room E450 B - McCormick Lakeside Center (Level 4)

Experimental Therapeutics

Experimental Therapeutics: Drug Resistance

Cochairs: Cihangir Duy, Philadelphia, PA; John J. Krais, St Louis, MO

- 2:30 p.m.** **Introduction.** John J. Krais, St Louis, MO
- 2:35 p.m.** **6381 SAMHD1high macrophages drive resistance to cytarabine in acute myeloid leukemia (AML) by pyrimidine metabolite deoxycytidine (dC).** Chuqi Wang, Singapore, Singapore
- 2:50 p.m.** **6382 DNA damage repair pathways enable a drug-tolerant persister state in RET-fusion NSCLC and precedes TKI resistance.** Fathema Z. Uddin, New York, NY
- 3:05 p.m.** **6383 Overcoming intrinsic mechanisms of cell cycle inhibitor resistance in estrogen receptor-positive (ER+) breast cancer.** Kimya L. Karimi, Duarte, CA
- 3:20 p.m.** **6384 CD24 promotes development of KRAS-mutant lung adenocarcinoma and response to KRAS-targeted therapy.** Zahraa Rahal, Houston, TX
- 3:35 p.m.** **6385 Heterogeneity in sensitivity to second-line inhibitors of therapy-resistant melanoma.** Gianna T. Busch, Philadelphia, PA
- 3:50 p.m.** **6386 Omomyc synergizes with PARP inhibition (PARPi) and reverts resistance to therapy in multiple PARPi-resistant triple-negative breast cancer models.** Fabio Giuntini, Barcelona, Spain
- 4:05 p.m.** **6387 Oral and selective ribonucleotide reductase (RNR) inhibitor, BBI-825, suppresses acquired resistance to mutant-specific, pan, and multi-RAS targeting inhibitors.** Rona Yaeger, New York, NY
- 4:20 p.m.** **Closing Remarks.** Cihangir Duy, Philadelphia, PA

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)

Immunology

Checkpoints and Modulators of Tumor Microenvironment

Cochairs: Thomas Frank Gajewski, Chicago, IL; Pawel Kalinski, Buffalo, NY

- 2:30 p.m. Introduction.** Thomas Frank Gajewski, Chicago, IL
- 2:35 p.m. 6402 Stress-induced HDAC8 reprogramming drives IL-11-mediated immune escape in melanoma.** Michael F. Emmons, Tampa, FL
- 2:50 p.m. 6403 In vivo CRISPR/Cas9 screening identifies fatty acid synthase (FASN) as a target to enhance anti-PD-1 therapy in pancreatic cancer.** Feng Guo, Indianapolis, IN
- 3:05 p.m. 6404 NOTCH1 drives immunogenicity through STING and improves survival with immune checkpoint blockade in small cell lung cancer.** Yoo Sun Kim, Bethesda, MD
- 3:20 p.m. 6405 T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC.** Margo I. Orlén, Philadelphia, PA
- 3:35 p.m. 6406 Conditional knockout of the aryl hydrocarbon receptor in macrophages and dendritic cells enhanced antigen presentation and T cell activation, thereby synergistically improving anti-cancer effects in combination with anti-PD-1.** Dong Kwon Kim, Seoul, Republic of Korea
- 3:50 p.m. 6407 PTPN22-based immunotherapy yields near-complete response against PDAC via multi-pronged immune modulation.** Soren Charmsaz, Baltimore, MD
- 4:05 p.m. 6408 Stromal cell PD-L1 potentiates epitope spreading in the germinal center.** Elliot Akama-Garren, Boston, MA
- 4:20 p.m. Closing Remarks.** Pawel Kalinski, Buffalo, NY

Room E350 - McCormick Lakeside Center (Level 3)

Molecular/Cellular Biology and Genetics

Epigenetic Regulation and Its Impact on Drug Response, Disease Pathogenesis, and Outcomes Across Pediatric and Adult Cancers

Cochairs: Daria A. Gaykalova, Baltimore, MD; Nita Ahuja, New Haven, CT

- 2:30 p.m. Introduction.** Daria A. Gaykalova, Baltimore, MD
- 2:35 p.m. 6409 Epigenetic regulation of drug and disease related genes impact outcomes in pediatric AML.** Naifah Alshameri, Gainesville, FL
- 2:50 p.m. 6410 Blood DNA methylation in association with immune checkpoint inhibitor related outcomes among patients with head and neck squamous cell carcinoma.** Gyeyoon Yim, Hanover, NH
- 3:05 p.m. 6411 The histone H3 E97K oncohistone creates a cellular histone H3 deficit and disrupts nucleosome stability.** Jixiu Shan, Gainesville, FL
- 3:20 p.m. 6412 Inactivation of CDK12 remodels the transcription machinery and promotes epigenetic plasticity.** Jing Liang, Helsinki, Finland
- 3:35 p.m. 6413 Exploring the role of DNMT1 in cell invasion and motility in docetaxel-resistant prostate cancer.** Carmen M. Ortiz-Sánchez, Ponce, Puerto Rico
- 3:50 p.m. 6414 Epigenetic signatures of oral HPV-related cancer risk in HIV-positive subjects from Puerto Rico.** Mayra S. Haedo-Cruz, San Juan, Puerto Rico
- 4:05 p.m. 6415 NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for Na.m.PT inhibition.** Angela Kim, New Haven, CT
- 4:20 p.m. Closing Remarks.** Nita Ahuja, New Haven, CT

Room E352 - McCormick Lakeside Center (Level 3)

Molecular/Cellular Biology and Genetics
Multi-omic Integration for Cancer
Evolution and Therapy

NOT ELIGIBLE FOR CME CREDIT

Cochairs: David G. Huntsman, Vancouver, BC, Canada; Carlos M. Caldas, London, United Kingdom

- 2:30 p.m.** **Introduction.** David G. Huntsman, Vancouver, BC, Canada
- 2:35 p.m.** **6350 Exploring genetic and non-genetic evolution of glioblastoma by integrating single cell DNA and RNA sequencing.** Fulvio D'Angelo, Miami, FL
- 2:50 p.m.** **6351 Characterizing the spatial heterogeneity of pregnancy-associated triple negative breast cancer.** Darya Veraksa, San Diego, CA
- 3:05 p.m.** **6352 Defining spatial molecular residual disease by personalized tumor tissue profiling.** Julia D. Ransohoff, Stanford, CA
- 3:20 p.m.** **6437 Mutational patterns in normal tissue hold the key to understanding the cellular origins of cancer.** Kirsten Kübler, Cambridge, MA
- 3:35 p.m.** **6438 Decoding the archetypes and ecotypes of triple-negative breast cancer in responses to chemotherapy.** Yun Yan, Houston, TX
- 3:50 p.m.** **6621 Multi-modal profiling reveals the role of somatic structural variations in renal cell carcinoma.** Yuwei Zhang, St. Louis, MO
- 4:05 p.m.** **6622 Dissecting in situ states of invading glioblastoma cells using single-cell and spatial transcriptomics.** Toshiro Hara, Ann Arbor, MI
- 4:20 p.m.** **Closing Remarks.** Carlos M. Caldas, London, United Kingdom

Room E351 - McCormick Lakeside Center (Level 3)

Multidisciplinary
Advances in Cancer Research: Unraveling Tumor
Biology, Therapy Resistance, and Novel Models

Cochairs: Lucia Borriello, Philadelphia, PA; Elda Grabocka, Philadelphia, PA

- 2:30 p.m.** **Introduction.** Lucia Borriello, Philadelphia, PA
- 2:35 p.m.** **6416 Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis.** David Falvo, New York, NY
- 2:50 p.m.** **6417 Prostate cancer exploits neurolysin to modulate the tumor microenvironment and therapy resistance via KIF11-mediated WNT secretion.** Ping Mu, Dallas, TX
- 3:05 p.m.** **6418 Non-genetic drug adaptation to MAPK pathway inhibitors in melanoma.** Varuna Nangia, Boulder, CO
- 3:20 p.m.** **6419 Stress-induced intratumoral senescence matrix shifts cancer evolution towards metastasis.** Lars Zender, Tübingen, Germany
- 3:35 p.m.** **6420 Association between added sugar, glycemic index, glycemic load, soda consumption, and fiber intake with breast cancer risk.** Liliana Gomez-Flores-Ramos, Cuernavaca, Mexico
- 3:50 p.m.** **6421 Tracking the evolution of non-small-cell lung cancer: Completion of the TRACERx longitudinal cohort.** Lydia Y. Liu, London, United Kingdom
- 4:05 p.m.** **6422 Colorectal polyp subtype discovery reveals a diverse phenotypic landscape beyond classic histological and developmental pathways.** Natalie C. Fisher, Belfast, United Kingdom
- 4:20 p.m.** **Closing Remarks.** Elda Grabocka, Philadelphia, PA

Room S402 - McCormick Place South (Level 4)

Prevention, Early Detection, and Interception

Hot Topics in Cancer Prevention: Development of Multi-Cancer Early Detection Tests, Assessment of the Immune Environment, Targets for Cancer Prevention, and Cancer Interception Trials

Cochairs: Sasha Stanton, Portland, OR; Maximilian Diehn, Stanford, CA

- 2:30 p.m.** **Introduction.** Sasha Stanton, Portland, OR
- 2:35 p.m.** **6423 Multiomic functional biomarkers for predicting the transition from inflammation to cancer.** Marine Fidelle, Villejuif, France
- 2:50 p.m.** **6424 Harnessing circulating neoantigen-specific T cells for immune surveillance and cancer prevention in Lynch syndrome.** Fahriye Duzagac, Houston, TX
- 6425 Evaluation of a plasma cell-free DNA methylation-based multi-cancer detection test.** William Greenleaf, Stanford, CA
- 3:05 p.m.** **6426 Cell-free DNA fragmentomes enable early identification of liver cirrhosis to facilitate cancer surveillance.** Akshaya V. Annapragada, Baltimore, MD
- 3:20 p.m.** **6427 Nous-209 off-the-shelf neoantigen immunotherapy induces robust neoantigen T cell response with the potential to intercept cancer in Lynch syndrome carriers.** Jason Willis, Houston, TX
- 3:35 p.m.** **6428 Changes in mammographic features and breast tissue gene expression associated with vitamin D supplementation.** Rulla M. Tamimi, New York, NY
- 3:50 p.m.** **6429 Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention.** James Yarmolinsky, London, United Kingdom
- 4:05 p.m.** **Closing Remarks.** Maximilian Diehn, Stanford, CA

Room S401 - McCormick Place South (Level 4)

Tumor Biology

The Local and Systemic Tumor Microenvironment in Cancer Progression

Cochairs: Milos Spasic, Boston, MA; Roberta Faccio, St. Louis, MO

- 2:30 p.m.** **Introduction.** Milos Spasic, Boston, MA
- 2:35 p.m.** **6430 Untangling the link between chronic stress and colorectal cancer.** Xue-Yan He, St. Louis, MO
- 2:50 p.m.** **6431 Endothelial SPARCL1 suppresses colorectal cancer metastases through dormancy induction and EMT inhibition in colonizing tumor cells.** Bisan A. Zohud, Erlangen, Germany
- 3:05 p.m.** **6432 Melanoma-driven alterations in lipid and iron metabolism in the bone marrow niche.** Alexis Erasta Carey, Baltimore, MD
- 3:20 p.m.** **6433 The interaction between netrin-1/neogenin modulates sympathetic innervation to promote tumorigenesis and accelerate pancreatic cancer progression.** Yosuke Ochiai, New York, NY
- 3:35 p.m.** **6434 Senolytics decrease senescent microglia, remodel the vasculature, and improve survival in older adults with glioblastoma during co-treatment with immunotherapy.** Manon Penco-Campillo, Maywood, IL
- 3:50 p.m.** **6435 Postpartum breast cancer, liver CYP450 metabolism and drug resistance.** Pepper Schedin, Portland, OR
- 4:05 p.m.** **6436 Metabolic masquerade: Glutamine's role in ovarian cancer dynamics.** Sammy Ferri-Borgogno, Houston, TX
- 4:20 p.m.** **Closing Remarks.** Roberta Faccio, St. Louis, MO



CLINICAL TRIALS MINISYMPOSIUM

2:30 p.m.–4:40 p.m.

Room S406 (Vista Ballroom) - McCormick Place South (Level 4)

Innovative Approaches to Key Molecular Targets

Cochairs: Jordi Rodon Ahnert, Houston, TX; Anna Spreafico, Toronto, ON, Canada

2:30 p.m. Chair Introduction. Jordi Rodon Ahnert, Houston, TX

2:35 p.m. CT262 Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656). Alison M. Schram, New York, NY

2:50 p.m. CT263 Efficacy and multiomic analysis of Niraparib in relapsed mesothelioma: NERO a randomized phase II trial. Dean Fennell, Leicester, United Kingdom

3:05 p.m. CT264 Mutant KRAS peptide vaccine combined with ipilimumab/nivolumab in advanced mismatch repair proficient/microsatellite stable (MMRp/MSS) colorectal cancer: Preliminary analysis from a phase I study. Hejia Henry Wang, Baltimore, MD

3:20 p.m. CT265 KRASG12Dtargeting using engineered exosomes in pancreatic cancer: Results from the iEXPLORE phase 1 trial. Valerie S. LeBleu, Houston, TX

3:35 p.m. CT266 D3S-001, a next generation GDP-bound KRAS G12C inhibitor, as monotherapy in KRAS G12C inhibitor resistant non-small cell lung cancer. Herbert H. Loong, Hong Kong, China

3:50 p.m. CT267 First results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumors. Susanna Ulahannan, Oklahoma, OK

4:05 p.m. CT268 Preliminary results from a first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors. Trupti Lingaraj, Boston, MA

4:20 p.m. CT269 First-in-human trial in patients with metastatic colorectal cancer using CRISPR-engineered tumor infiltrating lymphocytes in which the intracellular immune checkpoint CISH is inhibited. Emil Lou, Minneapolis, MN

4:35 p.m. Closing Remarks. Anna Spreafico, Toronto, ON, Canada



AWARD LECTURES

3:00 p.m.–3:45 p.m.

Room E353 C - McCormick Lakeside Center (Level 3)

AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention

Chair: Paul A. Scheet, Houston, TX

Funder Remarks. William L. Dahut, Bethesda, MD

Elucidating cancer etiology through multi-ethnic studies. Loic Le Marchand, Honolulu, HI

Room S105 - McCormick Place South (Level 1)

AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology

NOT ELIGIBLE FOR CME CREDIT

Chair: Ignacio Melero, Pamplona, Spain

Funder Remarks: Alicia Zhou, New York, NY

CAR T cells for cancer therapy. Crystal L. Mackall, San Francisco, CA

MAJOR SYMPOSIUM**4:00 p.m.–5:30 p.m.****NOT ELIGIBLE FOR CME CREDIT**

Room S106 - McCormick Place South (Level 1)

Science Policy Session**Modernizing Performance Statistics for Clinical Validation of Blood-based Cancer Screening Tests****Cochairs:** Peter Kuhn, Los Angeles, CA; Phillip G. Febbo, San Diego, CA**Speakers:** Robert A. Smith, Atlanta, GA; Tomasz M. Beer, Madison, WI; Christina A. Clarke Dur, Menlo Park, CA; Peter Sasieni, London, United Kingdom; Steven Skates; Elizabeth K. O'Donnell, Boston, MA**AWARD LECTURE****4:30 p.m.–5:15 p.m.**

Room S105 - McCormick Place South (Level 1)

AACR Award for Outstanding Achievement in Blood Cancer Research**Chair:** Ravindra Majeti, Stanford, CA**Funder Remarks:** Andrew J. Souers, North Chicago, IL**Curing aggressive lymphomas using multi-drug combinations targeting oncogenic survival pathwayse.** Louis M. Staudt, Bethesda, MD**AWARD LECTURE****5:00 p.m.–5:45 p.m.****NOT ELIGIBLE FOR CME CREDIT**

Room S103 - McCormick Place South (Level 1)

AACR-Women in Cancer Research Charlotte Friend Lectureship**Chair:** Shiva Malek, Cambridge, MA**Funder Remarks.** Kelsey Tinkum, Foster City, CA**Epigenetic pathways as targets in human cancer.** Shelley L. Berger, Philadelphia, PA**MEET-THE-EXPERT SESSIONS****5:00 p.m.–5:45 p.m.**

Room E450 B - McCormick Lakeside Center (Level 4)

New Targets and Gamma Delta T Cells — Extending Immunotherapy to More Cancers and More People

Adrian Hayday, London, United Kingdom

Room S102 - McCormick Place South (Level 1)

Advances in Modeling Lung Adenocarcinoma in the Mouse**5:00 p.m.** **New insights into EGFR-driven lung adenocarcinoma.** Katerina A. Politi, New Haven, CT**5:25 p.m.** **Studying epigenetic mechanisms in lung adenocarcinoma.** David Feldser, Philadelphia, PA

Room S404 - McCormick Place South (Level 4)

You've Analyzed Cancer Genomes and Identified High Risk Signatures - Now What?

Olufunmilayo I. Olopade, Chicago, IL

Room E450 A - McCormick Lakeside Center (Level 4)

Personalized Molecular Medicine Enabled by Multidisciplinary Approaches to Cancer Drug Discovery and Clinical Development

Paul Workman, London, United Kingdom

CAREER DEVELOPMENT FORUM**5:00 p.m.–6:30 p.m.****NOT ELIGIBLE FOR CME CREDIT**

Great Lakes AB - Marriott Marquis Chicago

Mentoring is Alive!**Cochairs:** John M. Carethers, La Jolla, CA; Brian M. Rivers, Atlanta, GA; Karen Winkfield, Nashville, TN**FORUMS****5:00 p.m.–6:30 p.m.**

Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)

AI-based Biomarkers and Digital Pathology in Precision Oncology**Chair:** Alexander T. Pearson, Chicago, IL

- 5:00 p.m. Chair Introduction.** Alexander T. Pearson, Chicago, IL
- 5:05 p.m. Foundations and future directions for cancer computational pathology.** Alexander T. Pearson, Chicago, IL
- 5:25 p.m. Computational imaging biomarkers in precision cancer care: Leveraging machine learning and AI for novel integrated diagnostics.** Despina Kontos, New York, NY
- 5:45 p.m. Cutting edge computational pathology models for clinical applications.** Faisal Mahmood, New York, NY

Room E451 - McCormick Lakeside Center (Level 4)

Testing Diet with the Rigor of Drug: Dietary Interventions to Improve Cancer Treatment Outcomes**Chair:** Jennifer McQuade, Houston, TX

- 5:00 p.m. Chair Introduction.** Jennifer McQuade, Houston, TX
- 5:05 p.m. Considerations for dietary interventions in active cancer populations: optimizing trial design.** Jennifer McQuade, Houston, TX
- 5:15 p.m. Low-carbohydrate diets in oncology: A critical appraisal of therapeutic efficacy and safety.** Marcus DaSilva Goncalves, New York, NY
- 5:35 p.m. High fiber dietary interventional trials in oncology: Can a whole foods plant rich diet actually improve cancer specific outcomes?** Urvi Shah, New York, NY

Room S401 - McCormick Place South (Level 4)

Unlocking the Power of PROs to Assess Tolerability in Cancer Clinical Trials**Chair:** Gita Thanarajasingam, Rochester, MN

- 5:00 p.m. Chair Introduction.** Lori M. Minasian, Rockville, MD
- 5:02 p.m. Leveraging PROs for characterizing tolerability in cancer clinical trials.** Lori M. Minasian, Rockville, MD
- 5:22 p.m. Tolerable is relative: Measuring what matters to patients.** Jill Feldman, Deerfield, IL
- 5:32 p.m. Chronic low-grade AEs and treatment discontinuation: Challenging assumptions about tolerability.** Lynne Wagner, Deerfield, IL
- 5:52 p.m. The myth of “generally well tolerated”: PROs of symptoms and function in cancer trials.** Gita Thanarajasingam, Rochester, MN

SPECIAL SESSION**5:00 p.m.–6:30 p.m.****NOT ELIGIBLE FOR CME CREDIT**

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)

Bringing Science to the Clinic: Overcoming Hurdles for Therapeutic Translation**Cochairs:** Keith T. Flaherty, Cambridge, MA; Timothy A. Yap, Houston, TX

- 5:00 p.m. Introduction.** Timothy A. Yap, Houston, TX
- 5:01 p.m. Introduction.** Keith T. Flaherty, Cambridge, MA
- 5:02 p.m. Addressing tumor evolutionary and context challenges for optimal therapeutic translation in the clinic.** Samra Turajlic, London, United Kingdom
- 5:14 p.m. Synthetic lethal therapeutic and biomarker strategies: Progress, pitfalls, and promise in novel clinical translation.** Timothy A. Yap, Houston, TX
- 5:26 p.m. Illuminating oncology drug development using advanced molecular biomarkers.** Kurt A. Schalper, New Haven, CT
- 5:38 p.m. Addressing the funding gaps in cancer medicine: Tricks of the trade.** Alexis Borisy, Cambridge, MA
- 5:50 p.m. Optimizing the odds of success in drug development entrepreneurship.** Keith T. Flaherty, Cambridge, MA
- 6:02 p.m. Panel Discussion**

PROFESSIONAL DEVELOPMENT SESSION**7:00 p.m.–9:00 p.m.****NOT ELIGIBLE FOR CME CREDIT**

Great Lakes EFG - Marriott Marquis Chicago

Building an Effective Mentorship Team: Essential Strategies at Every Stage in Your Career**Cochairs:** Sandra W. Ryeom, New York, NY; Ruben A. Mesa, Winston-Salem, NC; Shiva Malek, Cambridge, MA; Kristin A. Altwegg, Cambridge, MA



PLENARY SESSION

8:00 a.m.–10:00 a.m.

Arie Crown Theater - McCormick Lakeside Center (Level 2)

Opportunities in Predictive Oncology

Chair: David W. Craig, Duarte, CA

8:00 a.m. Chair Introduction. David W. Craig, Duarte, CA

8:05 a.m. Quantum cancer therapy: Targeting master regulators of cancer one cell at a time. Andrea Califano, New York, NY

8:32 a.m. Multi-scale modeling of malignancy: From virtual tumors to predictive oncology. Christina Curtis, Stanford, CA

8:59 a.m. Breast cancer dynamics in predicting response to immunotherapy. Marleen Kok, Amsterdam, Netherlands

9:26 a.m. Assembling digital tumors for predicting drug resistance. Trey Ideker, La Jolla, CA

9:53 a.m. Wrap-up and opportunities for the future. David W. Craig, Duarte, CA

POSTER SESSION

9:00 a.m.–12:00 p.m.

NOT ELIGIBLE FOR CME CREDIT

Halls A1-2, McCormick Place South

Complete titles and author listings for abstracts in the poster sessions are available in the online Itinerary Planner and the Annual Meeting App.

Tumor Biology

- Section 1 Heterogeneity of Pediatric Cancers and their Microenvironment
- Section 2 Multi-omics and the Predictive Power of the Tumor Microenvironment
- Section 3 Other Organisms and in Vivo/in Vitro Models

Section 4 Our Commensal Tumor Microenvironment and Its Role in Cancer

Section 5 The Soil Matters: Tumor Microenvironment Complexity and Targeting

Section 6 Vesicles in the Tumor Microenvironment

Section 54 Late-Breaking Research: Tumor Biology 3

Molecular/Cellular Biology and Genetics

Section 9 Genomic Profiling of Tumors 2

Section 10 Genomic Profiling of Tumors 3

Section 11 Metabolism and Signaling

Section 12 microRNAs and Other Noncoding RNAs 1

Section 13 Pathological Impact of Oncogenes and Tumor Suppressors

Section 53 Late-Breaking Research: Molecular/Cellular Biology and Genetics 3

Experimental and Molecular Therapeutics

Section 16 Antibody-Based Cancer Therapeutics 4

Section 17 Cellular Responses to Anticancer Drugs

Section 18 Drug Resistance in Molecular Targeted Therapies 5

Section 19 Mechanisms of Cancer Therapeutics

Section 20 New Nonclinical Models for Targets

Section 21 Novel Antitumor Agents 4

Section 22 Novel Cancer Therapeutic Targets and Drug Delivery Technologies

Section 23 Novel Targets and Pathways

Section 24 Protein Kinases and Phosphatases as Targets for Therapy

Section 51 Late-Breaking Research: Experimental and Molecular Therapeutics 4

Chemistry

Section 25 Lead Identification and Optimization

Section 26 Targeted Protein Degradation

Clinical Research

- Section 28 Advances in Translational Pediatric Cancer Research
- Section 29 Early Detection Biomarkers 2
- Section 30 Revolutionizing Cancer Care Through Inclusive Clinical Research
- Section 31 Immune Monitoring / Clinical Correlates
- Section 32 Liquid Biopsy: Circulating Nucleic Acids 4 / Predictive Biomarkers 1
- Section 34 Molecular Genetics and Epigenetics of Tumors
- Section 35 Targeted Therapies and Combinations 4
- Section 49 Late-Breaking Research: Clinical Research 4

Immunology

- Section 37 Novel Animal Models / Tumor Antigenicity/ Processing and Presentation
- Section 38 Novel In Vivo, In Vitro, and In Silico Models
- Section 39 Overcoming Checkpoint Inhibition and Tumor Suppression
- Section 40 T Cell Engagers and Novel Antibody-Based Therapies

Population Sciences

- Section 41 Innovations in Prevention and Cancer Care: Addressing Disparities, Inflammation, Survivorship, and Modifiable Risk Factors
- Section 42 Socioeconomic, Lifestyle, and Biological Drivers of Cancer Risk and Survival: Clinical Outcomes and Treatment Guidelines

Prevention, Early Detection, and Interception

- Section 43 Genetic and Environmental Determinants of Risk and Screening Methods

Bioinformatics, Computational Biology, Systems Biology, and Convergent Science

- Section 44 Artificial Intelligence and Machine/Deep Learning
- Section 45 Identification of New Cancer Vulnerabilities Through Convergence Science
- Section 46 Tumor Evolution, Clonal Progression, and Spatiotemporal Dynamics



ADVANCES IN DIAGNOSTICS AND THERAPEUTICS

10:15 a.m.–11:45 a.m.

Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)

Neoadjuvant Treatment for Solid Tumors: Why, How, and When?

Chair: Caroline Robert, Villejuif, France

10:15 a.m. Chair Introduction. Caroline Robert, Villejuif, France

10:20 a.m. Neoadjuvant treatment across tumor types: One size does not fit all. Myriam Chalabi, Amsterdam, Netherlands

10:45 a.m. Designing a neoadjuvant treatment today: How to align perspectives from patients, physicians, and regulators. Sapna P. Patel, Aurora, CO

11:10 a.m. Optimizing neoadjuvant cancer treatment: How to define the best strategy, timing, and follow-up management. Caroline Robert, Villejuif, France

Room S100 A (Grand Ballroom A) - McCormick Place South (Level 1)

Protein Degraders and Other Targeting Chimeras: Progress to the Clinic

Chair: Jian Jin, New York, NY

10:15 a.m. Chair Introduction. Jian Jin, New York, NY

10:15 a.m. Metabolism-rewiring molecular glues overcome K-Ras inhibitor resistance in PDAC. Fleur Ferguson, La Jolla, CA

10:40 a.m. Targeting non-enzymatic function of oncogenic proteins using PROTAC technology. Xufen Yu, Shanghai, China

11:05 a.m. New approaches to target undruggable proteins. Jian Jin, New York, NY



ADVANCES IN EARLY DETECTION AND INTERCEPTION

10:15 a.m.–11:45 a.m.

Room S406 (Vista Ballroom) - McCormick Place South (Level 4)
Lung Cancer Screening: Promises and Pitfalls

Chair: Lecia V. Sequist, Boston, MA

- 10:15 a.m. Chair Introduction.** Lecia V. Sequist, Boston, MA
- 10:20 a.m. How far are we from successful implementation of lung cancer in the US?** Raymond U. Osarogiagbon, Memphis, TN
- 10:45 a.m. Risk stratification for lung cancer screening.** Lecia V. Sequist, Boston, MA
- 11:10 a.m. Blood based biomarkers for lung cancer screening: Hype or hope.** Hilary A. Robbins, Lyon, France



ADVANCES IN HEMATOLOGIC MALIGNANCIES

10:15 a.m.–11:45 a.m.

Room E450 A - McCormick Lakeside Center (Level 4)
Chromothripsis in Hematological Malignancies

Chair: Faith E. Davies, New York, NY

- 10:15 a.m. Chair Introduction.** Faith E. Davies, New York, NY
- 10:20 a.m. Cause and consequences of complex chromosome rearrangements.** Don W. Cleveland, La Jolla, CA
- 10:45 a.m. Chromosome instability in blood cells of patients with Li-Fraumeni syndrome before cancer diagnosis.** Aurelie Ernst, Heidelberg, Germany
- 11:10 a.m. The prognostic implications of chromothripsis in hematological malignancies.** Faith E. Davies, New York, NY



ADVANCES IN ORGAN SITE RESEARCH

10:15 a.m.–11:45 a.m.

Room S404 - McCormick Place South (Level 4)
A Paradigm Shift in Therapies for Kinase-driven Hepatobiliary Cancer

Chair: Arndt Vogel, Hannover, Germany

- 10:15 a.m. Chair Introduction.** Arndt Vogel, Hannover, Germany
- 10:20 a.m. Evolving biomarkers for systemic treatment of HCC.** Arndt Vogel, Hannover, Germany
- 10:45 a.m. State of the art and emerging therapies in BTC.** Teresa Macarulla, Barcelona, Spain
- 11:10 a.m. Primary and acquired resistance to FGFR inhibitors in cholangiocarcinoma: Insights and future directions.** Lipika Goyal, Palo Alto, CA



ADVANCES IN PREVENTION RESEARCH

10:15 a.m.–11:45 a.m.

Room E451 - McCormick Lakeside Center (Level 4)
Interwoven Risks of Exposures and Environments: Mapping the Future of Cancer Prevention

Chair: Melissa B. Davis, Atlanta, GA

- 10:15 a.m. Chair Introduction.** Melissa B. Davis, Atlanta, GA
- 10:20 a.m. Deciphering prostate cancer's multifactorial etiology: An integrative molecular epidemiological approach.** Tsion Z. Minas, Baltimore, MD
- 10:45 a.m. Leveraging high resolution mass spectrometry based exposomics for decoding the role of chemical exposures in cancer.** Randolph Reyes Singh, New York, NY
- 11:10 a.m. The Grand Challenges of global research of disparities.** Melissa B. Davis, Atlanta, GA



ADVANCES IN THE SCIENCE OF CANCER DISPARITIES

10:15 a.m.–11:45 a.m.

Room S106 - McCormick Place South (Level 1)

Cancer and Indigenous Populations: From Risk Factors to Cancer Care Delivery to Policy

Chair: Dorothy A. Rhoades, Oklahoma City, OK

- 10:15 a.m.** **Chair Introduction.** Dorothy A. Rhoades, Oklahoma City, OK
- 10:20 a.m.** **Toward a cancer center care coordination and communication program for tribal health systems.** Dorothy A. Rhoades, Oklahoma City, OK
- 10:45 a.m.** **Considerations for precision oncology and artificial intelligence for Indigenous genomic data sovereignty and health disparities.** Krystal Tsosie, Tempe, AZ
- 11:10 a.m.** **Nation to nation to cancer centers: Exemplars of sovereignty across the cancer care continuum.** Rodney C. Haring, Buffalo, NY



MAJOR SYMPOSIUM

10:15 a.m.–11:45 a.m.

Room S103 - McCormick Place South (Level 1)

Biomolecular Condensates in Cancer: Mechanisms and Therapeutic Opportunities

Chair: Liling Wan, Philadelphia, PA

- 10:15 a.m.** **Introduction.** Liling Wan, Philadelphia, PA
- 10:20 a.m.** **Chromatin-associated condensates in gene regulation and cancer.** Liling Wan, Philadelphia, PA
- 10:45 a.m.** **New physical biology of oncoprotein condensates: Differential regulation of the transcriptome by phase separation.** Xiaokun Shu, San Francisco, CA
- 11:10 a.m.** **SY29-01 Compartmentalization of proteins and drugs in cancer cells.** Richard A. Young, Cambridge, MA

Room E450 B - McCormick Lakeside Center (Level 4)

Ferroptosis: From Breakthroughs to Therapeutic Opportunities in Metabolism, Immunity, and Metastasis

Chair: Brent R. Stockwell, New York, NY

- 10:15 a.m.** **Introduction.** Brent R. Stockwell, New York, NY
- 10:20 a.m.** **SY11-01 Ferroptosis and cancer metabolism: History, mechanisms, and therapeutic applications.** Brent R. Stockwell, New York, NY
- 10:45 a.m.** **Ferroptosis and tumor immunity.** Weiping Zou, Ann Arbor, MI
- 11:10 a.m.** **Ferroptosis and the metastatic microenvironment.** Jessalyn Marie Ubellacker, Boston, MA

Room S102 - McCormick Place South (Level 1)

From Cells to Systems: Unraveling the Heterogeneity of Stress-Induced Senescence in Cancer

Chair: Mina S. Sedrak, Los Angeles, CA

- 10:15 a.m.** **Introduction.** Mina S. Sedrak, Los Angeles, CA
- 10:16 a.m.** **Navigating the yin and yang of senescence: The complex interplay between cancer and aging.** Mina S. Sedrak, Los Angeles, CA
- 10:31 a.m.** **Harnessing age- and sex-differential changes within the tumor microenvironment to inhibit metastasis and promote therapy responses in melanoma.** Yash Chhabra, Philadelphia, PA
- 10:46 a.m.** **Defining and targeting senescence heterogeneity in prostate cancer: immune suppression, tumorigenesis, and therapy response.** Marcus Ruscetti, Worcester, MA
- 11:01 a.m.** **Uncovering the stress-aging-cancer axis: Implications for prevention and population health.** Electra D. Paskett, Columbus, OH

Room S401 - McCormick Place South (Level 4)

Hubs of Anti-Tumor Immunity: Lymph Nodes and Lymphoid Structures

Chair: Amanda W. Lund, New York, NY

- 10:15 a.m.** **Introduction.** Amanda W. Lund, New York, NY
- 10:20 a.m.** **SY20-01 Programming the lymphatic state to maintain immune surveillance and limit regional metastasis.** Amanda W. Lund, New York, NY
- 10:45 a.m.** **The activity and formation of tertiary lymphoid structures is governed by tumor site and stroma.** Tullia C. Bruno, Pittsburgh, PA
- 11:10 a.m.** **The role of lymph nodes in shaping B cell responses in ovarian cancer tumors.** Ziv Shulman, Rehovot, Israel

Room S105 - McCormick Place South (Level 1)

Intratumoral Microbiota and Microbiota-Derived Metabolome: Friend or Foe

Chair: Maria Rescigno, Milan, Italy

- 10:15 a.m.** **Chair Introduction.** Maria Rescigno, Milan, Italy
- 10:20 a.m.** **Title to be announced.** Florencia McAllister, Houston, TX
- 10:45 a.m.** **The intratumoral microbiota in cancer resistance to therapy.** Maria Rescigno, Milan, Italy
- 11:10 a.m.** **Exploring modalities to shape the tissue/tumor microbiome at gut-distal sites.** Marlies Meisel, Pittsburgh, PA



PLENARY SESSION **12:10 p.m.–1:30 p.m.**

Arie Crown Theater - McCormick Lakeside Center (Level 2)

AACR Annual Meeting 2025 Highlights: Vision for the Future

Cochairs: Lillian L. Siu, Toronto, ON, Canada; Matthew G. Vander Heiden, Cambridge, MA

- 12:10 p.m.** **Chair Introduction.** Lillian L. Siu, Toronto, ON, Canada
- 12:12 p.m.** **Chair Introduction.** Matthew G. Vander Heiden, Cambridge, MA
- 12:14 p.m.** **Basic cancer science and translational research.** Cory Abate-Shen, New York, NY
- 12:39 p.m.** **Prevention, early detection, population sciences, and disparities research.** Scarlett L. Gomez, San Francisco, CA
- 1:04 p.m.** **Clinical research and clinical trials.** Jayesh Desai, Melbourne, Australia